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Abstract 
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the second leading 
causes of cancer deaths in western countries. Nearly one-third of patients with PCa 
experience cancer recurrence or progression following primary treatment such as surgery or 
radiation therapy. The presence of quiescent cancer cells has been documented in many types 
of cancers, including prostate. Quiescent cells are Ki-67 protein-negative and reversibly 
arrested at the G0 phase. In PCa, the percentage of Ki-67-positive PCa cells is low in low risk 
disease, but increases in high risk and advanced PCa, suggesting that an increase in transition 
from G0 state to a proliferating state may contribute to PCa progression. Hence, how to 
increase the proportion of cancer cells at G0 over those in a proliferating state and/or to 
prevent the transition from G0 to a proliferating state is pertinent to the prevention of cancer 
progression and recurrence. However, our understanding of the signals required for 
maintaining cancer cells at G0 and/or impeding the transition from quiescent to a proliferating 
state is limited. 
In eukaryotes, the ubiquitin proteasome system (UPS) precisely regulates the cell cycle at key 
checkpoints by targeting cell cycle regulators for proteasome-mediated degradation. The UPS 
requires the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligases (E3) to work in concert to facilitate ubiquitination of target proteins. 
Ubiquitin conjugating enzyme 2C (UBE2C) is aberrantly overexpressed in a variety of 
cancers, including PCa. Accumulation of UBE2C stimulates cell proliferation, whereas 
silencing of UBE2C decreases cell proliferation. The significance of UBE2C in cell cycle exit 
and re-entry, however, has not been investigated. 
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The aim of this project was to define the role of UBE2C in the proportion of quiescent over 
proliferative PCa cells and transition to a proliferating state by quiescent PCa cells. 
Moreover, the concordance between UBE2C protein/mRNA levels in human PCa tissue and 
progression of PCa were determined. 
To establish the relationship of UBE2C the proportion of G0 cells, PCa cell lines were 
transfected with UBE2C siRNA or UBE2C expression plasmid. Silencing of UBE2C 
decreased cell proliferation, whereas overexpression of UBE2C increased cell proliferation, 
determined by measuring DNA content. Flow cytometric analysis of both DNA and RNA 
content were subsequently undertaken to investigate if manipulation of UBE2C changed the 
proportion of G0. Depletion of UBE2C led to accumulation of quiescent cells, while 
overexpression of UBE2C decreased the proportion of quiescent PCa cells.  
To further evaluate the relationship of UBE2C with cell cycle re-entry, we utilised contact 
inhibition in PC-3 or serum withdrawal in LNCaP and C4-2B cells to induce experimental 
quiescence. The quiescent state of PCa cells was confirmed by flow analysis. Cell cycle re-
entry was rendered by replating the contact-inhibited quiescent cells at low density, or by 
restoring serum to serum-deprived cells. UBE2C protein levels were decreased during cell 
cycle exit and increased upon cell cycle re-entry. Overexpression of UBE2C impeded cell 
cycle exit, and knockdown of UBE2C delayed cell cycle re-entry by quiescent PCa cells. 
Next, to determine the molecular mechanism underlying UBE2C action on cell cycle exit and 
re-entry, G0 regulatory proteins were examined by immunoblot. Knockdown of UBE2C 
expression increased the protein levels of p27 and decreased protein levels of SKP2 and 
PIRH2; both are components of E3 ligases responsible for p27 degradation. Additionally, the 
level of c-MYC was also decreased by UBE2C siRNA. Concomitantly, FBXW7, which 
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targets c-MYC for degradation, was increased. However, the silencing of UBE2C did not 
change protein levels of p27 nuclear exporter CRM1.  
Lastly, to examine the concordance between UBE2C mRNA levels and progression of PCa, 
12 datasets on PCa from ONCOMINE, an online database for genetic variation and mRNA 
expression in cancer, were analysed. Across these datasets, UBE2C mRNA was highly 
expressed in the metastasised form of PCa compared with organ-confined primary PCa or 
benign hyperplastic tissues. At protein levels, the aberrant overexpression of UBE2C was 
confirmed by immunostaining in PCa tissue specimens (n=70), and was found to be 
correlated with cancer progression in paired specimens of hormone-sensitive PCa and 
castration-resistant PCa from the same patient (n=8). 
In summary, this study has revealed that UBE2C plays a previously unrecognised vital role in 
the regulation of the proportion and transition of quiescent PCa cells. These findings suggest: 
(i) UBE2C blocks cell cycle exit and promotes cell cycle re-entry; (ii) UBE2C can 
downregulate p27 expression, possibly through augmenting SKP2 and PIRH2 expression; 
(iii) UBE2C can upregulate c-MYC expression, possibly through reducing FBXW7 
expression; and (iv) UBE2C mRNA and/or protein levels are aberrantly increased in the 
advanced form of PCa, and the increased expression of UBE2C is associated with PCa 
progression.   
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1.1. Background 
1.1.1. Prostate cancer 
Prostate cancer (PCa) is the second-most common cause of death in Australia—after 
cardiovascular diseases (Australian Institute of Health and Welfare (AIHW), 2016). In 2015, 
there were an estimated 126,800 new cases of cancer diagnosed in Australia (69,790 males 
and 57,010 females) (AIHW, 2016). The AIHW (2016) reported that, PCa accounted for 
24.7% of all new cancer cases in Australian males and 13% of male cancer deaths. The 
incidence is increasing rapidly as the population of males over the age of 50 grows 
worldwide (De Marzo et al., 2007). The American Cancer Society (ACS, 2016) claims 
almost 1 in 7 males will eventually develop PCa during their lifetime, and about 1 in 38 man 
will die of PCa. Adoption of serum prostate-specific antigen (PSA) screening has led to a 
dramatic shift towards the diagnosis of low risk PCa (Jemal et al., 2010). In fact, there are 
more than 2.9 million men in the United States who are living with PCa (ACS, 2016). 
However, approximately 20–40% of patients treated with radical prostatectomy will have 
tumour recurrence (Kupelian et al., 2006; Paller and Antonarakis, 2013). Androgen 
deprivation therapy (ADT) is provided to patients who develop recurrent or metastatic 
prostate tumours. Unfortunately, 80–90% of patients who received ADT ultimately 
developed castration resistant PCa (CRPC) 12–33 months after ADT (Lin et al., 2013); with a 
median overall survival of patients after tumour relapse only 1–2 years (Chuu et al., 2011). 
There is therefore an acute need to understand the primary risk factors and molecular basis of 
PCa in order to manage this significant health issue. 
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1.1.2. Risk factors for prostate cancer 
Researchers have defined several risk factors for PCa based on clinical, epidemiological and 
experimental observations. Some risk factors, like diet, can be avoided; others, like age, 
genetics and hormones, cannot be changed.  
1.1.2.1. Age 
Aging men have a higher risk of PCa. The American Cancer Society (2016) reported PCa is 
rare in American men younger than 40 with almost 6 in 10 cases of PCa found in men older 
than 65. The Cancer Institute of New South Wales (CIN, 2010) also stated that the incidence 
of PCa is relatively low in Australian men aged under 50, it increased sharply for the 50–55 
age bracket, and peaked in the 60–69 age bracket, as shown in Figure 1-1. Overall, the 
mortality rate of PCa increased gradually from age 50 to 69 years, increased sharply from 80 
years onwards (CIN, 2010). The median age for the diagnosis of PCa was 69, while the 
median age of death was 80 years (Tracey et al., 2009). 
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Figure 1-1. The age specific incidence rates of prostate cancer in New South Wales, 2010. 
The incidence rate rose sharply in men aged 50–55 years and peaked at ages 75–79 years 
(Left). The mortality of PCa increased gradually for patients between the ages of 40 and 64 
years, then sharply increased from 65 years onwards, then decreased  after the age of 85 
(Right) (CIN, 2010). 
 
1.1.2.2. Genetics 
Genetics is another possible risk factor for PCa. Men with a family history of more than one 
relative with PCa – a first-degree relative, such as father, or a family member diagnosed 
under the age of 60 – are at higher risk (Wigle et al., 2008). Moreover, the incidence of PCa 
is variable for different races, with some races more susceptible than others. For example, 
symptomatic carcinoma of the prostate is more common and occurs at an early age in African 
Americans than in whites, Asians or Hispanics (Lima et al., 2015; Siegel et al., 2014). 
According to the National Cancer Institute (NCI, 2002), the incidence of PCa is 
approximately two folds higher in African Americans, along with a three-fold higher 
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mortality rate. The African American Hereditary Prostate Cancer Study Network (AAHPC) 
recruited 77 African American extended families, encompassing a total of 418 men with PCa, 
to participate in the first genome-wide linkage study of PCa in African Americans. The 
results identified several regions of the human genome at 11q22, 17p11, and Xq21 that are 
associated with increased susceptibility to PCa (Baffoe-Bonnie et al., 2007). Furthermore, 
family members with a mutation in the breast cancer susceptibility gene (BRCA1/2) gene, a 
genetic mutation associated with breast and ovarian cancers, may also increase PCa risk in 
some men. However, this genetic mutation probably account for only a small percentage of 
PCa cases (Cavanagh and Rogers, 2015). 
1.1.2.3. Hormones 
Epidemiologic studies provide inconsistent evidence for the role of endogenous androgen 
levels in PCa development. However, there is still a possibility that endogenous androgen 
levels may influence the initiation and promotion of PCa (Wigle et al., 2008). For example, 
androgen interacts with the androgen receptor (AR) to regulate the transcription of androgen-
responsive genes that are essential for prostate growth (Shidaifat, 2009).  
1.1.2.4. Diet 
Diet appears to be a major determinant in the incidence rate of PCa with particular dietary 
substances involved still under investigation. Geographical and epidemiological evidence has 
linked diet to PCa, suggesting its role in the aetiology of the disease (ACS, 2016). The 
likelihood of the development of PCa may be minimised by eliminating a high consumption 
of red meat and processed animal polyunsaturated fat (Williams et al., 2010). High blood 
levels of omega 6, a polyunsaturated fatty acid derived from linoleic acid, was showed to 
increase the risk of developing advanced PCa by 70% (Wigle et al., 2008). This notion is 
consistent with results from animal studies, which have shown that an increased dietary 
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intake of linoleic acid might enhance the risk of developing advanced PCa (Leitzmann et al., 
2004). Furthermore, a case-controlled study conducted in Athens demonstrated an increased 
risk of PCa is associated with the consumption of dairy products and seed oils (Bosetti et al., 
2000). In addition, milk, a source of calcium, has also been reported to increase in the risk of 
PCa (Wigle et al., 2008). 
1.1.3. Tumour grade and stage 
1.1.3.1. Diagnosis of prostate cancer 
Most patients develop PCa without experiencing any symptoms, it causes a delay in proper 
diagnosis and treatment, thereby resulting in a high mortality rate(Tracey et al., 2009). An 
elevated level of PSA may indicate a higher chance of prostate diseases including benign 
prostatic hyperplasia (BPH) and PCa. However, there are also cases of PCa detected without 
increased PSA level (Thompson et al., 2004). Therefore, PSA determination in conjunction 
with digital rectal examination is recommended by a majority of clinical guidelines for the 
detection of PCa prior to the manifestation of symptoms (Schmid et al., 2004). Biopsy is 
made for pathological examination if an abnormality is found in PSA levels (PSA ≥ 4 ng/mL) 
and digital rectal examination. The grade and stage of PCa will then be examined.  
1.1.3.2. Grading 
The Gleason score, originally described by Dr Donald Gleason, is specifically used for 
grading a prostate biopsy (Gleason and Mellinger, 1974). A pathologist determines a Gleason 
score depending on the glandular pattern of the tissue, as shown in Figure 1-2. The Gleason 
score is generated as the sum of two scores obtained from both the primary and secondary 
pattern structure. The primary pattern (>50% of the total cancer cells observed) is a score 
between 1 and 5 depending on how cancerous the cells look. Then, the next most common 
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type of cancerous cell type (<50% but >5% of total cells observed) are also graded in the 
same way. This gives two separate scores out of 5. These scores are then added together to 
give the overall Gleason score out of 10. 
 
Figure 1-2. The Gleason score system for histological grading of prostate cancer. 
(Adapted from Orchid Fighting male cancer website: www.Orchid-cancer.org.uk). 
 
The Gleason score is normally associated with the aggressiveness of PCa (Table 1-1). 
Patients with low grade (Gleason ≤6) tumours have a slow progressing type of PCa. A 
Gleason score of 7 (3+4 or 4+3) is usually termed a moderate grade while those with a 
Gleason scores of 8 (3+5, 4+4, 5+3), 9 (4+5, 5+4) and 10 (5+5) have a hazard ratio of lethal 
cancer 7.4 times higher than those with Gleason score 3+4 (Penney et al., 2011). 
Additionally, researchers tend to divide a Gleason score of 7 group into two groups: 4+3 and 
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3+4, as a 3-fold increase of PCa mortality in the setting of 4+3 vs. 3+4 groups was observed 
(Stark et al., 2009).  
Table 1-1. Gleason scores in categorical order.  
Gleason score Risk 
≤6 Low Slow-growing and  less aggressive cancer 
7 Medium Faster-growing and  moderately aggressive cancer 
8–10 High Faster-growing and  aggressive cancer 
(Adapted from Cancer Council NSW website: www.cancercouncil.com.au). 
 
1.1.3.3. Staging 
The grade reflects how fast a cancer is growing, whereas the stage of PCa reflects how far the 
cancer has metastasised (spread). The most widely used staging system for PCa is the 
American Joint Committee on Cancer (AJCC) TNM system, which stands for Tumour, Node, 
and Metastasis. The T category refers to the extent of the primary tumour, N category scores 
whether the cancer has spread to nearby lymph nodes, an M exams whether the cancer has 
metastasised to other parts of the body (AJCC, 2015). The stages of PCa can be classified by 
combining the TNM rating, the PSA level in the blood and the Gleason score from a biopsy; 
these are summarised in Table 1-2. 
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Table 1-2. Anatomic stage and prognostic group of prostate cancer. 
Stage Tumour Nodes Metastasis PSA (ng/mL) Gleason Score  
I T1–2a N0 M0 <10 ≤6 
IIA 
T1 N0 M0 <20 7 
T1 N0 M0 10 ≤ PSA <20 ≤6 
T2a–b N0 M0 <20 ≤7 
IIB 
T2c N0 M0 Any  Any  
T1–2 N0 M0 <20 Any  
T1–2 N0 M0 Any  ≥8 
III T3a–b N0 M0 Any  Any  
IV 
T4 N0 M0 Any  Any  
Any T N1 M0 Any  Any  
Any T Any N M1 Any  Any  
Adapted from American cancer society: PCa www.cancer.org/cancer/prostatecancer. 
 
1.1.4. Current treatment 
Recent treatments for PCa reported by the Prostate Cancer Foundation of Australia ( PCFA, 
2016) include: active surveillance, radical prostatectomy, external beam radiotherapy, 
low/high dose brachytherapy, high intensity focused ultrasound, chemotherapy and androgen 
ablation therapy (Cooperberg et al., 2011). The choice of treatment depends on many aspects, 
such as the stage of the PCa, the level of PSA in the blood stream, the age and health 
condition of the patient as well as the side effects of treatment. Organ-confined PCa (OCPC) 
is treated by surgery or local irradiation (PCFA, 2013). At the advanced stage when 
metastases occur, PCa is treated with ADT, as the growth and division of PCa cells is highly 
dependent on androgen. Gonadotropin-releasing hormone antagonist may also be used to 
either reduce the level of androgen produced by the body or block the effects of androgen on 
cancer cells. As a result, it may shrink the size of the tumour, suppress its growth and reduce 
the level of PSA (ACS, 2016; AIHW, 2016).  
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However, most PCa eventually becomes androgen-independent and thus resistant to ADT 
(Lin et al., 2013). One of the approaches used for hormone refractory PCa is 
chemoprevention, which refers to the administration of synthetic or naturally occurring 
agents to block, reverse, or delay the process of carcinogenesis (Adhami et al., 2007). 
However, as both chemotherapy and chemoprevention possess limited efficacy for patients 
with advanced androgen refractory PCa, these patients generally have a poor prognosis.  
The mechanisms of how OCPC develops into CRPC remain to be defined. Therefore, it is 
important to enhance our understanding of the molecular basis of prostate carcinogenesis to 
improve future approaches for its treatment or possible prevention.  
1.2. Quiescent Cancer Cells 
Cancer is a consequence of uncontrolled cell division. Quiescent cancer cells, which are Ki-
67 negative and arrest at G0, have been found in various cancers including PCa (Coller, 2007; 
Jackson, 1989). These quiescent cancer cells are in a reversible state of arrest, and have been 
found to re-entre cell cycle in response to proliferative environmental signals (Desoize and 
Jardillier, 2000). Recent studies in PCa have shown that the increased proportion of 
proliferative over quiescent ratio in PCa cells represents an inherent mechanism that at least 
partially explains recurrence in PCa patients (Almog, 2010; Brackstone et al., 2007; 
Udagawa, 2008).  The Ki-67 protein immunostaining in PCa showed a low positivity in low 
grade and low volume disease, but increases in high risk and advanced disease, suggesting an 
accelerated transition from quiescent to a proliferative state during disease progression 
(Jhavar et al., 2009; Keshari et al., 2011; Khatami et al., 2009; Nagao et al., 2011). However, 
while the regulation of cell cycle progression is well understood, the signal required for PCa 
cell to exit and re-enter the cell cycle is still elusive. To understand the role of quiescent 
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cancer cells in regulation of PCa progression, the basic cell cycle regulation will be 
summarised below. 
 
 
Figure 1-3. The cell cycle in terms of proliferative versus quiescent cancer cells.  
When cells cease proliferation, they exit the cycle and enter a non-dividing, quiescent state 
known as G0. These quiescent cancer cells are in a reversible state of arrest. Quiescent 
cancer cells re-entre cell cycle in response to proliferative environmental signals. Yellow, 
cells in S phase, DNA replication starts and the amount of DNA increases. Green, cells in 
G2/M phase, the DNA replication continues until the DNA content reaches a tetraploid (4N) 
state. Tetraploid cells in the G2 phase start preparing for division and enter the M phase 
when the cells divide into two identical daughter cells. The daughter cells continue on to 
another division cycle or enter the G0 phase.  
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1.2.1. Phases of the cell cycle 
The basic cell cycle is divided into four sequential phases: gap 1 (G1), synthesis (S), gap 2 
(G2) and mitosis (M) (Figure 1-4A). Passage through the cell cycle is strictly controlled by 
cyclin/cyclin-dependent kinase (CDK) complexes and regulated at three checkpoints, 
including G1 (restriction) check point, G2/M DNA damage check point and anaphase or the 
spindle assembly checkpoint (SAC). The timely activation of CDKs by the binding of 
characteristic partner cyclins and subsequent phosphorylation of specific substrates regulates 
progression through the different stages of the cell cycle. Each cyclin exhibits a pattern of 
expression and degradation throughout the progression of the cell cycle (Figure 1-4C). 
Cyclins D and E, known as G1 cyclins, bind to CDK4/6 and CDK2, respectively, resulting in 
G1/S transition. Cyclins A and B are mitotic cyclins; cyclin A/CDK2 and cyclin A/ CDK1 
complexes are required for S phase progression and the cyclin B/CDK1 complex is required 
to transition from G2 to M phase. Following their activation, CDKs are inactivated by the 
degradation of partner cyclins in order for the cell cycle to progress. Checkpoints prevent 
cells from entering a new phase until they have successfully completed the previous one. 
Upon DNA damage, checkpoints will be activated to arrest cells for DNA repair or initiation 
of apoptosis (Takahashi-Yanaga and Sasaguri, 2008; Walczak et al., 2010). 
The G1, S and G2 phases are collectively known as interphase. Mitosis can be staged into 
prophase, prometaphase, metaphase, anaphase and telophase (Figure 1-4A&B). In interphase, 
individual chromosomes cannot be seen because the chromatin is decondensed in the nucleus. 
During prophase, chromatin condenses into chromosomes and the chromosomes become 
highly separated. Nuclear envelope breakdown marks the transition from prophase to 
prometaphase so that the individual chromosomes are no longer constrained in the nucleus. 
As shown in Figure 1-4B, during prometaphase, kinetochore-microtubules (KMTs) connect 
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the spindle microtubules (MTs) and the kinetochores on the chromosomes (Brinkley and 
Stubblefield, 1966). The chromosome aligns at the spindle equator, which defines metaphase. 
The MTs emanate from the centrosomes and extend their plus ends towards the cell cortex. 
Chromosome segregation occurs during anaphase after loss of the sister chromatid cohesion 
(Perez de Castro et al., 2007). The movement of the chromosomes towards the poles occurs 
during early anaphase, and the two spindle poles separate during late anaphase. The nuclear 
envelope begins to reform and the DNA begins to decondense during telophase. Cytokinesis 
divides the cytoplasm of the cell so that the two daughter nuclei are segregated into 
individual cells  (Walczak et al., 2010).  
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Figure 1-4. A schematic graph of the cell cycle.  
A. Cell cycle phases. B. Individual phases of mitosis. C. Fluctuating levels of cyclins (Takahashi-Yanaga and Sasaguri, 2008). 
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1.2.2. Known cell cycle regulators 
When cells cease proliferation, either due to specific antimitogenic signals or to the absence 
of proper mitogenic signalling, they exit the cycle and enter a non-dividing, quiescent state 
known as G0. The G0 regulatory proteins p27 and c-MYC, plays a key role in regulating cell 
cycle re-entry (Bretones et al., 2015; Chu et al., 2008). 
1.2.2.1. p27 
In 1994, a 27 kDa protein was found to possess a capacity to inhibit the activity of CDK2 
following treatment of mink lung epithelial cells with transforming growth factor (TGFβ) 
(Polyak et al., 1994). This protein was named the CDK inhibitor 1B or p27. As a member of 
the kinase inhibitor protein (KIP) family, p27 was also named as p27KIP1 and thought to 
control cell cycle progression via binding and inhibiting cyclin-CDK complexes in G1 
(Polyak et al., 1994) or even beyond G1 (Grimmler et al., 2007; James et al., 2008; O'Hagan 
et al., 2000; Sheaff et al., 1997).  
The p27 gene is located on chromosome 12p13 (Pietenpol et al., 1995). The CDK-inhibitory 
domain resides at the N-terminal portion of p27 and is sufficient to arrest cells at G0/G1. The 
carboxyl terminal (C-terminal) portion of p27 is less conserved in the KIP family and 
contains a nuclear localisation signal (NLS) (Russo et al., 1996). p27 regulates G0/G1 –S 
progression by inhibiting cyclin/CDK complexes, including cyclin E/A-CDK2 (Aleem et al., 
2005; James et al., 2008; Ray et al., 2009; Russo et al., 1996), cyclin D-CDK4/6 (James et 
al., 2008; Ray et al., 2009) and cyclin B-CDK1 (Aleem et al., 2005). 
The protein levels of p27 are tightly regulated, being typically high during G0/G1 and falling 
sharply just before cell cycle entry into the S phase (Chu et al., 2008). In G0 phase, p27 is 
markedly increased in the nucleus of G0-arrested cells (Besson et al., 2006; Rivard et al., 
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1996). The increase in p27 inhibits CDK/cyclin complexes, blocking the phosphorylation of 
retinoblastoma (Rb) (Dyson, 1998). Rb physically associates with E2F factors and inhibits 
E2F-dependent transcription, thereby hindering cell cycle re-entry (Dyson, 1998). Whereas, 
the protein level of p27 decreased upon cell cycle re-entry, CDKs phosphorylate Rb (p-Rb), 
releasing E2F to promote transcription of cyclins and thus entering the cell cycle (D'Antonio 
et al., 2010; Nakayama and Nakayama, 2006) (Figure 1-5).  
In addition, in quiescent states, p-Rb also binds to the anaphase promoting complex, or 
cyclosome-cadherin-1 (APC/CCDH1), resulting in the efficient proteolysis of S-phase kinase-
associated protein 2 (SKP2) and in the subsequent accumulation of p27 (Santamaria and 
Pagano, 2007). Cadherin-1 (CDH1), an activator of APC/C, is active in G0 and G1 (Skaar and 
Pagano, 2008). From late mitosis to mid-G1, dephosphorylated CDH1 binds and activates 
APC/C, and the major function of APC/CCDH1 is to maintain a low CDK activity in G0/G1 
(Santamaria and Pagano, 2007). Thus, the leading keepers of quiescence and differentiation – 
p-Rb, CDH1, SKP2 and p27 – are tightly linked to each other through proteolytic 
mechanisms (Santamaria and Pagano, 2007). During cell cycle re-entry, the increased level of 
proviral integration site mis-1 (Pim-1) stabilises SKP2 by phosphorylation and also inhibits 
APC/C activity by phosphorylating CDH1, protecting SKP2 from degradation. p27 is then 
targeted by SKP2 for degradation (Cen et al., 2010). Consistent with notion, SKP2 levels are 
decreased in G0 and increased in G1 (Krek et al., 2000) (Figure 1-5). 
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Figure 1-5. p27 stability and its regulation.  
Proteins in yellow, promoting cell cycle re-entry. Proteins in Green, halting cell cycle re-
entry. Proto-oncogenes, keeping tumour suppressors in check. Tumour suppressors, 
inhibiting proto-oncoproteins (Santamaria and Pagano, 2007). 
 
p27, as a tumour suppressor, is inversely correlated with the prognosis of cancer patients 
(Sgambato et al., 2000). p27 is haploinsufficient, with the loss of a single p27 allele being 
sufficient to increase tumour incidence (Fero et al., 1998). Decreased levels of p27 protein, in 
particular nuclear-expressed p27, is implicated in disease progression and poor prognosis in 
lung, head and neck, colon, breast, ovary and PCa (Chu et al., 2008). p27-null mice show 
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multiorgan hyperplasia, retinal dysplasia, increased body size and tumour formation (Fero et 
al., 1996; Kiyokawa et al., 1996), suggesting an indispensable function of p27. Low protein 
levels or cytoplasmic expression of p27 is associated with cancer aggressiveness and poor 
clinical prognosis (Chu et al., 2008). The main cause of low p27 expression in cancer is 
unlikely via mutations or epigenetic silencing, but rather through aberrant p27 degradation, 
repressed p27 expression, and increased cytoplasmic localisation (Chu et al., 2008). Hence, 
understanding the regulation of p27 expression via both transcriptional and post-translational 
mechanisms will provide a potential new target for therapeutic intervention. 
1.2.2.2. p27 post-translational regulator:SKP2 
SKP 2 is an F-box protein that composed of 424 amino acids (Katoh et al., 2013). SKP2  is a 
component of a E3 ligase called the SKP1-cullin-F-box (SCF) SKP2 complex, that targets 
several key cell cycle regulators for degradation, such as p27, p21, p57 and cyclin E (Gstaiger 
et al., 2001; Kitagawa et al., 2009; Marti et al., 1999). Although SKP2 mediates the 
degradation of both positive and negative cell cycle regulators, its overexpression leads to 
cell cycle progression via degradation of p27 (Gstaiger et al., 2001). The ubiquitination and 
subsequent degradation of p27 depends on its phosphorylation at Thr187 by cyclin-CDK 
complexes. SKP2 specifically recognises phosphorylated p27 at Thr187 (Carrano et al., 1999).  
Therefore, SKP2 is a p27 post translational regulator. Studies in human and experimental 
tumours have observed the inverse correlation of decreased p27 with elevated SKP2 
expression (Cen et al., 2010). Increased protein levels of SKP2 were found to be associated 
with reduced p27 in a subset of oral epithelial dysplasia and carcinomas when compared with 
normal epithelial cells/tissue (Gstaiger et al., 2001).  
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1.2.2.3. p27 post-translational regulator: PIRH2 
p53-induced RING-H2-type ubiquitin ligase (PIRH2) is a p27-interacting protein. PIRH2 
degrades p27 in G1 phase independent of phosphorylation state in both the nucleus and 
cytoplasm (Hattori et al., 2007). PIRH2 interacts with p27 through the RING finger domain 
(Hattori et al., 2007). The expression of PIRH2 is low in G0, but is induced in late G1 to S 
phase in human glioblastoma (T98G) cells (Hattori et al., 2007). Knockdown of PIRH2 
thereby prevented the cell cycle re-entry of serum-starved cells following the restoration of 
serum (Hattori et al., 2007). Hence, PIRH2 is another negative regulator of p27 via ubiquitin-
dependent proteasomal degradation (Hnit et al., 2015).  
 
1.2.2.4. p27 nuclear exporter: CRM1 
As an inhibitor of DNA duplication and cell division, p27 exerts its anti-proliferative action 
inside the nucleus. Chromosome region maintenance 1 (CRM1) is a carrier protein for 
nuclear export (Wang et al., 2013), which mediates the cytoplasmic translocation of p27 
through binding to its CDK interacting site (Chu et al., 2008). CRM1 activity is low during G0 
and increases markedly during the G1–S phase progression. In early G1, phosphorylation of p27 
facilitates its binding to CRM1 and subsequent transport from the nucleus to the cytoplasm 
(Ishida et al., 2002). Interestingly, proteasome inhibition in mid-G1 does not impair nuclear 
import of p27, but rather leads to accumulation of p27 in the cytoplasm. This suggests that export 
of p27 precedes its degradation for at least part of the cellular p27 pool, and that active CRM1-
mediated export of p27 to the cytoplasm may be linked to cytoplasmic p27 ubiquitination and 
proteolysis. CRM1-dependent nuclear export of p27 and cytoplasmic degradation therefore 
permits the incremental activation of cyclin E-CDK2 and thus G1–S phase transition (Connor et 
al., 2003).In CRM1 siRNA-treated ovarian cancer cells, a reduction of CRM1 protein levels 
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and coincident accumulation of phosphorylated p27 in the nuclear fraction were observed 
(Wang et al., 2013). These data suggest that CRM1 plays an essential role in the subcellular 
localisation of p27 and subsequently in cell cycle regulation. CRM1-positive expression in 
ovarian cancer was associated with higher tumour grade and lymph node metastases (Hnit et 
al., 2015; Wang et al., 2013).  
1.2.2.5. c-MYC 
c-MYC is a cellular proto-oncogene associated with a variety of human cancers and is 
strongly implicated in the control of cell cycle progression, cell metabolism, apoptosis, cell 
differentiation, tumour expansion and accelerating tumour progression (Whitfield and 
Soucek, 2012). The human MYC gene family is composed of MYC, MYCN and MYCL1, and 
all three MYC gene products have similar effects on cell cycle progression (Bretones et al., 
2015). The levels of c-MYC expression are crucial for cell cycle re-entry. c-MYC mRNA 
levels are virtually undetectable in quiescent cells but increase within one to three hours upon 
mitogen stimulation (Kelly et al., 1983). Forced expression of c-MYC induces cell cycle re-
entry of quiescent cells, but the downregulation or inactivation of c-MYC results in the 
impairment of cell cycle progression (Bretones et al., 2015). Importantly, amplification of c-
MYC is found in nearly half of human solid tumours (Beroukhim et al., 2010), including 
thirty per cent of PCa (Bretones et al., 2015). 
In addition, previous studies already show in the absence of c-MYC, the expression of p27 is 
increased even during the G0/S transition (Mateyak et al., 1999). Transient overexpression of 
MYC in Jurkat T cells and breast cancer cells increased binding of the MYC homology box II 
to the p27 promoter, directly repressing p27 gene transcription (Bretones et al., 2015; 
Chandramohan et al., 2008). How c-MYC represses the protein level of p27 is not fully 
understood but is thought to be, at least in part, through its ability to selectively induce E3 
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ubiquitin ligase components SKP2, cullin 1 (CUL1) and CDC28 protein kinase regulatory 
subunit 1 (CKS1), which are all necessary for p27 ubiquitination and degradation (Bretones 
et al., 2011; Keller et al., 2007; O'Hagan et al., 2000). Other MYC target genes, such as E2F 
(E2F1, E2F2 and E2F3) transcription factors, may also play a role in regulating p27, by 
inducing cyclin E expression (Muller et al., 1997; Pérez-Roger et al., 1997).  
1.2.2.6. C-MYC post-translational regulator: FBWX7 
Regulation of c-MYC protein degradation has attracted attention. The F-box protein of E3 
ubiquitin ligase, FBXW7, plays a key role in c-MYC protein degradation in a Thr58-
dependent manner (Welcker et al., 2004); this residue is often mutated in cancer (Yada et al., 
2004). Accordingly, FBXW7 is thought to be a tumour suppressor (Welcker et al., 2004). 
FBXW7 is one of the few proteins that stimulates c-MYC degradation by ubiquitination 
(Amati, 2004) and inhibits c-MYC transcriptional activity (Farrell and Sears, 2014). Loss of 
FBXW7 leads to the accumulation of c-MYC protein and excessive proliferation in the 
hematopoietic system and the epidermis (Ishikawa et al., 2013; Matsuoka et al., 2008; 
Thompson et al., 2007). Ablation of FBXW7 leads to the accumulation of c-MYC and 
promotes tumourigenesis in vivo (King et al., 2013). While the turnover of c-MYC is largely 
dependent on FBXW7, SKP2 is another F-box protein of E3 ligase that participates in 
degrading c-MYC by binding to the MB2 domain, whereas FBXW7 targets the MB1 domain 
of c-MYC (Yada et al., 2004).  
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1.3. Ubiquitin Conjugating Enzyme 2C (UBE2C) 
1.3.1. The ubiquitin proteasome system 
In eukaryotes, the ubiquitin proteasome system (UPS) precisely regulates the cell cycle at key 
checkpoints by targeting cell cycle regulators for proteasome-mediated degradation. The UPS 
requires the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and 
ubiquitin ligases (E3) to work in concert to facilitate ubiquitination of target proteins (Figure 
1-6). Of the ubiquitin enzymes, E1 is responsible for activating ubiquitin by attaching the 
molecule to an active site Cys and subsequently transfers the ubiquitin to the E2 active site 
Cys via a thioester linkage. The E2 then donates the ubiquitin from its Cys to Lys of the 
target protein through E3-mediated specificity. The E3 enzyme is also responsible for binding 
to the target protein destined for degradation (Figure 1-6). The human genome contains two 
genes coding for E1, ~38 genes for E2 and >600 genes for E3 (Ye and Rape, 2009). 
 
Figure 1-6. Schematic overview of ubiquitination pathway (Ye and Rape, 2009). 
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While monoubiquitination regulates ubiquitin-dependent endocytosis, reorganisation of 
protein complexes, DNA repair and transcriptional regulation, the labelling of target proteins 
for degradation requires polyubiquitination (Lin et al., 2002; Ye and Rape, 2009). The 
assembly of poly-ubiquitin chains is usually initiated by initiating-E2s through the transfer of 
the first ubiquitin to Lys on a substrate. Subsequently, the E2-E3 pair switches to chain 
elongation. The decision of whether a Lys residue in the substrate or in the ubiquitin will 
receive the next ubiquitin is often made by the elongating E2s. However, some initiating E2s 
extend short ubiquitin chains, before the elongating E2s take over, thereby increasing the rate 
of ubiquitin chain formation. The covalent addition of a single ubiquitin, referred to as 
monoubiquitination, can alter protein localisation or its interactions (Mocciaro and Rape, 
2012; Mukhopadhyay and Riezman, 2007). At least four ubiquitin molecules have been 
attached to Lys48 and Lys11 and are required for targeting proteins for degradation by the 26S 
proteasome (Hershko et al., 1994; Ye and Rape, 2009). In eukaryotes, most proteins are 
degraded by the 26S protein, which is a multi-subunit protease that contains a barrel-like 20S 
proteolytic core particle that houses the active sites and a 19S regulatory particle that governs 
substrate recognition and entering into the 20S core particle (Mocciaro and Rape, 2012; 
Thrower et al., 2000).  
E3 enzymes are grouped according to their domains. The majority of E3 belong to the RING 
domain group including the SCF complex and APC/C complex (Meyer and Rape, 2011). E3s 
have been the focus of many studies due to their deregulation being implicated in cancer. 
However, the crucial role of E2s in the regulation of cell cycle progression and in particular 
cancer development and progression has only been suggested recently.  
Emerging evidence indicates that the ubiquitin-conjugating enzyme 2C (UBE2C) possesses 
oncogenic property. The UBE2C is highly conserved and its human homolog (also known as 
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UbcH10) was cloned in 1997 (Townsley et al., 1997). UBE2C is essential for cell cycle 
progression, as mutation of the active site (Cys114Ser) inhibits destruction of mitotic cyclins 
(Townsley et al., 1997). Accumulation of UBE2C stimulates cell proliferation and 
anchorage-independent growth in vitro and in vivo (Hao et al., 2012). UBE2C mRNA and/or 
protein levels are aberrantly increased in a wide range of human cancers (van Ree et al., 
2010), and high expression of UBE2C is associated with poor clinical outcomes in at least six 
cancer types (Hao et al., 2012; van Ree et al., 2010). Additionally, a tumour phenotype 
emerges when UBE2C is overexpressed in transgenic mice (Hao et al., 2012). 
1.3.2. Structure of UBE2C  
E2s are classified into four classes and all share a conserved core domain containing the 
catalytic Cys residue. Class I consists of the core domain only and requires the presence of an 
E3 for conjugation of ubiquitin. Class II and III have C- and N-terminal extensions from the 
core domain, respectively. These extensions may contribute to target protein recognition and 
regulate the conjugation of ubiquitin to target protein. Class IV contains both C and N-
terminal extensions (Wing and Jain, 1995). UBE2C is a class III E2 enzyme. 
The human UBE2C gene is located at 20q13.12. There are eight transcript variants through 
alternative splicing. The UBE2C protein referred to in this thesis is the product of splice 
variant 1 with the longest reading frame. The full length UBE2C contains 179 amino acids 
with a molecular weight of 19.7 kDa (Lin et al., 2002; Townsley et al., 1997). The first 28 
residues comprise an N-terminal extension with various motifs that will be discussed in detail 
below; the remaining residues form the core domain (Figure 1-7A). The UBE2C protein 
structure (PDB:1I7K) contains a four-stranded antiparallel β-sheet (B1–4), a conserved 310-
helix (310) and four α-helices (H1–4;  Figure 1-7B). It is intriguing to envisage that a protein 
with a size of ~20 kDa is able to interact with three to four different proteins, i.e., ubiquitin, 
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E1, E3 and possibly the target protein (Jiang and Basavappa, 1999). Hence, a unique 
structural feature of UBE2C must be maintained to allow these interactions. 
1.3.3. The E2 core domain 
The catalytic Cys114 responsible for ubiquitin adduct formation is located between B4 and the 
310. The three-residues-per-turn geometry of the 310 places the positively-charged Lys119 
residue in close proximity to the active site Cys114, contributing to ubiquitin adduct formation 
(Lin et al., 2002). The four β turns (1–4) provide the contact surface for the active site Cys114. 
The residues Gln36 (H1), Leu39 (H1), Leu59 (B2) and Phe60 (B2) are predicted to regulate E2 
thioester transfer by interacting with the E1 ubiquitin-fold domain (Olsen and Lima, 2013) 
(Figure 1-7B). UBE2C interacts with the E3 through Loop 1 (89–95), Loop 2 (122–127) and 
the N-terminal H1. The binding residues for APC/C include Lys33, Met43, Met44 and Asp47 in 
H1, Phe53 in B1, Tyr91 and Ala124 in Loop 1 and 2 (Jin et al., 2008; Lin et al., 2002) (Figure 1-
7B). It remains to be determined if UBE2C is recruited by APC2 or APC11 (the core subunits 
of APC/C) or by the binding site created by APC2 and APC11 complex (Nagy et al., 2012; 
Summers et al., 2008). The degradation of UBE2C by ubiquitination also requires Cys114 and 
a destruction box (D-box)-like motif involving residues 129–132 (Arg129-X-X-Leu-X-X-
(Leu132/Ile135)-X-Asp) (Lin et al., 2002; Rape and Kirschner, 2004). UBE2C also contains a 
RWD domain, which includes a key Glu38 residue in H1 and a Tyr89Pro90XXXPro94 motif. 
The UBE2C RWD domain is thought to be involved in the E2–E3 interaction and in E2 
dimer formation (Lin et al., 2002; Nameki et al., 2004).  
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Figure 1-7. The structure of UBE2C.  
A. Predicted functional motifs in UBE2C (1–179). Green, QNP motif (Gln4, Asn5 and Pro8); 
Red, initiation motif (Arg6, Arg17 and Lys18). B. Secondary structure in core domain of 
UBE2C (30–175). Green, α-helices, 310-helix and β-sheets. Yellow stick, active site Cys114. 
Orange, Lys119. The interaction site of UBE2C to E1 (Left) is shown in red, the four β-turns 
near the active site are labelled 1–4 and marked as yellow or blue. The loop 1–2 and the 
interaction sites of UBE2C to APC/C (Right) are shown in red; the D-box like motif is 
shown in blue. This figure was created with PyMOL (PDB ID: 117). 
 
1.3.3.1. The N-terminal extension 
The UBE2C N-terminal extension is not essential for ubiquitin-adduct formation but 
contributes to the regulation of APC/C activity as a part of an inhibitory mechanism (Lin et 
al., 2002). This is achieved mainly by enhancing the sensitivity of APC/C to its 
pseudosubstrate inhibitor Emi1 and BubR1, and by conferring D-box-APC/C engagement, 
which in turn limits the orientation or recruitment of target protein Lys near the E2 active site 
(Summers et al., 2008). In addition, the interaction between the QNP motif (Gln4, Asn5 and 
Pro8) and the APC/C is required for negative regulation of APC/C activity. In the absence of 
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the QNP motif, the UBE2C core domain strongly promotes APC/C activity. The initiation 
motif within the N-terminal extension promotes the autoubiquitination of UBE2C (Rape and 
Kirschner, 2004; Summers et al., 2008; Williamson et al., 2011). Specifically, the candidate 
residues for initiation motif – Arg6, Arg17 and Lys18 – are required for ubiquitin chain 
initiation (Williamson et al., 2011). Deletion of the N-terminal residues 1–27 impairs 
formation of ubiquitin chains (Summers et al., 2008). The N-terminal residues 10–28 are also 
needed for its own degradation by binding to the 26S proteasome (Zhao et al., 2010) (Figure 
1-7B).  
1.3.4. Biological function of UBE2C 
Ubiquitin-conjugating enzyme 2C, as an exclusive partner of APC/C, participates in the 
degradation of a family of APC/C target proteins by initiating Lys11-linked ubiquitin chains 
(Jin et al., 2008; Meyer and Rape, 2011). The human APC/C is composed of 14 subunits, and 
the catalytic core consists of a cullin subunit (APC2) and RING domain subunit (APC11). 
The human APC/C has more than 55 reported target proteins in Homo sapiens. Of these, 37 
are involved in cell cycle S and M phases (e.g., cyclin A, cyclin B, p21 and securin), 11 are 
cell-cycle related in general (e.g., E2-C, E2F1, JNK and SKP2), and two are APC/C co-
activators (CDC20 and CDH1) (Meyer and Rape, 2011).  
1.3.4.1. Ubiquitin conjugation 
The most common degradation motifs in APC/C target proteins are the D-box and KEN-box. 
The D-box is recognised by APC/C co-activators CDC20 and CDH1, whereas the KEN-box 
(with amino acid sequence KEN(X)nP) is recognised by CDH1 only (Meyer and Rape, 2011). 
Upon recruitment by APC/C, CDC20 and CDH1 serve as D- and KEN-box receptors for 
various APC/C target proteins. Following binding to target proteins, APC/CCDC20 and 
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APC/CCDH1 provide a scaffold for UBE2C to be recruited and oriented, such that the UBE2C 
facilitates Lys11-ubiquitin transfer from UBE2C to target proteins (Figure 1-8). A sequence 
element named the TEK box (~20 residues downstream of the D- or KEN-box in target 
proteins) mediates the assembly of Lys11-linked ubiquitin chains. The TEK box forms a 
charged patch around Lys11 and exposes the Lys residue in the target protein to the active site 
of UBE2C, directing Lys11 ubiquitin chain transfer (Jin et al., 2008; Meyer and Rape, 2011). 
By mediating the binding of target proteins to APC/C, the positively-charged initiation motifs 
in the N-terminus of UBE2C allow APC/C to fine-tune the timing of protein degradation (Jin 
et al., 2008).  
 
Figure 1-8. APC/C catalyses the formation of Lys11-linked chains.  
APC/C enhances the ubiquitination of substrates by employing UBE2C enzymes. 
 
1.3.4.2. Degradation of key proteins regulating cell cycle progression 
Ubiquitin-conjugating enzyme 2C is required for destroying mitotic cyclins and other 
mitosis-related substrates (Aristarkhov et al., 1996; Arvand et al., 1998; Rape and Kirschner, 
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2004; Rape et al., 2006). During metaphase, UBE2C promotes anaphase progression by 
degrading securin and cyclin B via APC/CCDC20. Separase is a protease that degrades the 
cohesin rings that link the two sister chromatids together. Typically, securin inactivates 
separase by forming the securin-separase binding complex. By degrading securin and 
consequent activation of separase, sister chromatids are separated and thus UBE2C directly 
promotes anaphase onset (Hao et al., 2012). Cyclin B forms a complex with CDK1 which 
remains active through the cell cycle until mitosis, where UBE2C-APC/CCDC20 induces 
degradation of cyclin B, rendering CDK1 inactive. CDK1 inactivation is required to keep 
CDH1 dephosphorylated and thus forming a complex with APC/C by replacing CDC20. This 
is a prerequisite step for mitotic exit and G1–S progression (Arvand et al., 1998).  
1.3.4.3. Regulation of the mitotic spindle checkpoint 
The metaphase to anaphase transition is tightly controlled by the SAC or mitotic checkpoint 
(Figure 1-9). SAC proteins include Mitotic arrest deficient-like 2 (MAD2), Budding 
uninhibited by benzimidazoles 3 (Bub 3) and Bub Receptor 1 (BubR1). The SAC is on to 
ensure proper kinetochores attachment and correct chromosome segregation. SAC proteins 
inhibit APC/C activity by sequestering CDC20. Upon proper kinetochore attachment, SAC 
function is switched off. UBE2C can also switch off SAC by non-degradative ubiquitination 
of CDC20, causing its dissociation from other SAC proteins. Although this action is APC/C-
dependent, UBE2C plays an indispensable role in controlling the molecular switch of the 
SAC mechanism. Conversely, USP44, a deubiquitinating enzyme, mediates the 
deubiquitination of CDC20 thus preventing premature anaphase onset (Hao et al., 2012; 
Reddy et al., 2007; Williamson et al., 2011). 
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Figure 1-9. The function of UBE2C.  
CDC20 (a co-activator of APC/C) is inhibited by SAC proteins (MAD2, Bub3 and BubR1). ARP/C and UBE2C facilitate the disassembly of 
SAC by ubuitination and USP44 antagonises ubiquitination. The freed CDC20 complexes with APC/C and UBE2C, which in turn enhances 
recruitment of protein for degradation via ubiquitination. Degradation of securing activates seperase, which then degrades the cohesion rings, 
leading to sister chromatids separating and anaphase onset. Degradation of cyclin B inactivates CDK1, which is required to keep CDH1 active 
and thus mitotic exit. D, D-box. KEN, Ken-box. TEK; TEK-box. 
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1.3.5. Expression, activation and turnover 
1.3.5.1. UBE2C expression 
Predicted transcription factor binding sites at the UBE2C promoter have been identified, 
including binding sites for c-Rel, Pax-2, Pax-2a, CP1A, CP1C (GeneCard: GC20P044442), 
NF-1, SRF, TGIF, Meis-1 and c-MYC (Hao et al., 2012). UBE2C can be an AR target gene 
in PCa cells and is responsive to hyperphosphorylated MED1 (Mediator-1, AR co-activator 
mediator-1) in AR-negative PCa cells (Chen et al., 2011). UBE2C expression can also be 
induced by the oestrogen receptor in breast cancer cells (Wang et al., 2013). UBE2C mRNA 
and protein levels were also shown to be upregulated when EWS/FLI1 (a transcription factor 
highly expressed in Ewing’s sarcoma and primitive neuroectodermal tumour) was transfected 
into NIH3T3 cells (Arvand et al., 1998).  
UBE2C is localised in the nucleus and the cytoplasm and its levels are cell-cycle regulated: 
levels of UBE2C are low in G1 (van Ree et al., 2010; Walker et al., 2008) accumulate 
gradually during S and G2 with a peak at mitosis, and then sharply decrease as cells exit from 
mitosis (Arvand et al., 1998; Nath et al., 2011; Walker et al., 2008) (Figure 1-10). However, 
UBE2C levels are not completely undetectable during telophase and early G1 phase (Rape 
and Kirschner, 2004; van Ree et al., 2010; Walker et al., 2008). Van Ree et al. (2010) have 
also shown that the UBE2C staining is low in G1 and G2 phases in mouse embryonic 
fibroblasts, and UBE2C transcript levels are low or undetectable in quiescence (Arvand et al., 
1998; Yamanaka et al., 2000). In quiescent cells induced by contact inhibition or serum 
deprivation, UBE2C mRNA and protein levels are low or undetectable (Arvand et al., 1998; 
Walker et al., 2008). After add-back of 20% fetal calf serum (FCS) for 14 h, UBE2C levels 
began to rise (2 h before cyclin A, i.e., cells progressed towards S phase). Overall, the 
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UBE2C level reappears in G1 phase together with or before cyclin A (Walker et al., 2008) 
(Figure 1-10).  
  
Figure 1-10. Sequential degradation of APC/C substrates during mitosis.  
P, prophase. PM, prometaphase. M, metaphase. A, anaphase. T, telophase (van Ree et al., 
2010; Williamson et al., 2011). 
 
1.3.5.2. UBE2C activation 
Ubiquitin is activated by E1 in an ATP-dependent manner and then transferred to E2. Hence, 
when not bound to E3, free E2s are mostly loaded with ubiquitin (at least four Lys11-linked 
ubiquitins are required for 26S proteasome degradation). Free E2s with pre-loaded ubiquitin 
are available for activation by E3s in order to transfer ubiquitin to a target protein (Ye and 
Rape, 2009). E3s induce conformational change in E2 in the presence of target proteins, 
which positions UBE2C Asn106 near the active site. This stabilises an oxyanion intermediate 
in the transition state, causing the full activation of UBE2C.  
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1.3.5.3. UBE2C turnover 
Interestingly, UBE2C is degraded in a process described as autoubiquitination, in association 
with APC/CCDH1 but not APC/CCDC20 (Grutzmann et al., 2004; Rape and Kirschner, 2004). 
Throughout mitosis, the APC/C is saturated with targeting proteins, which spares UBE2C 
degradation as well as APC/C inactivation. After complete target protein destruction, the 
APC/C ubiquitinates UBE2C (Meyer and Rape, 2011; Rape and Kirschner, 2004). The 
degradation of UBE2C is a slow process because of deubiquitination enzymes (DUBs), 
which remove ubiquitin from UBE2C. Most DUBs are activated upon the dissociation of 
ubiquitin-labelled UBE2C from APC/CCDH1 (Rape et al., 2006). The exact DUB responsible 
for deubiquitination of Lys11-ubiquitin chains is yet to be identified. 
1.3.6. Medical applications 
The role of UBE2C is not limited to promoting cell growth, but also promoting tumour 
invasion and metastasis. Okamoto et al. (2003) examined the expression levels of UBE2C in 
24 human cancerous cell lines by using quantitative real time reverse transcription-
polymerase chain reaction (RT-qPCR). UBE2C mRNA is barely detectable in the majority of 
normal tissues (Okamoto et al., 2003). In contrast, UBE2C mRNA and/or protein is 
expressed at high levels in leukemia, lymphoma and melanoma (TCGA data via cBioPortal: 
UBE2C), and cancers, such as late-stage prostate (Tzelepi et al., 2012; Wang et al., 2009), 
thyroid (Pallante et al., 2005), esophageal (Lin et al., 2006), breast (Berlingieri et al., 2007), 
ovarian (Berlingieri et al., 2007), lung, gastric, colon (Li et al., 2014), bladder and uterine 
(Okamoto et al., 2003; Vasiljevic et al., 2013; Wagner et al., 2004; Xie et al., 2014). An 
association between the levels of UBE2C and tumour grade/poor prognosis is reported in 
cancers of the adrenal gland, breast, colon, liver, lung and ovary (Hao et al., 2012; Okamoto 
et al., 2003; van Ree et al., 2010).  
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The mechanism of UBE2C upregulation in oncogenic conditions is largely unresolved (Nath 
et al., 2011). The amplification of the UBE2C gene has been reported (Hao et al., 2012; 
Vasiljevic et al., 2013). Another possible mechanism is the overexpression or hyperactivation 
of proteins upstream of UBE2C, such as the AR and MED1 in advanced PCa, the oestrogen 
receptor in breast cancer and c-MYC in other cancer types. Out of 7,949 unique cancer 
samples, 20 harbour somatic mutations in UBE2C gene (COSMIC: COSG4332). Based on 
the three-dimensional structure of UBE2C, the Arg129Ser mutation identified in lung 
squamous cell carcinoma tissue (COSMIC: COSM724441) could be biologically significant, 
because alterations in the UBE2C putative D-box motif have been shown to stabilise UBE2C 
against destruction. Conversely, anti-cancer drugs (e.g., tamoxifen, all-trans retinoic acid 
[ATRA], Icaritin, mTOR inhibitor Everolimus, imidazoquinoline derivatives, PI3K inhibitor 
[BEZ235] , cell cycle inhibitor-779 [CCI-779]) and expression of a tumour suppressor gene 
chromosome 2 open reading frame 40 [C2ORF40]) downregulate UBE2C mRNA levels, 
leading to suppression of cancer cell proliferation in vitro and in vivo (Hao et al., 2012; Kato 
et al., 2015; Lu et al., 2013; Sun et al., 2015). UBE2C transgenic mice are prone to develop a 
broad spectrum of spontaneous tumours as well as carcinogen-induced lung tumours with 
evidence of precocious degradation of cyclin B, extra centrioles, chromosome lagging and 
aneuploidy (van Ree et al., 2010). In an in vivo study, UBE2C silencing decreased the 
invasiveness of advanced PCa cells (Wang et al., 2011). Together, these results strongly 
suggest that UBE2C is causally involved in cancer development and progression. 
1.3.6.1. UBE2C in prostate cancer 
The UBE2C-APC/C pathway has recently been implicated in the progression to AR-mediated 
CRPC (Tzelepi et al., 2012; Wang et al., 2009). In a study performed by Wang et al. (2009), 
the authors claimed UBE2C is a CRPC-specific AR target gene, which has an essential role 
in promoting CRPC cell growth by increasing the pool of active APC/C. Recently, two CRPC 
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cell-specific AR-bound enhancers were found to locate between –32.8 kb and +41.6 kb from 
the transcription start site (TSS) of the UBE2C gene. The two enhancers interact with 
UBE2C promoter through chromatin looping in androgen-independent PCa cells (AIPC, 
LNCaP-abl) but not in androgen-dependent PCa cells (ADPC, LNCaP). The chromatin 
looping is required for UBE2C gene expression and AIPC cell growth (Wang et al., 2009). 
Consistent with this notion, silencing of AR co-activator MED1, FoxA1 and AR 
collaborating factor (GATA2), significantly decreased the activity of AR-bound UBE2C 
enhancers and promoters, thus decreasing the UBE2C gene expression in LNCaP-abl but not 
in LNCaP cells. In addition, in an in vivo study, overexpression of UBE2C increased, 
whereas silencing UBE2C decreased, invasiveness of LNCaP-abl and bone metastasised 
subline of LNCaP (C4-2B) but not LNCaP cells (Wang et al., 2011). Collectively, UBE2C is 
AR-dependent but androgen-independent, which is necessary for the progression of AR-
positive CRPC. 
However, the molecular mechanisms underlying UBE2C in AR-negative PCa cells have not 
been fully elucidated. Wang’s group (2011) also investigated the UBE2C enhancer activities 
in PC-3 cells. The mRNA and protein level of UBE2C in PC-3 (AR-negative) cells is 
significantly greater compared with LNCaP (AR positive) cells. By comparing recruitment of 
enhancers to UBE2C promoter in PC-3 and LNCaP cells, greater recruitment of FoxA1 and 
MED1 was found in PC-3 cells. Notably, MED1 is phosphorylated at Thr1032 by PI3K/AKT 
(Wu et al., 2011). Phosphorylated MED1is necessary for UBE2C locus looping by enhancing 
recruitment of FoxA1, Pol II and TATA binding protein (TBP) to the UBE2C promoter and 
increase protein-protein interactions on chromatin (Wu et al., 2011). Nevertheless, UBE2C is 
markedly upregulated in small-cell prostate carcinoma (SCPC), which does not express AR. 
Collectively, the overexpression of UBE2C in AR-negative PCa cells could derive from 
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hyperactive UBE2C enhancers and promoter activity (Tzelepi et al., 2012) induced by 
CDC20 (Nath et al., 2011), p-MED1 and FoxA1 (Chen et al., 2011; Liu et al., 2015).  
Overexpression of UBE2C in cancer cells that do not express AR is poorly understood and 
likely to be complicated. Silencing of UBE2C blocks the cell proliferation of AIPC (abl) and 
AR-negative CRPC (PC-3) cells but not ADPC-AR positive (LNCaP) cells, providing a 
potential new target for therapeutic intervention (Chen et al., 2011; Wang et al., 2009).  
1.4. Hypothesis and Aims  
Collectively, previous studies have suggested that UBE2C may play a role in cell cycle 
regulation and tumourigenesis. The overarching goal of the project is to define the role of 
UBE2C in regulating the proportion of quiescent over proliferative PCa cells and transition to 
a proliferating state by quiescent cancer cells. Moreover, the concordance between UBE2C 
protein/mRNA levels and progression of PCa is determined. 
It is hypothesised that UBE2C plays an important role during cell cycle exit of cycling cells 
and re-entry of quiescent PCa cells. Specifically, exit to G0 phase and cycle re-entry from G0 
phase are accomplished via mechanisms involving UBE2C in regulation of p27, SKP2, 
PIRH2, CRM1, c-MYC and FBXW7.  
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1.4.1. Aims  
The specific aims of this project are:  
1.4.1.1. To define the effect of UBE2C expression on the proportion of 
G0 cells in prostate cancer cells  
To establish the relationship of UBE2C and the proportion of G0 cells, three PCa cell lines 
LNCaP, C4-2B and PC-3 are transfected with UBE2C siRNA or UBE2C expression plasmid. 
The proportion of G0 cells are verified by cell cycle analysis with Hoechst 33258 and Pyronin 
Y double staining. 
1.4.1.2. To verify the effect of UBE2C expression on cell cycle exit and 
cell cycle re-entry in prostate cancer cells  
We utilise contact inhibition in PC-3 or serum withdrawal in LNCaP and C4-2B cells to 
induce cell cycle exit, and replate PC-3 cells at low density or replenish serum in LNCaP and 
C4-2B to render cell cycle re-entry. To evaluate the relationship of UBE2C with cell cycle 
exit, three PCa cell lines are transfected with UBE2C expression vector during exit. To study 
the action of UBE2C on cell cycle re-entry, UBE2C is silenced by RNA interference during 
release from quiescence. The cell cycle distribution and quantification of G0 cells are 
determined by flow cytometry analysis with Hoechst 33258 and Pyronin Y double staining. 
1.4.1.3. To determine the mechanism underlying UBE2C action on cell 
cycle exit and re-entry.  
To identify the mechanisms by which UBE2C influences cell cycle exit in PCa cells, we 
firstly determine the schedule of cell cycle exit (i.e., the time required to synchronise 
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maximal cells at G0 phases) or re-entry (i.e., the time required to release maximal cells from 
G0 phases) with UBE2C expression vector or siRNA. We then determine the change in 
protein levels of G0-regulatory proteins (p27 and c-MYC) and its own regulators through a 
time course. By comparing with the schedule of cell cycle exit or re-entry, we can determine 
if the change in G0-regulatory proteins is prior to or after the change in cell cycle status. This 
is important as it helps to determine if the change in G0-regulatory proteins is the cause or 
consequence of a change in cell cycle status. 
1.4.1.4. To examine the concordance between UBE2C levels and 
progression of prostate cancer  
In order to establish the correlation of UBE2C expression with the PCa progression, the 
protein levels of UBE2C in human PCa tissues are investigated. The protein levels of UBE2C 
are determined in non-cancerous prostate tissues and PCa specimens by 
immunohistochemistry. To further examine whether development of hormone refractory is 
associated with expression of UBE2C, we compared the immunostaining of UBE2C in paired 
PCa specimens obtained from the same patient before and after the development of CRPC. 
To extend the study of UBE2C to mRNA level, differential expression analyses comparing 
PCa microarray with respective non-cancerous tissues as well as clinicopathology-based 
cancer subtypes are explored in 12 prostate datasets download from ONCOMINE database. 
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2. Materials and Methods 
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2.1. Cell Lines and Cell Culture 
2.1.1. Prostate cancer cell lines 
The bone metastasised PCa cell line, PC-3 (Cat. #: CRL-1435; American Type Culture 
Collection, USA), and the lymph node metastasised PCa cell line, LNCaP (Cat. #: CRL-
1740; American Type Culture Collection, USA) and bone metastasised subline of LNCaP, 
C4-2B cells (kindly provided by A/Prof Yong Li, St George Hospital, Research and 
Education Centre, Australia) were grown in RPMI 1640 (Cat. #: A1049101l; Life 
Technologies, Australia) supplemented with 10% v/v fetal bovine serum (FBS, Life 
Technologies, Australia), penicillin (100 U/mL; Sigma Aldrich, Australia) and streptomycin 
(100 μg/mL; Sigma Aldrich, Australia). The prostate epithelial cells (PrEC) were established 
directly from primary cultures of BPH specimens in our laboratory as described (Yao et al., 
2010). PrEC cells were grown in EpiGRO human Prostate Complete Media Kit (hPCM; 
Millipore, Australia). Nontumourigenic HPV18 immortalised human prostate epithelial cells 
RWPE-1 (Cat. #: CRL-11609; American Type Culture Collection, USA) were maintained in 
keratinocyte–serum-free medium (Life Technologies, Australia) supplemented with 5 ng/mL 
human recombinant epidermal growth factor 1-53 (Life Technologies, Australia) and 50 
µg/mL bovine pituitary extract (Life Technologies, Australia). All the cells were cultured at 
37 °C in a humid atmosphere containing 95% air and 5% CO2, with media refreshed every 72 
h.  
2.1.2. Passaging of prostate cancer cells 
Cells were routinely cultured in Corning® T75 flasks (Cat. #430641) to 70–80% confluence. 
To subculture cells, the medium was aspirated and cells rinsed with 5 mL of warm phosphate 
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buffer saline (PBS), followed by 1 mL of TrypLETM Select (GIBCO®, USA) solution at 37 
°C until the cell layer was dispersed. Detached cells were then collected by centrifugation 
(300xg for 6 min) and resuspended in 15 mL fresh cell culture media. Cells were replated at a 
dilution of 1:3 to 1:6 into new T75 flasks. A hemocytometer and trypan blue (Cat#: 
15250061, Thermo Fisher Scientific, Australia) were used to estimate viable cell density prior 
to seeding. The passage number of cells in this study was 19–36 for LNCaP cells, 25–45 for 
PC-3 cells, 17-39 for C4-2B cells. 
2.1.3. Cryopreservation of cell lines 
PC-3, LNCaP and C4-2B cells were prepared for cryopreservation by gently trypsinising sub-
confluent cells with TrypLETM Select. After centrifugation, the cell pellet was first 
resuspended in RPMI containing 20% (v/v) FBS and then added to an equal volume of 10% 
(v/v) DMSO in cell culture medium. Liquid nitrogen cryotanks were used for long-term 
storage of cells. 
2.1.4. Experimental quiescent cell models 
Experimental quiescence was elicited by contact inhibition and serum starvation according to 
a procedure described previously (Yao et al., 2015). PC-3 cells were cultured in 10% FBS to 
achieve 100% confluence and the confluence maintained for 3 days. LNCaP and C4-2B cells 
were grown in the presence of 10% FBS until 70% confluence. FBS was then removed from 
medium for up to 7 days. Quiescent PC-3, LNCaP and C4-2B cells were rendered for cell 
cycle re-entry by split at a low density and serum restoration, respectively. 
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2.2. Transfection  
2.2.1. Small interfering RNA transfection 
Genetic silence of gene expression was achieved using siRNAs derived specifically against 
the UBE2C gene (siUBE2C). The sequence of siUBE2C is demonstrated in Table 2-1; 
Scramble Control (NC) with a non-targeting sequence of the same GC content (Stealth Select 
RNAi™ siRNA, 12935300; Invitrogen, Life Technologies, Australia) was used to disregards 
potential off-target effects of siRNAs. All siRNAs were purchased from Invitrogen (Life 
Technologies, Australia).  
Table 2-1. The sequence of Stealth RNAiTM siRNAs against UBE2C.  
siUBE2C Cat. # Sequence 
Set 1 HSS174074 
5’–CAGUAUAUGAAGACCUGAGGUAUAA–3’ 
5’–UUAUACCUCAGGUCUUCAUAUACUG–3’  
Set 2 HSS145952 
5’–GAACCCAACAUUGAUAGUCCCUUGA–3’  
5’–UCAAGGGACUAUCAAUGUUGGGUUC–3’  
Set 3 HSS145953 
5’–GAAGGUACCUGCAAGAAACCUACUCA–3’ 
5’–UGAGUAGGUUUCUUGCAGGUACUUC–3’  
 
Cells were transfected with 20 nM siUBE2Cs using Lipofectamine™ 2000 (Life 
Technologies, Australia) according to the manufacturer’s protocol. Prior to each experiment, 
Lipofectamine™ 2000 (1:100) and 40 nM siUBE2C were mixed with Opti-MEM medium 
(GIBCO®, USA) and incubated for 5 min in separate tubes at room temperature. 
Lipofectamine™ 2000 solution and siRNA solution were combined in a 1:1 ratio and 
incubated at room temperature for 20 min. The mixture was then mixed with the desired 
number of cells and plated according to experiment set-up (Table 2-2). The media was 
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replenished after 8–24 h and cells left to propagate for a maximum of 7 days from exposure 
to siRNA. 
Table 2-2. The amount of siUBE2Cs and Lipofectamine™ 2000 used for siRNA transfection in 
experiment set-ups. 
Transfection reagent 
96-well 
plate 
6-well  
plate 
T25  
flask 
T75  
flask 
siRNA mixture         
NC/siUBE2C (µL) 0.25 2.5 5 10 
Opti-MEM (µL) 25 250 500 1000 
Lipofectamine™ 2000 mixture     
Lipofectamine™ 2000 (µL) 0.25 2.5 5 10 
Opti-MEM (µL) 25 250 500 1000 
Total per well or flask (µL) 50 500 1000 2000 
Complete medium (µL) 200 2000 4000 8000 
Final concentration (nM) 20 20  20  20  
 
2.2.2. Plasmid transfection  
pJS55 plasmid-encoding UBE2C-AU1 (Cat. #: 8506; Addgene, Cambridge, MA) and 
dominant negative (C114S) UBE2C-DN (Cat, #: 8507; Addgene, Cambridge, MA) was 
kindly provided by Dr. J. V. Ruderman. Competent DH5alpha cells were incubated with 
DNA plasmid (1 μg) for 30 min on ice. The transformation mix was heated at 37 oC for 1 min 
and then incubated for 2 min on ice. The transformation mix was inoculated on a 10 cm agar 
plate with ampicillin (100 μg/mL) for overnight selection Individual colonies grown on LB 
plates were collected and grown overnight in LB medium containing ampicillin (100 µg/mL) 
at 37 °C with continuous shaking. DNA purification was performed using the QIAprep Spin 
Midi Kit (Qiagen, USA) according to the manufacturer's instructions. 
For overexpression, PC-3 cells were transfected with 1.5 μg UBE2C plasmid, dominant 
negative (DN) UBE2C plasmid, or control empty vector using Lipofectamine™ RNAiMAX 
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(Invitrogen, Life Technologies, Australia) according to the manufacturer’s protocol. Prior to 
each experiment, Lipofectamine™ RNAiMAX (7 µL per 1.5 µg plasmid) and vectors were 
mixed with Opti-MEM medium (GIBCO®, USA) and incubated for 5 min in separate tubes at 
room temperature. Lipofectamine™ RNAiMAX solution and plasmid solution were 
combined into a 1:1 ratio and incubated at room temperature for another 20 min. The mixture 
was then mixed with the desired number of cells in a 50 mL Eppendorf tube for 2 h. The 
media was replenished after 2 h and cells left to propagate for a maximum of 72 h post-
transfection followed by cell cycle analysis or protein extraction.  
2.3. Cell Cycle Analysis 
2.3.1. Flow cytometry analysis of the cell cycle using 
propidium iodide 
PC-3 or LNCaP cells seeded in 6-well plates were treated with siUBE2Cs and NC according 
to above procedures. At the end of treatment, the cells were trypsinised, spun down and re-
suspended in 300 μL PBS. The cells were then fixed by adding 700 μL ethanol drop-wise to 
each sample under a constant vortex and then stored at 4 ºC for at least overnight. Following 
fixation, cells were washed in PBS and incubated in PBS containing 20 μg/mL propidium 
iodide (PI) and 100 μg/mL RNase for 1 h. The cells were then washed and resuspended in 
PBS with 5% (v/v) FBS before being measured by flow cytometry analysis. Positive nuclear 
stained with PI were gated and cells in each cell cycle phase measured using FlowJo (Version 
10; Tree Star Inc., USA). 
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2.3.2. Flow cytometry analysis of the cell cycle using Hoechst 
33258 and Pyronin Y 
The PCa cells treated in T25 flasks were rinsed by warm PBS, tripsinised and collected for 
cell counting. Cells were pelleted by centrifugation at 300xg for 6 min, and resuspended in 
300 µL PBS. To fix cells, 700 µL ethanol was added slowly in to each sample during vortex. 
The fixed samples were then stored at –20 °C until use. After being washed twice with PBS 
containing 5% FBS, the cell suspensions were incubated in PBS containing Hoechst 33258 (4 
µg/mL; Sigma Aldrich, Australia) at 37 °C for 45 min in the dark, then Pyronin Y (8 µg/mL; 
Sigma Aldrich, Australia) was directly added to each sample for a further 15 min incubation. 
The staining solution was removed and cells were resuspended in 500 µL of PBS and 
subjected to flow analysis with the flow cytometer (FACSCanto II) equipped with BD 
FACSDiva software (BD Biosciences, Australia) and then analysed using FlowJo software 
(Version 10; Tree Star Inc., USA). 
2.3.3. Flow cytometry analysis of the cell cycle using Hoechst 
33258, Pyronin Y and p-Rb (p-Ser807/811) 
For co-staining with p-Rb (p-Ser807/811),  the cell suspensions were incubated in PBS 
containing Hoechst 33258 (4 µg/mL; Sigma Aldrich, Australia) and p-Rb (p-Ser807/811) with 
Alexa Fluor® 647 (20 µL/test, BD Biosciences, Australia) at 37 °C for 45 min in the dark, 
then Pyronin Y (8 µg/mL; Sigma Aldrich, Australia) was directly added to each sample for a 
further 15 min incubation. The staining solution was removed and cells were resuspended in 
500 µL of PBS and subjected to flow analysis. 
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2.4. SYBR Green Assay 
The PCa cells were plated in 96-well plates at 6,000 cells per well for PC-3 and C4-2B cells 
and at 10,000 cells per well for LNCaP cells in 200 µL of medium supplemented with serum. 
To overexpress or knockdown UBE2C, 50 µL of the Opti-MEMTM medium containing the 
siUBE2Cs or plasmid was added to each well. The same number of cells was aliquoted as at 
baseline and stored at –80 °C until use. After each indicated time, the medium was gently 
aspirated from the plates and rinsed twice with cold PBS. 100 µL of lysis buffer containing 
SYBR Green (Cat. #: S-7563, Invitrogen, Life Technologies, Australia) at 1:10,000 v/v 
dilution was added to each well. The lysis buffer was made up of nine portions of buffer A 
(10 mM Tris-pH 7.5 and 2 M NaCl) and one portion of buffer B (100 mM Tris-pH 7.5, 200 
mM disodium EDTA and 10% Triton X-100). The cells were then lysed in the dark for 30 
min. The frozen aliquots used as baselines were thawed at room temperature, lysed in the 
same buffer and transferred to the treatment plate containing the same type of cells. The 
fluorescence intensity of SYBR Green-stained DNA was measured using a plate reader 
(FLUOstar Omega; BMG Labtech, Germany) and the change of SYBR Green intensity over 
the study period was determined by subtracting baseline fluorescence intensity from each 
treatment. 
2.5. Immunoblotting 
2.5.1. Protein extraction 
Cells were washed twice with cold PBS (Amresco) and incubated with lysis buffer (RIPA-
buffer, containing 65 mM Tris, 50 mM NaCl, 10 M HCl, 5 mM EDTA, 1% NP-40, 0.5% 
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sodium deoxycholate, 0.1% SDS and 10% glycerol at pH 7.4 (Sigma Aldrich, Australia); 1% 
(v/v) 5 M sodium fluoride; 1% (v/v) protease inhibitor cocktail  (Calbiochem,  Millipore, 
USA) on ice in darkness for 20 min. Cells were then scraped off by rubber policemen 
(Costor, Mexico) on ice and collected into 1.5 mL Eppendorf tubes; all pipette tips, rubber 
policemen and Eppendorf tubes were pre-chilled at –20 ⁰C to preserve protein in cell lysates. 
To further avoid protein loss, samples were spun at highest speed for 30 seconds to eliminate 
air bubbles. Sonication or the ‘freeze and thaw method’ were performed to further break open 
cell nuclear membranes, release nuclear contents and thus homogenise proteins from cellular 
cytoplasm and nuclei. To avoid protein denatured during sonication, samples were sonicated 
on ice. 
2.5.2. Protein quantification 
The protein concentration was determined using Bio-Rad detergent compatible (Dc) protein 
assay (Bio-Rad Laboratories, CA). For reference purposes, bovine serum albumin (BSA; 10 
mg/mL; Sigma Aldrich, Australia) was diluted with RPIA buffer to 7 known concentrations 
(0, 0.25, 0.5, 1, 2, 3 and 4 mg/mL). A 96-well plate was used and duplicates were performed 
for each standard and sample. Each well was loaded in sequence with 25 μL of a solution of 
Reagent A (an alkaline copper tartrate solution), 5 μL of BSA protein standard/sample, and 
200 μL of Reagent B (a dilute Folin reagent). The plate was incubated in darkness for 15 min 
for colour reaction and the absorbance was measured at 690 nm using a spectrophotometer 
(FLUOstar Omega Microplate Reader; Imgen Technologies, VA). All the absorbance values 
were subtracted with the mean absorbance of blank wells. Protein concentrations of cell 
lysates were evaluated using the trend-line equation of a BSA standard curve. A standard 
curve was prepared each time the assay was performed. The loading volume required for 50 
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µg of protein was calculated based on the protein concentration of each sample. Samples 
were then aliquoted and stored in –80 °C until further analysis. 
2.5.3. Gel preparation 
There are two sodium dodecyl sulphate polyacrylamide gels (SDS-PAGEs): the resolving gel 
and the stacking gel. The sieving properties of SDS-PAGE gels are determined by the 
percentage of acrylamide and hence the pore size of the gel; for example, on lower 
percentage polyacrylamide gels, acrylamide forms a loose mash network, so proteins move 
through the gel at a faster rate. The stacking gel was 4% (low) acrylamide gel, whereas, the 
percentage of resolving gel (8–12.5%) was chosen according to the molecular weight of the 
protein of interest (shown in Table 2-3). The lower the molecular weight of the protein, the 
greater the acrylamide concentration was used and vice versa (Figure 2-1). 
 
Table 2-3. The component of resolving gel and stacking gel. 
 
Percentage of gel 8% 10% 12.50% Percentage of stack 4% 
40: 0.8% w/v 
acrylamide: 
bisacrylamide 
1 mL 1.25 mL 2.35 mL 
40:0.8% w/v 
acrylamide: 
bisacrylamide 
500 µL 
1.0 M Tris-HCl pH 
8.8 3 mL 3 mL 3 mL 1 M Tris-Cl pH6.8 630 µL 
20% SDS 38 µL 38 µL 38 µL 20% SDS 25 µL 
dH2O 3.421 mL 2.921 mL 2.35mL dH2O 3.655 mL 
Mix together. Add APS and TEMED just before pouring 
10% APS 36 µL 36 µL 36 µL 10% APS 25 µL 
TEMED 7.5 µL 7.5 µL 7.5 µL TEMED 5 µL 
Total volume 7.5 mL 7.5 mL 7.5 mL Total volume 5 mL 
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Figure 2-1. The separation and migration of proteins by SDS-PAGE. 
The distribution of proteins by size (kDa) in different percentages of acrylamide gels (Bio-Rad, Australia). 
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The Mini-PROTEAN® cell kit from Bio-Rad was used for gel casting. Two glass gel plates 
(1.5 mm) were assembled and locked into green Bio-Rad frame clips and subsequently into 
the gel casting stand. To make each gel, the solutions required to resolve the gel monomer are 
shown in Table 2-3; 10% ammonium persulphate (APS; Sigma-Aldrich, USA) and N, N, N’, 
N’-tetramethylethylenediamine (TEMED; Merck, USA) were added just prior to pouring the 
gel. The mixture of reagents was promptly poured into assembled gel plates and a small layer 
of distilled water added on the top to produce a clean, straight top of the resolving gel. The 
distilled water was poured off after 45 min polymerisation. Similarly, the stacking gel 
mixture (Table 2-3) was then poured on top of the resolving gel in the assembled glass plates. 
A 10- or 15-well (1.5 mm) comb was seated and aligned with the top of the short plate to 
form the loading wells. Following 30 min of polymerisation, the gel casting was wrapped in 
plastic wrap and stored at 4 °C with running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS). 
2.5.4. Transferring 
After electrophoresis was complete, the power supply was turned off and the electrical leads 
disconnected. The gel was removed from the gel cassette by carefully separating the two 
glass gel plates using the releaser. Proteins on the resolving gel were transferred onto a 
nitrocellulose membrane (Hybond™-C Extra; Amersham Biosciences, USA) for 
immunoblotting analysis. Prior to transferring, nitrocellulose membranes, filter papers and 
sponges were soaked in transferring buffer (25 mM Tris, 192 mM glycine with 10-20% 
methanol). The transfer cassette sandwich (Mini Trans-Blot Cell; Bio-Rad) was assembled in 
the following order: a) 1 layer of filter sponge, b) 4 layers of filter paper, c) gel, d) 
nitrocellulose membrane, e) 4 layers of filter paper, and f) 1 layer of filter sponge. Wet- 
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transfer was then carried out at 100 V for 2–3 h on ice. During transfer, the transfer buffer 
was stirred to maintain an even ion distribution and temperature in a mini-tank. 
2.5.5. Blocking and immunodetecting 
Following transfer, the nitrocellulose membrane was washed in 1X PBST (10X PBS solution 
and 0.05 % (v/v) TWEEN®20, pH 7.5) for 5 min to remove SDS in the transferring buffer. To 
avoid nonspecific antibody binding, membranes were blocked in 1% skim milk in 1X PBST 
for 30–60 min. Membranes were then washed three times in 1X PBST, changing the buffer 
every 5 min. All primary antibody hybridisation was performed in PBST with 1% skim milk. 
The optimal dilution of each primary antibody, which was determined experimentally, is 
listed in Table 2-4. Membranes were incubated with primary antibody overnight at 4°C. The 
next day, membranes were washed three times in PBST for 15 min, changing the buffer every 
5 min. Then the membranes were incubated with horse radish peroxidase (HRP)-conjugated 
secondary antibody (anti-mouse A4416 or anti-rabbit A0545; Sigma-Aldrich, Australia) and 
Precision Strep Tactin-HRP Conjugate (Bio-Rad, Australia) for at least 3 h on ice. All 
secondary antibodies were diluted 1:10000 in PBST with 1% skim milk. The membranes 
were rinsed in PBST and incubated with SuperSignal West Pico Chemiluminescent Substrate 
(Cat #:34078; Thermo Fisher Scientific, Australia) or Clarity™ Western ECL (enhanced 
chemiluminescence) Blotting Substrate (Cat #:1705060, Bio-Rad, Australia). 
Immunolabelled protein bands were captured by ChemiDoc™ XRS+ System (Bio-Rad, 
Australia). Two loading controls, α-TUBULIN and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), were used to avoid overlapping signals from proteins of interest 
that had a similar molecular weight. Densitometry of the immunoblot results was performed 
using software Image J (1.38x, National institutes of health, USA) to quantify the ratio of 
53 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 2 
band intensity between the protein of interest and the housekeeper protein (GAPDH or α-
TUBULIN). 
Table 2-4. Primary antibody in western blotting. 
Antigen Supplier Cat. # Species Dilution % Gel Molecular size (kDa) 
p27  Santa Cruz sc-528 Rabbit 1 in 500 10.00% 27 
PIRH2  Santa Cruz sc-67033 Rabbit 1 in 500 10.00% 36 
SKP2  Santa Cruz sc-7164 Rabbit 1 in 500 10.00% 42 
c-MYC  Santa Cruz sc-70469 Mouse 1 in 500 10.00% 60 
UBE2C  Boston Biochem A-650 Rabbit 1 in 1000 12.50% 19 
FBXW7  Abcam ab180472 Rabbit 1 in 1000 10.00% 110 
CRM1  Santa Cruz sc-74454 Mouse 1 in 1000 10.00% 110 
GAPDH  Santa Cruz sc-137179 Mouse 1 in 20000 6.0–12.5% 37 
α-TUBULIN Santa Cruz sc-5286 Mouse 1 in 10000 6.0–12.5% 50 
 
2.6. Immunostaining 
2.6.1. Prostate cell pellet preparation 
The expression of UBE2C was determined by immunostaining. The experimental cells in 
each T75 flask were washed twice by PBS and detached by TriplETM Select. All cells within 
the cell culture media, PBS and TriplETM Select were collected by centrifugation (300xg for 6 
min) into 1.5 mL Eppendorf tubes. Cell pellets were fixed in 10% formalin at 4 ºC overnight. 
The formalin was removed by centrifugation and the cells were washed in PBS again, coated 
and solidified in agarose (2% agarose in PBS), dehydrated and embedded in paraffin blocks. 
5 µm sections were cut on a microtome (FinessTM, Thermo Fisher Scientific, Australia) and 
collected onto Superfrost Plus slides (Menxel-Glaser, Germany). Slides were dried at 45 ºC 
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overnight. In addition, slides were baked at 60 oC for 20 min to minimise the possibility that 
sections may come off the slides prior to immunostaining.  
2.6.2. Human tissue preparation 
The collection of patient specimens for the analysis in this study was approved by the Central 
Sydney Area health Service (X04-318) and Western Area Health Service Ethics Committee 
(HREC2000/9/4.18 [1089]). Immediately after surgery with tumour-free resection margins, a 
sample of prostate tumour tissue was obtained. Specimens were delivered to the pathology 
lab and macroscopically analysed by pathologists who also selected a small cancer fragment 
before fixation. Human tissue samples contained adjacent BPH and PCa tissue (n=17), 
unpaired BPH (n=36) and PCa (n=70), and paired Hormone sensitive PCa (HSPC) and CRPC 
(n=8). The paired HSPC and CRPC specimens (n=8) were derived from patients who initially 
underwent transurethral resection of the prostate and were diagnosed with PCa, but after 
ADT became castration resistant. The 5 µm section of the human tumour tissues sample was 
provided by Dr Charles Chan and his colleagues as described previously (Tan, 2011). 
Fractionated tissue sections were then stored at −80 °C till use.  
2.6.3. Immunostaining analysis 
For deparaffinisation, sections were left in xylene for 20 min for cell samples, and overnight 
for human tissues, and rehydrated in downgrading ethanol (100%, 95%, and 70%) through to 
distilled water. Heat-induced antigen retrieval was performed to at least partially reverse the 
formalin-modified tertiary structure of proteins. Tissue sections were heated in 10 mM Tris-
EDTA buffer (20.0 mM Tris, 13.4 mM EDTA, 12.4 mM tri-sodium citrate, 0.05% 
TWEEN®20, pH 8.0) for 20 min. Slides were left in hot buffer, cooled down at room 
temperature and rinsed with distilled water. Slides were again washed in Tris-buffered saline 
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containing TWEEN®20 (TBST; 200 mM Tris-HCl, 150 mM NaCl, 10 mM Tris-base, 0.5% 
TWEEN®20, pH 7.5). To reduce hydrophobic binding of primary antibody to tissue proteins, 
sections were blocked by incubating slides with 10% v/v normal animal horse serum (NHS; 
JRH, USA) in TBST for 20 min. 10% NHS was flicked off prior to incubation in the primary 
antibody. All primary antibody labelling was performed in 10% horse serum in TBST, 
overnight at 4 ºC. Primary antibody was not added to 10% NHS in TBST in the method 
control slides. Simultaneously, isotype control was carried out with rabbit or mouse 
immunoglobulin (DakoCytomation, Denmark) at the same concentration as the primary 
antibody.  
As avidin interacts with biotin with high affinity, peroxidase-conjugated avidin was mixed 
with biotin to form a large complex prior to secondary antibody incubation. Sequentially, the 
avidin-free sites in the peroxidase-conjugated complex interacted with the biotin-conjugated 
secondary antibody; thus, a positive signal was amplified. The next day, biotin-conjugated 
secondary anti-rabbit or anti-mouse antibody (Vector Laboratories, Australia) and Vectastain 
Avidin-Biotin complex kit (ABC; Vector Laboratories, Australia), were diluted to 1:1000 in 
TBST contains 1% NHS. Slides were incubated with secondary antibody and ABC for 30 
min and 40 min at room temperature, respectively. Between each of these incubations, 
sections were rinsed with distilled water and TBST. For peroxide enzymes, 3’ 
diaminobenzidine tetrachloride (DAB) chromogen is used to produce a brown colour in 
labelled positive cells. Sections were therefore incubated with DAB (Dako, USA) for 6 min 
or until brown colour was observed. The reaction was stopped by rinsing the slides with 
distilled water. Haematoxylin counterstain was carried out, followed by quick dips in acidic 
ethanol and Scott’s Blue solution, a cellular nuclear counterstain developed for blue staining. 
The slides were dehydrated in graded alcohol (75%, 95% and 100%) and mounted in Di-n-
butylPhthalate in Xylene (DPX; BDH, England). 
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2.7. Reverse Transcription and Quantitative Real-Time 
Polymerase Chain Reaction 
2.7.1. Preparation of total RNA samples 
Media was aspirated from the 6-well plates, and then the plates were washed twice with cold 
PBS before incubation with 350 μL of each lysis buffer (RLT buffer, containing guanidine 
thiocyanate (Qiagen, USA); and 14.3 M (1% v/v) β-mercaptoethanol (Sigma-Aldrich, 
Australia) on ice for 10 min. Cells were then lysed, flicked and collected. Sterile, RNase-free 
pipette tips were used to transfer the cell lysates to Qiagen shredder purple columns to clean 
up cell pellet debris. The flow through obtained from the columns was collected by 
centrifugation for 2 min at maximum speed. The flow through were then mixed with an equal 
amount of 70% RNase-free ethanol prior to transfer to Qiagen mini-pink columns. The 
Qiagen mini-pink columns were centrifuged for 15 seconds at maximum speed to allow the 
precipitated RNA to bind to the column matrices. The resulting flow through – containing 
ethanol, DNA debris and lysis buffer – was discarded. RNA precipitate was first washed by 
700 μL of RW1 buffer to remove RNA-bound protein. Flow through – containing protein and 
ethanol – was collected by centrifugation at maximum speed for 15 seconds, and discarded. 
To remove any remaining heavy metal, DNA, wash buffer and/or ethanol, the sample was 
washed twice with second wash buffer (RPE) and centrifuged again at maximum speed for 1 
min. The samples within the Qiagen mini-pink columns were transferred to fresh RNase-free 
tubes. Commercially available RNase-free water (30 μL) was added to dissolve RNA and 
total RNA was then extracted by centrifugation for 1 min. The quality and quantity of the 
extracted RNA samples was determined using the NanoDorp ND-1000 Spectrophotometer 
(Biolab, Australia).  
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2.7.2. Reverse transcription  
To enable the PCR analysis of RNA molecules, single strand RNA was transcribed into 
DNA. A reverse transcriptase (RT) enzyme was utilised alongside an oligonucleotide primer, 
to create a complementary DNA (cDNA) copy.  
Primers were designed to cross exon-intron boundaries, preventing the amplification of 
genomic DNA. The RT reaction commenced with the addition of 50 ng/mL Random 
Hexamer, 20 mM dNTP mix and 50 μM Oligo (dT), 2 μg samples having been made up to 20 
μL with diethylpyrocarbonate (DEPC)-treated water. Following 5 min at 65 ºC to denature 
the secondary structure of RNA, samples were cooled down with ice for a minimum of 1 min. 
10 μL of Synthesis Mix (10X RT buffer, 25 mM MgCl2, 0.1 M DTT, 40 U/μL RNase OUT 
and 200 U/μL SuperScript III RT; Invitrogen, USA) was added prior to incubation. Non-RT 
controls – sample with no SuperScript III – were included to verify the contamination level of 
cDNA, which may have yielded less than optimal results. Final incubation temperatures 
varied:  
Annealing: 25 ºC for 10 min 
cDNA synthesis: 50 ºC for 50 min 
Terminate reaction: 85 ºC for 5 min 
Store cDNA: hold at 4 ºC  
Store samples: hold at –20 ºC until use.  
2.7.3. Polymerase chain reaction  
Each reaction per sample contained master mix (SYBR Green I, diluted 1:400 from stock 
solution; Invitrogen, USA), qPCR (a ‘ready-to-use’ cocktail containing dNTPs, 3 mM MgCl2 
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and Platinum Taq Polymerase; Invitrogen, USA), forward and reverse primers and DEPC-
treated water) and diluted cDNA template, made up to a 20 μL.  
Primers were synthesised by Geneworks (Hindmarsh, Australia). Each primer set (forward 
and reverse) was designed to exclude genomic DNA from amplification as follows. 
UBE2C primer sequence  
Forward: 5′–TGGTCTGCCCTGTATGATGT–3' 
Reverse: 5′–AAAAGCTGTGGGGTTTTTCC–3' 
TBP primer sequence  
Forward 5′–GAACCACGGCACTGATTTTC–3' 
Reverse: 5′–CCCCACCATGTTCTGAATCT–3' 
p27 primer sequence  
Forward: 5'–GGCCTCAGAAGACGTCAAAC–3'  
Reverse: 5'–ACAGGATGTCCATTCCATGA–3'  
c-MYC primer sequence  
Forward: 5'–GGATTTTTTTCGGGTAGTGGAA–3'  
Reverse: 5'–TTCCTGTTGGTGAAGCTAACGTT–3' 
15 μL of the primer with master mix were loaded into each of the sample tubes to ensure 
accurate distribution between samples. A total of 5 μL of cDNA was diluted by 620 μL water 
in each template sample so that 5 μL of template (1/625 dilution) was added to the pre-loaded 
master mix sample tubes. This was performed to ensure accurate distribution of sample 
cDNA. Triplicates were carried out for each sample to obtain more reliable data.  
2.7.4. Standard curve  
Each run was performed with a standard for the housekeeping or GOI, a non-RT control, and 
no-template controls (water blank) for each primer set and efficacy of each standard was 
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compared. Standard samples were prepared using serial 1:5 dilutions of one template cDNA 
sample, with a starting concentration of 1/625 dilution for a total of five standard points (each 
dilution run in triplicate). 5 μL of each standard template was again added into separate pre-
loaded housekeeping and GOI master mix sample tubes.  
Samples were amplified using a Rotor-gene 6.0 RT-PCR machine set to the following 
conditions:  
1st hold temperature: 50 ºC for 2 min 
2nd hold temperature: 95 ºC for 10 min 
Cycling of three PCR temperatures:  
95 ºC for 10 seconds  
56 ºC for 15 seconds  
72 ºC for 20 seconds 
40 repeat cycles  
3rd hold temperature: 65 ºC for 90 seconds 
Melt curve start temperature: 65 ºC 
Raise by 1 ºC each step 
Hold 5 seconds on each step afterwards 
End temperature: 95 ºC 
 
2.7.5. Data analysis  
The peak present in the melt curve occurs when there is a rapid increase in the rate of 
fluctuating florescence. Fluorescence decreases as temperature increases. Non-template 
control (water) only displays a peak when primer dimers are present.  
The threshold cycle parameter (CT) is the calculated fractional cycle number at which the 
PCR product crosses a threshold of detection (Figure 2-2). The higher the initial amount of 
template DNA, the more PCR products is accumulated. In addition, a high initial amount of 
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template DNA also results in the fluorescent intensity reaching the threshold value earlier, 
i.e., a lower CT value. The change of the CT Value was then notmaliazed with TBP and 
analysed by The Relative Expression Software Tool (REST, version 2009).   
 
Figure 2-2. The RT-PCR amplification plot features.  
CT value is the cycle number at which the set threshold crosses into the exponential phase. 
The slope of this exponential phase is a measure of efficiency.  
 
2.8. Statistical Analysis 
Statistical comparison was performed using NCSS/PASS version 12.0 (NCSS Statistical and 
Power Analysis Software, USA). The scores of UBE2C level in prostate tissue were analysed 
by paired t-test. The processed data was analysed using one-way ANOVA to determine if a 
significant change had occurred. Fisher’s least significant difference multiple-comparison test 
(significance at p<0.05) and Kruskal-Wallis multiple-comparison z-value test (significance at 
z-value >1.96) were applied. 
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3. The Effect of Manipulation 
of UBE2C Expression on the 
Proportion of Quiescent 
Prostate Cancer Cells  
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3.1. Introduction 
In a mature mammalian prostate gland, the majority of epithelial cells are in a state of 
proliferative quiescence (Hartwell et al., 1974; Kriegenburg et al., 2008). Only a select 
population of cells, referred to as stem cells, proliferate in a controlled manner to replenish 
lost cells or those damaged after injury (Visvader and Clevers, 2016). Cancer is a 
consequence of uncontrolled cell proliferation. When cancer cells cease proliferation, either 
due to specific anti-mitogenic signals or to the absence of proper mitogenic signaling, they 
exit the cell cycle and enter a quiescent state; these cells also known as quiescent cancer cells 
(Malumbres and Barbacid, 2001). Quiescent cancer cells, which are Ki-67 protein-negative 
and arrest in a reversible state of G0, have been found in various cancers including prostate 
(Coller, 2007; Jackson, 1989). Hence, cancer is made up of both actively proliferative and 
quiescent cancer cells. Recent studies in PCa have shown that the increased proportion of 
proliferative over quiescent ratio in PCa cells represents an inherent mechanism that at least 
partially explains recurrence in PCa patients (Almog, 2010; Brackstone et al., 2007; 
Udagawa, 2008). Ki-67 protein immunostaining in PCa showed a low positivity in low grade 
and low volume disease, but increases in high risk and advanced disease, suggesting an 
accelerated transition from quiescent to a proliferative state during disease progression 
(Jhavar et al., 2009; Keshari et al., 2011; Khatami et al., 2009; Nagao et al., 2011). These 
clinical observations propose that a strategy to prevent cancer progression and recurrence is 
to increase the exit of cycling cancer cells to G0 phase and/or to prevent the transition from 
G0 to a proliferating state. However, our understanding of the signals required for 
maintaining cancer cells at G0 and/or impeding the transition from quiescent to proliferating 
state is limited. 
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UBE2C is an E2 enzyme that, when associated with an E3 ligase, mediates the proteolysis of 
a series of key mitotic cell cycle regulators (Xie et al., 2014). UBE2C is considered an 
oncogene associated with a variety of cancers and its overexpression is associated with 
proliferation of tumour cells (Hao et al., 2012). In PCa cells, overexpression of UBE2C 
promoted cell proliferation, whereas depletion of UBE2C expression suppresses growth of 
cells (Wang et al., 2011). Importantly, van Ree et al. (2010) showed that overexpression of 
UBE2C alone in mice is sufficient to induce a broad spectrum of spontaneous tumours as 
well as carcinogen-induced lung tumours. These data further support the oncogenic role of 
UBE2C in tumour development. However, whether UBE2C play a role in the proportion and 
transition of quiescent cancer cells is unclear.  
The aim of studies described in this chapter is to define if UBE2C plays a role in influencing 
the proportion of quiescent PCa cells.  
3.2. Materials and Methods 
3.2.1. Prostate cancer cell lines 
The PCa cell line LNCaP, PC-3 and C4-2B cells and the noncancerous prostate cells, PrEC 
and RWPE-1, were cultured as described in Chapter 2.1.1.  
3.2.2. Immunocytochemistry  
The sample blocks were prepared as described in Chapter 2.6.1. The Expression of UBE2C 
in cells was determined by immunocytochemical staining as described in Chapter 2.6.3. 
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3.2.3. Transfection of prostate cancer cells with siRNA 
Prostate cancer cells were transfected with 20 nM siUBE2C or NC and seeded in 6-well 
plates for immunoblotting or qRT-PCR, in T25 flask for flow cytometry analysis or in 96-
well plates for SYBR Green assay   as described in Chapter 2.2.1. 
3.2.4. Transfection of prostate cancer cells with plasmid  
For overexpression, PCa cells were gown in T75 flasks until semi-confluent, cells were then 
trypsinised and transfected with plasmid according to Chapter 2.2.2. Thereafter, cells were 
harvested for SYBR Green assay, immunoblotting, qRT-PCR or flow cytometry analysis. 
3.2.5. SYBR Green assay 
The DNA content of PCa cells was determined using SYBR Green assayThe fluorescence 
intensity of SYBR Green-stained DNA was measured as decribed in Chapter 2.4. 
3.2.6. Immunoblotting 
The cells were treated in 6-well plates and cell lysates were prepared with a lysis buffer. 
Immunoblotting was performed as described under Chapter 2.5. The primary antibodies 
used in this section were listed in Table 2-4. 
3.2.7. Flow cytometry analysis of cells stained with 
propidium iodide 
The cell cycle phase distribution of PCa cells was determined by flow cytometric analysis of 
cells stained with PI as described in Chapter 2.3.1.  
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3.2.8. Flow cytometry analysis of cells stained with DNA and 
RNA dye 
The cell cycle phase distribution of PCa cells was determined by flow cytometric analysis of 
cellular DNA and RNA content as described in Chapter 2.3.2. The triple staining with p-Rb 
(p-Ser801/811) was performed as described in Chapter 2.3.3. 
3.2.9. Statistical analysis  
The statistical software NCSS version 12.0 was used for statistical analysis as described in 
Chapter 2.8 
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3.3. Results 
3.3.1. Knockdown of UBE2C increased the quiescent 
subpopulation in prostate cancer cells 
3.3.1.1. Determine UBE2C expression in prostate cell lines by 
immunocytochemical analysis 
To determine the expression of UBE2C in all PCa cell lines used in this study, immuno-
cytochemical analysis was performed. Immunostaining of PCa cell lines with anti-UBE2C 
antibody showed positive staining in LNCaP cells, PC-3 and C4-2B cells (Figure 3-1). 
Expression of UBE2C was observed at both the membrane and cytoplasm in all PCa cells. 
There was a negative or low staining in non-cancerous cell lines including PrEC and RWPE-
1 cells. No staining was seen in the cells incubated with antibody isotype control.  
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Figure 3-1. Expression of UBE2C in prostate cell lines.  
Prostate cell lines were maintained in T75 flasks and allowed to reach 70–80% confluence. Cells were then collected and embedded in 
paraffin, sectioned and stained with anti-UBE2C antibody (A-165, 1:600). Representative images of non-cancerous prostate cells (PrEC and 
RWPE-1) and PCa cell lines (LNCaP, PC-3 and C4-2B) were taken at 400X magnification. Scale bar=20 µm.  
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3.3.1.2. Effect of UBE2C siRNA on UBE2C expression by 
immunoblotting 
To validate the effect of UBE2C knockdown, we transfected three PCa cell lines (PC-3, 
LNCaP and C4-2B) with UBE2C siRNAs. PC-3, LNCaP and C4-2B cell lines were treated 
for 72 h with Opti-MEM, NC or three sets of siUBE2C, and lysates were analysed by 
immunoblotting. Results showed UBE2C knockdown is more effective in siUBE2C set 1 
(C1) and set 3 (C3) compared to set 2 (C2) in all three PCa cell lines (Figure 3-2). 
Accordingly, C1 and C3 were selected for further study. 
3.3.1.3. Knockdown of UBE2C decreased cell proliferation in prostate 
cancer cell lines 
The hallmark for cell proliferation is the synthesis of DNA. To monitor the change of cellular 
DNA content upon UBE2C knockdown, SYBR Green assay was performed on PC-3, LNCaP 
and C4-2B cell lines. SYBR Green is a dye of double-stranded DNA. DNA content was 
significantly reduced in PC-3, LNCaP and C4-2B cells following UBE2C knockdown 
compared with control cells (p<0.05). Transfection of LNCaP cells with siUBE2C C1 and C3 
reduced SYBR Green intensity by 65% and 33%, respectively within 3 days compared to 
control cells. An approximate 50% and 90% reduction was observed in PC-3 and C4-2B 
cells, respectively (Figure 3-3).  
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Figure 3-2. Evaluation of knockdown of UBE2C with siUBE2C.  
PCa cells were seeded in 6-well plates with Opti-MEM, 20 nM NC or siUBE2Cs, including 
C1, C2 and C3. Cells were lysed 72 h post-transfection. Levels of UBE2C protein in PC-3, 
LNCaP and C4-2B cells were examined by western blot (anti-UBE2C antibody, A-165, 
1:1000). α-TUBULIN expression was determined as a control to assure equal protein 
loading. A. Representative immunoblotting image in PCa cells. B. Histogram representing 
densitometric analysis are mean±SD. *, P< 0.05 versus NC in each cell line. The results are 
representative of three experiments. 
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Figure 3-3. Effect of UBE2C knockdown on DNA content in prostate cancer cells.  
PC-3, LNCaP and C4-2B cells were transfected with 20 nM NC, C1 or C3 in 96-well 
plates; non-treated cells included as baseline. After 72 h transfection, cells were harvested, 
stained with SYBR Green and analysed for DNA content. Results are expressed as mean ± 
SD of three independent experiments. * p<0.05 as compared with NC in each cell line. 
 
3.3.1.4. Genetic silencing of UBE2C in cell cycle distribution by 
propidium iodide staining  
To delineate the cell cycle status of PCa cells, the cell cycle phase distribution of PCa cells 
was analysed by measuring the DNA content using flow cytometric analysis of PI-stained 
cells (Figure 3-4). The doublets were gated out by using PI parameters Area versus Width as 
shown in Figure 3-4A. The selected singlet cells were then presented in a DNA frequency 
histogram (Figure 3-4B–D). On the basis of differences in DNA content alone, G0/G1 cells 
were identified with low DNA content; G2/M cells with DNA content twice that of G0/G1 
cells; and S phase cells with intermediate DNA content. The DNA content histograms (Figure 
3-4B–D) were deconvoluted using FlowJo-V10 Dean-Jett-Fox model algorithms. The 
average percentage of cells in G0/G1 phase for human PCa cell lines maintained in log phase 
growth was 44.1% for PC-3 cells, 33.8% for LNCaP cells and 53.7% for C4-2B cells.  
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To validate the role of UBE2C in cell cycle phase distribution, we next genetically knocked 
down UBE2C in PCa cell lines. PCa cells were treated with NC or siUBE2Cs, the protein 
level of UBE2C was measured after 24, 48 and 72 h treatment by western blot (Figure 3-5). 
The expression of UBE2C protein was reduced in both C1 and C3-treated PC-3 and C4-2B 
cells 24 h after siUBE2Cs transfection. Notably, 48–72 h was required for both sets of 
siUBE2C to diminish UBE2C protein levels in LNCaP cells, suggesting a cell line-dependent 
difference in response to siUBE2C in the three PCa cell lines. 
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Figure 3-4. DNA content histogram of prostate cancer cell lines using single parameter 
flow cytometer (PI staining).  
Prostate cell lines were maintained in T25 flasks and allowed to reach 70–80% confluence. 
Cells were then collected and fixed in 70% ethanol at 4 ºC. The cells were then stained by 
PI and subjected to flow cytometric analysis. A. The single cells were gated out by using PI 
parameters Area versus Width. B. DNA content histogram of PC-3 cells. C. DNA content 
histogram of LNCaP cells. D. DNA content histogram of C4-2B cells. This figure was 
created with FlowJo Dean-Jett-Fox model. The Dean-Jett-Fox model fitted the 2N 
population with a purple Gaussian distribution, the 4N population with a green Gaussian 
distribution, and the S population with a yellow polynomial.  
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Figure 3-5. Expression of UBE2C in siUBE2C-transfected prostate cancer cells.  
PC-3, LNCaP and C4-2B cells were transfected with 20 nM NC, C1 or C3 in 6-well plates 
with a time course experiment. The cells were harvested 24, 48 and 72 h following 
transfection. Levels of UBE2C protein in PC-3, LNCaP and C4-2B cells were examined by 
western blot analysis. A. Representative immunoblotting image in PCa cells. B. Histogram 
representing densitometric analysis are mean± SD. *, P< 0.05 versus NC in each cell line. 
The results are representative of three experiments. 
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Next, we examined the effects of siUBE2Cs on cell cycle progression by PI staining. In PC-3 
and C4-2B cells, reducing UBE2C protein levels caused an increase in the proportion of cells 
in G2/M phase, compared to the cells treated with NC. Furthermore, the PC-3 cells in G0/G1 
phase were decreased upon siUBE2C transfection, whereas no change was observed in C4-
2B cells. However, loss of UBE2C in LNCaP cells increased the fraction of cells in G0/G1 but 
no significant change in the fraction of cells in S and G2/M phase. The average percentage of 
each phase of the cell cycle in three different PCa cell lines after knockdown UBE2C over 3 
days are summarised in Table 3-1. 
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Table 3-1. The effect of siUBE2C on cell cycle distribution analysed by PI flow (Mean±SD). 
 
Phase 
G0/G1 (%) S (%) G2/M (%) 
PC-3 cells 
24h 
NC 46.0 ± 3.4 24.6 ± 0.3 27.3 ± 3.7 
C1 44.2 ± 1.8 29.1 ± 3.3 24.6 ± 0.6 
C3 42.2 ± 0.2 30.9 ± 0.2* 24.2 ± 1.4 
48h 
NC 47.3 ± 1.6 27.7 ± 1.6 22.5 ± 1.6 
C1 36.9 ± 1.3* 25.9 ± 0.1 34.9 ± 1.0 
C3 51.3 ± 5.6 26.2 ± 1.3 20.0 ± 1.0 
72h 
NC 48.9 ± 0.1 27.3 ± 0.4 20.6 ± 0.5 
C1 45.2 ± 0.6 26.7 ± 3.8 25.9 ± 4.0* 
C3 38.6 ± 0.9* 24.5 ± 0.1 38.6 ± 0.6* 
LNCaP cells 
24h 
NC 65.4 ± 0.9 17.9 ± 2.4 14.2 ± 0.4 
C1 63.3 ± 1.6 21.1 ± 0.8 14.0 ± 0.7 
C3 65.0 ± 0.2 20.9 ± 1.1 13.2 ± 0.4 
48h 
NC 62.2 ± 1.8 17.7 ± 0.4 13.5 ± 3.7 
C1 63.3 ± 5.9 22.6 ± 3.7 11.2 ± 1.0 
C3 63.3 ± 3.3 21.8 ± 1.1 13.8 ± 2.8 
72h 
NC 60.8 ± 1.6 15.1 ± 0.6 15.4 ± 2.3 
C1 60.6 ± 3.6 18.5 ± 1.3 10.3 ± 1.4 
C3 68.4 ± 0.8* 17.7 ± 1.1 11.4 ± 0.8 
C4-2B cells 
24h 
NC 45.2 ± 1.0 38.5 ± 0.7 13.8 ± 1.4 
C1 43.9 ± 1.0 42.4 ± 1.8 12.0 ± 1.2 
C3 40.8 ± 0.7 40.7 ± 0.0 13.7 ± 0.6 
48h 
NC 61.4 ± 2.5 21.1 ± 1.9 15.0 ± 1.1 
C1 63.4 ± 1.5 23.7 ± 3.8 11.2 ± 1.6 
C3 65.0 ± 0.6 23.8 ± 1.1 10.6 ± 0.0 
72h 
NC 67.1 ± 3.7 25.5 ± 1.1 5.7 ± 0.5 
C1 64.6 ± 1.4 25.4 ± 2.0 7.4 ± 0.9* 
C3 66.1 ± 0.8 25.4 ± 0.8 7.2 ± 0.0* 
 
For PI-cell cycle analysis, the cells were fixed in 70% ethanol and kept at –20 ºC until PI 
staining followed by flow cytometry. Representative quantification data of three 
independent double staining experiments. * p<0.05 vs. NC. 
 
77 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 3 
3.3.1.5. Depletion of UBE2C decreased Ki-67 staining in PC-3 cells 
Since the effects of silencing of UBE2C on the proportion of cells in G0/G1 phase varies 
between different cell lines, we employed immunocytochemical staining of Ki-67 to further 
elucidate the role of UBE2C on the proportion of quiescent and proliferating cells. PC-3 cells 
were used to determine the expression of Ki-67. Ki-67 staining demonstrated a marked 
decrease in the percentage of Ki-67-positive cells in both sets of siUBE2C-treated PC-3 cells 
compared to NC-treated control cells (Figure 3-6). Collectively, knockdown of UBE2C is 
expected to increase the proportion of G0 cells in PC-3 cells. 
 
Figure 3-6. Ki-67 staining in siUBE2C-treated PC-3 cells.  
PC-3 cells were transfected with 20 nM NC, C1 or C3 in T75 flasks for 72 h. Prostate cell 
lines were maintained in T75 flasks and allowed to reach 70–80% confluence. Cells were 
then collected and embedded in paraffin, sectioned and stained with anti-Ki-67 antibody 
(1:2000). Representative image (200X magnification) of PC-3 cells with Ki-67 staining was 
taken at 200X magnification. Scale bar=50 µm. 
 
3.3.1.6. Validation of flow cytometric analysis of HP double staining by 
quiescent prostate cancer cells 
The decreased Ki-67-positive PC-3 cells together with decreased G0/G1 phase in the same 
cell line raised an interesting possibility: although the fraction of cells in G0 and G1 phase 
decreased, the proportion of G0 over proliferating G1 cells could be altered. We employed HP 
double staining to further elucidate this possibility. The HP double staining method provides 
an in vitro measurement to distinguish cells in G0 from G1 phase. To verify the method, the 
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PCa cells were synchronised at G0 and then measured by flow cytometric analysis using HP 
double staining. By using both Ki-67 immunostaining and PI staining, our laboratory 
previously demonstrated that to achieve quiescence in PC-3 and LNCaP cells requires 3 days 
contact inhibition (CID3) and 7 days serum withdrawal (SWD7), respectively (Yao et al., 
2015). Consistent with our published previous PI staining result, cell stains with HP double 
staining also showed about 80% of PC-3 cells and 90% of LNCaP cells were synchronised 
into G0/G1 phase (Figure 3-7 and Figure 3-8).  
To further validate the method, we performed a time course experiment to synchronise PC-3, 
LNCaP and C4-2B cells at indicated time intervals (Figure 3-7, Figure 3-8, Figure 3-9). By 
simultaneously determining DNA and RNA content, G0 cells were gated out by their low 
Pyronin Y staining (low total RNA content) and 2N DNA content (Figure 3-7). Flow 
cytometric analysis revealed a significant increase in G0 cells in synchronised PC-3 (Figure 
3-7), LNCaP (Figure 3-8) and C4-2B cells (Figure 3-9) in a time-dependent manner, 
compared to non-synchronised PCa cells (p<0.05). The percentage of cells in G0 phase was 
28% in non-contact inhibited (NOCI) cells, but approximately 70% after synchronisation in 
CID3 samples (Figure 3-7). In addition, our observations were consistent with the notion that 
although the total percentage of cells in G0/G1 remained around 85% during 3 days’ contact 
inhibition, there was a significant increase in the G0 population but a decrease in the G1 
population.  
Similar results were observed in LNCaP and C4-2B cells. The proportion of cells in G0 phase 
increased from 14.6% to 76.7% in LNCaP cells after 7 days’ serum withdrawal (Figure 3-8), 
while C4-2B cells rose from 11.5% to 84.8% upon synchronisation (Figure 3-9). 
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Figure 3-7. Validation of HP double-staining in PC-3 cells.  
NOCI, PC-3 cells were cultured in 10% FCS with no contact inhibition. Cells were analysed 
for cell cycle distribution by HP double staining by simultaneously labelling the cells with 
both DNA and RNA. Boxes outline cells in G0, G1, S and G2/M. G0 and G1 both have 2N 
DNA content so the G1 box is directly over the G0 box, with the G0 cells having less total 
RNA. CID1–CID3, PC-3 cells were maintained in a confluent state in T25 flasks for up to 3 
days. Thereafter, cells were collected for cell cycle analysis by using the same gating.  
A. Representative flow image in PC-3 cells. B. Histogram illustrates the cell cycle 
distribution during cell cycle exit. * p<0.05 vs. NOCI. 
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Figure 3-8. Validation of HP double staining in LNCaP cells.  
10% FCS, LNCaP cells were grown in 10% FCS medium in T25 flasks. Cells were analysed 
for cell cycle distribution by HP double staining by simultaneously labelling the cells with 
both DNA and RNA. Boxes outline cells in G0, G1, S and G2/M. SWD3-D5; LNCaP cells 
were serum-deprived in T25 flasks for up to 7 days. Thereafter, cells were collected for cell 
cycle analysis by using the same gating. A. Representative flow image in LNCaP cells.  
B. Histogram illustrates the cell cycle distribution during cell cycle exit. * p<0.05 vs. 10% 
FCS. 
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Figure 3-9. Validation of HP double staining in C4-2B cells.  
10% FCS, C4-2B cells were grown in 10% FCS medium in T25 flasks. Cells were analysed 
for cell cycle distribution by HP double staining by simultaneously labelling the cells with 
both DNA and RNA. Boxes outline cells in G0, G1, S and G2/M. SWD3-D5; C4-2B cells 
were serum-deprived in T25 flasks for up to 7 days. Thereafter, cells were collected for cell 
cycle analysis by using the same gating. A. Representative flow image in C4-2B cells. B. 
Histogram illustrates the cell cycle distribution during cell cycle exit. * p<0.05 vs. 10% 
FCS. 
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3.3.1.7. Validation of flow cytometric analysis of HP double staining by 
p-Rb (Ser807/811)  
It is well established that Rb is hypophosphorylated at Ser807/811 in quiescent cells, resulting in 
an inhibition of cell cycle progression (Serrano et al., 1993; Sherr and Roberts, 1995). To 
further validate the HP double staining method, PCa cells were co-stained with HP double 
stain and anti-p-Rb (Ser807/811) with Alexa Fluor® 647antibody. Simultaneous incubation with 
anti-p-Rb (Ser807/811) antibody demonstrated an equivalent staining pattern as Pyronin Y when 
compared to Hoechst staining, as shown in Figure 3-10. The low RNA content cells were 
indeed hypophosphorylated at Ser807/811. Morover, the staining patterns for p-Rb (Ser807/811) 
and Pyronin Y were highly correlated in all three PCa cells, further demonstrating the 
capability of HP double staining to accurately distinguish G0 cells from G1 cells (Figure 3-
11). 
Therefore, HP double staining was employed in subsequent studies to determine the cell 
cycle distribution, including quiescent cells. Additionally, 3 day contact inhibition and 7 day 
serum withdrawal were used to render quiescence in PCa cells for the following studies. 
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Figure 3-10. Distribution of cell cycle in PC-3 cells.  
PC-3 cells were cultured in 10% FCS with no contact inhibition; cells were collected and 
fixed in 70% ethanol and kept at –20 ºC until Hoechst, Pyronin Y and p-Rb (p-Ser807/811) 
with Alexa Fluor® 647 triple staining and subsequent flow cytometry. A and B. The 
bivariate dot pot of DNA and RNA. A. Boxes outline quiescent cells, and cells in G1, S and 
G2/M phases. B. Boxes outline proliferative cells and quiescent cells. C and D. The 
bivariate distribution of DNA and p-Rb (p-Ser807 /811). This figure was created with FlowJo. 
The cells gated in A and B was converted to C and D by change Pyronin Y parameter to p-
Rb parameter. C. Cells in blue correspond to quiescent cells gated in Figure A, Red refers 
to G1 cells, yellow refers to S phase cells and green refers to G2/M cells. D. Cells in blue 
correspond to quiescent cells, whereas red refers to proliferative cells gated in Figure B. 
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Figure 3-11. The correlation of p-Rb (p-Ser807/811) and Pyronin Y in prostate cancer cell lines. 
Non-synchronised and synchronised PCa cells were collected and fixed in 70% ethanol and 
kept at –20 ºC until Hoechst, Pyronin Y and p-Rb (p-Ser807/811) with Alexa Fluor® 647 
triple staining and subsequent flow cytometry. The image is a representative bivariate dot 
plot of p-Rb (p-Ser807/811) and RNA in PCa cells. FCS, baseline cells with 10% FCS. SWD7, 
serum withdrawal for 7 days. NOCI, no contact inhibition. CID3, contact inhibition 3 days. 
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3.3.1.8. Knockdown of UBE2C increased the G0 subpopulation in PC-3 
cells 
To determine the effect of UBE2C on PC-3 cell cycle status including the G0 subpopulation, 
PC-3 cells were transfected with 20 nM NC or siUBE2Cs for up to 3 days and subjected to 
HP double staining. Upon 48 h UBE2C knocking down, the escalation in the level of 
quiescence became significant compared to NC (p<0.01). The percentage of cells in G0 phase 
was 23% in control cells, but 36–40% after being treated siUBE2Cs (Figure 3-12). 
Consistently, there was a significant decrease in G1 population following 24 h siUBE2Cs 
treatment compared to the NC (p<0.01). At 48 and 72 h, both the decrease in G0 and increase 
in G1 fractions reached significance compared to the NC (p<0.01). Depletion of UBE2C also 
led to G2/M arrest following 3 days siUBE2C transfection (p<0.01). However, silencing of 
UBE2C did not significantly change the subpopulation of S phase cells in PC-3 cells (p=0.3). 
These results provide evidence that UBE2C-knockdown arrested PC-3 cells at G0 phase of 
the cell cycle. 
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Figure 3-12. Knockdown of UBE2C induced cell cycle exit in PC-3 cells.  
PC-3 cells were transfected with 20 nM NC, C1 or C3 in 6-well plates with a time course 
experiment. The cells were harvested 24, 48 and 72 h following transfection. Cells were 
analysed for cell cycle distribution by HP double staining by simultaneously labelling the 
cells with both DNA and RNA. Boxes outline cells in G0, G1, S and G2/M. Representative 
flow image and quantification data of three experimental repeats. * p<0.05 vs. NC for each 
time point. This figure was created with FlowJo-V10. 
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3.3.1.9. Knockdown of UBE2C increased the G0 subpopulation in 
LNCaP cells 
To investigate the effect of UBE2C in LNCaP, cells were transfected with control or 
siUBE2Cs and cell cycle distribution was analysed by HP double staining. LNCaP cells 
displayed a significant accumulation of cells in G0 at 72 h post-transfection of siUBE2Cs 
compared to NC (p<0.01). The percentage of cells in G0 phase was 23% in control cells, but 
43% after treatment with C1 and 48% in C3-treated cells (Figure 3-13). A significant 
decrease in G1 population was found following 3 days siUBE2Cs treatment compared to the 
NC (p<0.01). Knockdown of UBE2C also led to a significant arrest in the G2/M phase of the 
cell cycle after 48 and 72 h transfection. We found no effect of UBE2C knockdown on the S 
phase in LNCaP cells (p=0.7). These results indicate the loss of UBE2C led to accumulation 
of G0 phase of the cell cycle in LNCaP cells. 
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Figure 3-13. Knockdown of UBE2C induced cell cycle exit in LNCaP cells.  
LNCaP cells were transfected with 20 nM NC, C1 or C3 in 6-well plates with a time course 
experiment. The cells were harvested 24, 48 and 72 h following transfection. Cells were 
analysed for cell cycle distribution by HP double staining by simultaneously labelling the 
cells with both DNA and RNA. Boxes outline cells in G0, G1, S and G2/M. Representative 
flow image and quantification data of three experimental repeats. * p<0.05 vs. NC for each 
time point. This figure was created with FlowJo-V10. 
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3.3.1.10. Knockdown of UBE2C increased the G0 subpopulation in C4-
2B cells 
To further investigate the effect of UBE2C in cell quiescence, C4-2B cells were transfected 
with either NC or siUBE2Cs and the distribution of G0 cells was monitored by HP double 
staining (Figure 3-14). There was a 73% increase in population of quiescent cells upon 
UBE2C knockdown for 48 h compared to control cells, and the fraction of G0 cells was 
observed to reach the maximum at 72 h (227% of control; p<0.01). The decrease in 
population of cells in G1 and S phases become significant 48 h after siUBE2Cs transfection 
compared to control cells. In addition, knocking down UBE2C increased G2/M-phase cells 
following 3 days siUBE2Cs treatment compared to the NC (p<0.01). These results indicate 
decrease of UBE2C promoted the accumulation of G0 cells in C4-2B cells. 
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Figure 3-14. Knockdown of UBE2C induced cell cycle exit in C4-2B cells.  
C4-2B cells were transfected with 20 nM NC, C1 or C3 in 6-well plates with a time course 
experiment. Cells were analysed for cell cycle distribution by HP double staining by 
simultaneously labelling the cells with both DNA and RNA. Boxes outline cells in G0, G1, S 
and G2/M. Representative flow image and quantification data of three experimental repeats. 
* p<0.05 vs. NC for each time point. This figure was created with FlowJo-V10. 
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In summary, the population of quiescent G0 cells was elevated by downregulation of UBE2C 
protein levels in all three PCa cells lines. A time line illustrating the change of UBE2C 
protein and the cell cycle distribution is summarised in Table 3-2. 
Table 3-2. The summary schedule for the change of UBE2C protein level relative to cell cycle 
distribution in LNCaP, PC-3 and C4-2B cells after siUBE2C treatment.  
, indicates a significant change compared to NC, p<0.05. 
 
3.3.2. Overexpression of UBE2C decreased the quiescent 
subpopulation in prostate cancer cells 
We have shown that knockdown UBE2C increased quiescent cells. To further confirm the 
functional role of UBE2C in cell cycle status, UBE2C was overexpressed in PCa cells, the 
cell proliferation was determined by SYBR Green assay, and the cell cycle distribution was 
analysed by HP double staining.  
3.3.2.1. Overexpression of UBE2C confirmed by immunoblotting 
To validate the role of UBE2C overexpression on PCa cells, we first measured the level of 
exogenous UBE2C expression in three PCa cell lines by western blotting. The pJS55 plasmid 
containing UBE2C-AU1 (UBE2C) or DN UBE2C-AU1 was kindly provided by Dr JV 
Ruderman (Harvard Medical School, Boston, MA) (Townsley et al., 1997). The UBE2C and 
UBE2C-DN differ by a cysteine-to-serine conversion at residue 114, which is part of the 
UBE2C active site. The PC-3, LNCaP C4-2B cells treated with empty vector were included 
as another negative control. UBE2C protein levels were increased within the first 24 h post-
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transfection and reached the maximum at 48 h in PC-3 and C4-2B cells, whereas an effective 
increase in UBE2C protein levels was only shown 48 h post-transfection in LNCaP cells 
(Figure 3-15). 
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Figure 3-15. Expression of UBE2C in prostate cancer cells by western blotting.  
Expression vector containing empty vector (Empty), UBE2C or UBE2C-DN was transfected 
into PCa cells. The cell culture media were replenished after 2 h following induction; cells 
were harvested 24, 48 and 72 h following transfection. Cells were then lysed and analysed 
by immunoblotting. A. Representative immunoblotting image in PCa cells. B. Histogram 
representing densitometric analysis are mean± SD. *, P< 0.05 versus Empty vector in each 
cell line. The results are representative of three experiments. 
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3.3.2.2. Upregulation of UBE2C expression promoted cell proliferation 
by SYBR Green assay 
To determine the effect of an increase in UBE2C levels on cell proliferation, PC-3, LNCaP 
and C4-2B cells were transfected with empty vector, or vector containing UBE2C or UBE2C-
DN, and subjected to SYBR Green assay. All three PCa cells showed a significant increase in 
DNA content 48 h after transfection with UBE2C vector compared with empty vector 
(p<0.05; Figure 3-16). UBE2C-DN was also included to determine if UBE2C activity is 
required for cell proliferation. There was no difference observed in cells cultured with 
plasmids containing UBE2C-DN compared to empty vector control (Figure 3-16). These 
observations suggest that the UBE2C active site is involved in UBE2C-mediated cell growth 
promotion. 
 
Figure 3-16. The overexpression of UBE2C increased cell proliferation in prostate cancer cells 
by SYBR Green assay.  
Expression vector containing empty vector (Empty), UBE2C or UBE2C-DN was transfected 
into PC-3 and LNCaP cells. The cell culture media were replenished after 2 h following 
induction; cells were harvested 48 h following transfection. * p<0.05 vs. empty vector. 
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3.3.2.3. Upregulation of UBE2C expression reduced G0 cell distribution 
in PC-3 cells by HP double staining 
To measure the cell cycle progression, in particular the percentage of cells in G0 phase, PC-3 
cells were transfected with either empty vector, or vector containing UBE2C or UBE2C-DN, 
then cell cycle distribution was analysed by HP double staining (Figure 3-17). Comparing the 
percentage of cells in G0 phase revealed overexpression of UBE2C reduced G0 cells by 35–
46% after 24, 48 and 72 h transfection compared to empty vector-treated cells (p<0.05). In 
addition, the G1 population following UBE2C transfection was significantly raised compared 
to the cells cultured in the presence of empty vector (p<0.05). We found excess UBE2C-DN 
expression had no impact on the distribution of the cell cycle in PC-3 cells (Figure 3-17). 
Together, our observation indicates the upregulation of wild type UBE2C expression 
promotes cell cycle progression in PC-3 cells. 
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Figure 3-17. The effect of overexpressing UBE2C on cell cycle distribution in PC-3 cells.  
Expression vector containing empty vector (Empty), UBE2C or UBE2C-DN was transfected 
into PC-3 cells. The cell culture media were replenished after 2 h following induction, cells 
were harvested 24, 48 and 72 h following transfection. For cell cycle analysis, cells were 
fixed in 70% ethanol and kept at –20 ºC until Hoechst and Pyronin Y staining and 
subsequent flow cytometry. Quantification data of three independent experiments in PC-3. 
* p<0.05 vs. empty vector. # p<0.05 vs. wild type UBE2C transfected sample. 
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3.3.2.4. Upregulation of UBE2C reduced G0 cell distribution in LNCaP 
cells by HP double staining 
To examine whether the overexpression of UBE2C regulated G0 cell distribution, LNCaP 
cells were co-stained with HP and subjected to flow analysis. Similar to PC-3 cells, 
overexpression of UBE2C in LNCaP cells decreased the subpopulation of G0 cells compared 
to the cells treated with empty vector (p<0.01; Figure 3-18). Moreover, LNCaP showed a 
higher fraction of G1 and S phase cells after 48 h transfection. We found excess UBE2C-DN 
expression had no impact on the distribution of the cell cycle in LNCaP cells. However, the 
percentage of cells in G2/M phase was slightly escalated with excess expression of UBE2C 
and UBE2C-DN (p<0.05). Collectively, these results suggesting that the amplification of wild 
type UBE2C promoted cell cycle progression in LNCaP cells. 
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Figure 3-18. The effect of UBE2C vector on the proportion of cells in G0 in LNCaP cells.  
Expression vector was transfected into LNCaP cells. The cell culture media were 
replenished after 2 h following induction; cells were harvested 48 h following transfection. 
For cell cycle analysis, cells were fixed in 70% ethanol and kept at –20 ºC until HP staining 
and subsequent flow cytometry. Representative flow image and quantification data of three 
independent experiments in LNCaP cells. * p<0.05 vs. empty vector. Empty, empty vector. 
DN, vector containing UBE2C-DN. 
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3.3.2.5. High expression of UBE2C reduced G0 cell distribution in C4-
2B cells by HP double staining 
To determine whether the upregulation of UBE2C regulated G0 cell distribution in PCa cells, 
C4-2B cells were co-stained with HP and analysed by cell cycle analysis. Comparing the 
percentage of cells in G0 phase revealed overexpressing UBE2C in C4-2B cells reduced G0 
cells by approximately 20–30% after 48 and 72 h transfection compared to empty vector-
treated cells (p<0.05; Figure 3-19). Furthermore, C4-2B cells showed a higher fraction of G1 
after 48 h transfection. We found UBE2C-DN expression had no significant impact on the 
distribution of the cell cycle in C4-2B cells. Collectively, these results suggesting that the 
amplification of wild type UBE2C promoted cell cycle progression in C4-2B cells. 
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Figure 3-19. The effect of overexpressing UBE2C on cell cycle distribution in C4-2B cells.  
Expression vector containing empty vector (Empty), UBE2C or UBE2C-DN was transfected 
into C4-2B cells. The cell culture media were replenished after 2 h following induction, 
cells were harvested 24, 48 and 72 h following transfection. For cell cycle analysis, cells 
were fixed in 70% ethanol and kept at –20 ºC until Hoechst and Pyronin Y staining and 
subsequent flow cytometry. Quantification data of three independent experiments in PC-3. 
* p<0.05 vs. empty vector. # p<0.05 vs. wild type UBE2C transfected sample. 
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3.3.3. Overexpression of UBE2C impeded cell cycle exit in 
prostate cancer cells 
3.3.3.1. UBE2C protein levels are reduced during cell cycle exit 
As noted above, the expression of UBE2C appears to be correlated to the proportion of 
quiescent and proliferating cells in PCa cells. To verify the presence of this correlation 
between UBE2C expression and in-cell cycle progression, we then examined the UBE2C 
level in PCa cells during cell cycle exit. The experimental quiescence of three PCa cell lines 
was achieved and verified in Figure 3-7-Figure 3-9. The decline of UBE2C protein was 
started at day 1 after contact inhibition or serum withdrawal for each of the cell lines. Further 
decrease of UBE2C was found in a time-dependent manner. To diminish UBE2C into an 
undetectable level in LNCaP and C4-2B cells required 5 days serum deprivation, whereas 3 
days contact inhibition was not able to reduce UBE2C level completely in PC-3 (Figure 3-
20). The timeframe required to enrich quiescent cells and the corresponding UBE2C level 
during cell cycle exit in PCa cells is summarised in Table 3-3. 
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Figure 3-20. The expression of UBE2C protein during cell cycle exit.  
A. PC-3 cells were rendered to quiescent status by 3 day contact inhibition. B. LNCaP and 
C. C4-2B cells were made quiescent by 7 day serum withdrawal. Levels of UBE2C protein 
in PC-3, LNCaP and C4-2B cells were examined by western blot analysis. α-TUBULIN 
expression was determined as a control to assure equal protein loading. NOCI, no contact 
inhibition. CID3, contact inhibition 3 days. FCS, baseline cells with 10% FCS. D1–7, day 
1–7 with serum withdrawal. The results are representative of three experiments. Left. 
Representative immunoblotting image in PCa cells. Right. Histogram representing 
densitometric analysis are mean± SD. *, P< 0.05 versus NOCI or FCS in each cell line. The 
results are representative of three experiments. 
 
Table 3-3. The timeframe required for enriching quiescent cells and the corresponding UBE2C 
level during cell cycle exit in prostate cancer cells.  
Re-entry 
UBE2C 
level by 
Western 
blot 
D1 D2 D3 D5 D7 
Change in 
G0 fraction 
by flow 
cytometry 
D1 D2 D3 D5 D7 
PC-3 ↓ ↓↓ ↓↓↓ 
  
↑ ↑↑ ↑↑↑ 
  LNCaP ↓ ↓↓ ↓↓ ↓↓↓ ↓↓↓ 
  
↑ ↑↑ ↑↑ 
C4-2B ↓ ↓↓ ↓↓ ↓↓↓ ↓↓↓ 
  
↑ ↑↑ ↑↑↑ 
↓, a decrease occurred. ↑, an increase occurred. The number of arrows indicates the level of 
change. D1–7, time following contact inhibition or serum starvation. 
103 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 3 
3.3.3.2. Overexpression of UBE2C impeded cell cycle exit in PC-3 cells 
Based on the study described above, the UBE2C level is decreased during cell cycle exit. 
However, whether the decreased UBE2C protein level is a cause or a merely a reflection of 
cell cycle status was unknown. To investigate the effects of UBE2C on cell cycle 
progression, we first transfected PC-3 cells with either empty, UBE2C or UBE2C-DN vector. 
Next, these transfected PC-3 cells were induced to quiescence by maintaining 100% 
confluency for indicated time intervals (Figure 3-21). Cells were then subjected to HP double 
staining and subsequent flow cytometric analysis. Upon contact inhibition, the fraction of G0 
cells was increased in a time-dependent manner in all cells. But, the increase in the fraction of 
G0 in UBE2C-transfected cells was less than that in empty and UBE2C-DN treated PC-3cells, 
suggesting the high expression of UBE2C significantly delayed cell cycle exit of PC-3 cells. 
It is interesting to note that there was a significant increase in the percentage of cells in G2/M 
in UBE2C-DN transfected cells compared with empty or UBE2C-treated cells. 
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Figure 3-21. Distribution of cell cycles in UBE2C-overexpressing PC-3 cells during cell cycle 
exit.  
PC-3 cells were first transfected with expression vectors. The cell culture media were 
replenished after 2 h following induction and seeded into T25 flasks for another 22 h to 
allow attachment and contact inhibition. Thereafter, cells synchronised by contact 
inhibition for times indicated. Cells were then harvested, fixed in 70% ethanol and kept at  
–20 ºC until HP double staining and subsequent flow cytometry. Representative flow image 
and quantification data of three independent experiments in PC-3 cells. * p<0.05 vs. empty 
vector. Empty, empty vector. DN, vector containing UBE2C-DN. CID1–3, contact 
inhibition 1–3 days. 
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3.3.3.3. Overexpression of UBE2C impeded cell cycle exit in LNCaP 
cells 
To confirm the effects of UBE2C on cell cycle progression in another PCa cell line, the 
relationship of UBE2C and cell cycle exit was also tested in LNCaP cells. LNCaP cells were 
first transfected with expression vector; serum was removed 24 h post-transfection. Due to 
the limitation of the sensitivity of LNCaP to expression vector, LNCaP cells were induced to 
quiescence by serum starvation for only 1 day. The UBE2C overexpressed LNCaP cells 
showed less cells in quiescence compared with the cells transfected with empty vector and 
UBE2C-DN (Figure 3-22). The percentage of cells in G0 phase was 8% in UBE2C 
overexpressed LNCaP cells, whereas 20% in both empty vector and UBE2C-DN treated 
cells. 
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Figure 3-22. Distribution of cell cycles in serum-starved LNCaP cells with UBE2C 
overexpression.  
LNCaP cells were first transfected with expression vectors. The cell culture media were 
replenished after 2 h following induction and seeded into T25 flasks for another 22 h to 
allow attachment. Thereafter, cells were serum-deprived for another 24 h. Cells were then 
harvested, fixed in 70% ethanol and kept at –20 ºC until HP staining and subsequent flow 
cytometry. Representative flow image and quantification data of three independent 
experiments in LNCaP cells. * p<0.05 vs. empty vector. Empty, empty vector. DN, vector 
containing UBE2C-DN. 
 
 
107 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 3 
3.3.3.4. Overexpression of UBE2C impeded cell cycle exit in C4-2B 
cells 
To confirm the cellular effects of UBE2C on cell cycle exit, cell cycle distribution of UBE2C 
overexpressed C4-2B cells were also tested. C4-2B cells were first transfected with 
expression plasmid; and then serum was removed 24 h post-transfection. Thereafter, C4-2B 
cells were induced to quiescence by serum withdrawal for up to 3 days (Figure 3-23). Cells 
were then subjected to HP double staining and subsequent flow cytometric analysis. During 
cell cycle exit, the fraction of G0 cells was increased in a time-dependent manner. However, 
the increase in the fraction of G0 in UBE2C-transfected cells was less than that in empty and 
UBE2C-DN treated C4-2B cells. After 3 days serum starvation, the proportion of quiescent 
cells increased to 80% in empty vector or UBE2C-DN transfected control cells, whereas only 
67% in UBE2C-overexpressing C4-2B cells, suggesting the high expression of UBE2C 
significantly postponed cell cycle exit of C4-2B cells. Therefore, overexpression of UBE2C 
delayed cell cycle exit in PCa cells. 
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Figure 3-23. Distribution of cell cycles in UBE2C-overexpressing C4-2B cells during cell cycle 
exit.  
C4-2B cells were first transfected with expression vectors. The cell culture media were 
replenished after 2 h following induction and seeded into T25 flasks for another 22 h to 
allow attachment and then serum withdrawal for up to 3 days. Cells were then harvested, 
fixed in 70% ethanol and kept at –20 ºC until HP double staining and subsequent flow 
cytometry. Representative flow image and quantification data of three independent 
experiments in C4-2B cells. * p<0.05 vs. empty vector. Empty, empty vector. DN, UBE2C-
DN. SRD1–3, serum replenished (SR) 1–3 days. 
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3.3.4. Knockdown of UBE2C impeded cell cycle re-entry 
Following the revelation that overexpression of UBE2C delayed cell cycle exit in PCa cells, 
we next addressed the question of whether knockdown of UBE2C can delay the cell cycle re-
entry. PCa cells were induced to quiescence and then transfected with siUBE2Cs at the time 
when the cells were released from the quiescence. The cell cycle distributions of PCa cells 
were determined by HP double staining. Moreover, the concordance between UBE2C protein 
levels and cell cycle progression were also determined. 
3.3.4.1. Validation of cell cycle re-entry by HP double staining  
To validate if the quiescent cells re-enter the cell cycle, PC-3, LNCaP and C4-2B cells were 
first induced to experimental quiescence. The G0 arrested PC-3 cells were re-plated at lower 
density for 3 days to achieve cell cycle re-entry (RPD1–3). During the period of cell cycle re-
entry, the percentage of quiescent cells decreased by 55% in RPD3 PC-3 cells compared with 
CID3 samples (Figure 3-24). In LNCaP and C4-2B cells, cell cycle re-entry was rendered by 
restoration of serum to serum-deprived cells for a period of 7 days (SRD1–7). Upon release 
from quiescence, quiescent LNCaP and C4-2B cells re-entered the cell cycle, as a significant 
decrease of G0 cells was observed for both LNCaP cells (76.5% to 27.6%) and C4-2B cells 
(87.8% to 19.4%; Figure 3-25 & Figure 3-26).  
110 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 3 
 
Figure 3-24. Distribution of cell cycles in PC-3 cells during cell cycle re-entry.  
CID3: PC-3 cells were synchronised to G0 by contact inhibition in T25 flasks for 3 days. 
Thereafter, cells were collected for cell cycle analysis using HP double staining. Boxes 
outline cells in G0, G1, S and G2/M. RPD1–3; quiescent PC-3 cells were re-plated at lower 
density to allow cell re-entry to the cell cycle. The cell cycle distribution was analysed 
using the same gating. A. Representative flow image in PC-3 cells. B. Histogram illustrates 
the cell cycle distribution during cell cycle re-entry. * p<0.05 vs. CID3. 
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Figure 3-25. Distribution of cell cycles in LNCaP cells during cell cycle re-entry.  
SWD7: LNCaP cells were synchronised to G0 by serum deprivation in T25 flasks for 7 
days. Thereafter, cells were collected for cell cycle analysis using HP double staining. 
SRD3-D7, cell cycle re-entry was rendered by restoration of serum to serum-deprived cells 
for up to 7 days. The cell cycle distribution was analysed using the same gating.  
A. Representative flow image in LNCaP cells. B. Histogram illustrates the cell cycle 
distribution during cell cycle re-entry. * p<0.05 vs. SWD7. 
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Figure 3-26 Distribution of cell cycles in C4-2B cells during cell cycle re-entry.  
SWD7: C4-2B cells were synchronised to G0 by serum deprivation in T25 flasks for 7 days. 
Thereafter, cells were collected for cell cycle analysis using HP double staining. SRD3-D7, 
cell cycle re-entry was rendered by restoration of serum to serum-deprived cells for up to 7 
days. The cell cycle distribution was analysed using the same gating. A. Representative 
flow image in C4-2B cells. B. Histogram illustrates the cell cycle distribution during cell 
cycle re-entry. * p<0.05 vs. SWD7. 
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3.3.4.2. UBE2C protein levels are increased during cell cycle re-entry  
To determine the correlation of UBE2C protein level and cell cycle status, immunoblotting 
was performed to detect the change of UBE2C during cell cycle re-entry. Upon cell cycle re-
entry, a marked increase of UBE2C protein levels was detected during cell cycle re-entry in 
PC-3, LNCaP and C4-2B cells (Figure 3-27). Consistent with our flow results shown above, 
which showed that the cells re-enter the cell cycle progressively after release, UBE2C protein 
levels increased gradually during cell cycle re-entry in a time-dependent manner. Thus, the 
UBE2C protein level is suggested to be positively correlated to the transition of quiescent to 
proliferating cells in PCa cells. The timeframe required for a PCa cell to re-enter the cell 
cycle and its corresponding UBE2C protein level is summarised in Table 3-4. 
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Figure 3-27. Expression of UBE2C protein in prostate cancer cells during cell cycle re-entry.  
Quiescent PCa cells were induced to quiescence by 3 day contact inhibition or 7 day serum 
withdrawal. The cell cycle re-entry was achieved by re-plating cells at lower density for 3 
days or serum restoration for 7 days. Levels of UBE2C protein in PC-3, LNCaP and C4-2B 
cells were examined by western blot analysis. α-TUBULIN expression was determined as a 
control to assure equal protein loading. CID3, contact inhibition for 3 days. RPD1–3 
quiescent PC-3 cells were re-plated at lower density to allow cell re-entry to the cell cycle. 
SWD7, serum withdrawal for 7 days. SRD1–3, serum replenished for 1–3 days. Left. 
Representative immunoblotting image in PCa cells. Right. Histogram representing 
densitometric analysis are mean±SD. *, P< 0.05 versus CID3 or SWD7 in each cell line. 
The results are representative of three experiments. 
 
Table 3-4. The timeframe required for enriching cell re-entry and the corresponding UBE2C 
level during cell cycle re-entry in prostate cancer cells.  
Re-entry 
UBE2C  
level by 
western  
blot 
D1 D2 D3 D5 D7 
Change in 
G0 fraction 
by flow 
cytometry
 
D1 D2 D3 D5 D7 
PC-3 ↑ ↑↑ ↑↑↑ 
  
↓ ↓ ↓↓ 
  
LNCaP  ↑ ↑ ↑↑ ↑↑↑   
↓ ↓↓ ↓↓ 
C4-2B ↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↑↑↑ ↓ ↓↓ ↓↓↓   
↓, a decrease occurred. ↑, an increase occurred. The number of arrows indicates the level of 
change. D1–7, time following release from quiescence. 
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3.3.4.3. Knockdown of UBE2C impeded cell cycle re-entry in PC-3 cells 
To determine the role of UBE2C in regulating cell cycle re-entry, we employed contact 
inhibition in PC-3 to synchronise cells to quiescence. PC-3 cells were then transfected with 
either NC or siUBE2Cs at the time when the cells were induced to cell cycle re-entry. The 
knockdown of UBE2C during cell cycle re-entry was confirmed by immunoblotting. The 
effect of siUBE2C on the proportion of cells in G0 phase during cell cycle re-entry was 
determined in a time course experiment. By comparing the percentage of G0 cells before and 
after the induction of cell cycle re-entry, depletion of UBE2C retained 15–25% more G0 cells 
than NC treated PC-3cells (Figure 3-28). As expected, there was a significant decrease in G1 
population following 24 h treatment with siUBE2Cs compared to the NC after release from 
quiescence (p<0.01). Knockdown of UBE2C also led to G2/M arrest following 3 day release 
from quiescence (p<0.01). The percentage of S-phase cells remained unchanged or decreased 
only in C3-treated PC-3 cells 24 h after cell cycle re-entry (p<0.05). The results provide 
evidence that knockdown of UBE2C delays cell cycle re-entry by quiescent PC-3 cells. 
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Figure 3-28. The effect of siUBE2C on the distribution of cell cycles in PC-3 cells during cell 
cycle re-entry.  
CID3: PC-3 cells were synchronised to G0 by contact inhibition in T25 flasks for 3 days. 
PC-3 cells were then transfected with NC, C1 or C3 at the time when the cells were induced 
to cell cycle re-entry. RPD1–3, the quiescent PC-3 cells were re-plated at lower density to 
allow cell re-entry to the cell cycle. A. Representative immunoblotting image in PC-3 cells. 
B. Histogram representing densitometric analysis are mean± SD (n=3).  *, P< 0.05 vs. NC 
at each time point. The effect of siUBE2C on the proportion of cells in G0 phase during cell 
cycle re-entry was determined by using HP double staining. The cell cycle distribution was 
analysed using the same gating. C. Representative flow image in PC-3 cells. D. Histogram 
illustrates the cell cycle distribution during cell cycle re-entry. * p<0.05 vs. NC at each 
time point. 
 
3.3.4.4. Knockdown of UBE2C impeded cell cycle re-entry in LNCaP 
cells 
To verify the results obtained from PC-3 cells that UBE2C siRNA impeded cycle re-entry, 
we synchronised LNCaP cells using serum withdrawal method. LNCaP cells were then 
transfected with 20 nM either NC or siUBE2Cs at the time when the cells were released from 
quiescence. By comparing the percentage of G0 cells with or without UBE2C depletion, the 
percentage of G0 cells decreased after cell cycle release. The effect of siUBE2C was observed 
48 h after release by serum restoration, which was 40% higher in siUBE2C-treated cells 
compared to NC-treated cells (Figure 3-29). Moreover, depletion of UBE2C retained 110% 
more G0 cells than NC-treated LNCaP cells after release for 3 days.  
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Figure 3-29. The effect of siUBE2C on the distribution of cell cycles in LNCaP cells during cell 
cycle re-entry.  
SWD7: LNCaP cells were synchronised to G0 by serum deprivation in T25 flasks for 7 
days. LNCaP cells were then transfected with NC, C1 or C3 at the time when the cells were 
induced to cell cycle re-entry. SRD1–3, cell cycle re-entry was rendered by restoration of 
serum to serum-deprived cells for up to 7 days. A. Representative immunoblotting image in 
LNCaP cells. B. Histogram representing densitometric analysis are mean± SD (n=3).  *, P< 
0.05 vs. NC at each time point. The effect of siUBE2C on the proportion of cells in G0 
phase during cell cycle re-entry was determined by using HP double staining. The cell cycle 
distribution was analysed using the same gating. C. Representative flow image in LNCaP 
cells. D. Histogram illustrates the cell cycle distribution during cell cycle re-entry. * 
p<0.05 vs. NC at each time point. 
 
The results further support the notion that knockdown of UBE2C retains cells in quiescent 
state. Notably, there was no impact of siUBE2C in the quiescence of LNCaP cells at first day 
of release by serum restoration. This observation may be explained by comparing the protein 
level of UBE2C in NC-treated cells, although the protein level of UBE2C in SRD1 was 
increased compared with SWD7, it remained relatively low compared with SRD2 or SRD3. 
In addition, approximately 70% of LNCaP cells were arrested at G0 phase after SRD1, 
compared to 80% of cells in SWD7 samples, suggesting the majority of LNCaP cells 
remained quiescent after 24 h serum restoration. The quiescent LNCaP cells required more 
than 24 h to re-enter the cell cycle. Therefore, siUBE2C impeded cell cycle re-entry in SRD2. 
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3.3.4.5. Knockdown of UBE2C impeded cell cycle re-entry in C4-2B 
cells 
To further extend the above described study to anther cell line, the same experiment was 
repeated in C4-2B cells. The cell cycle re-entry was hindered in C4-2B cells treated with 
siUBE2C after 2–3 day serum restoration in comparison with control conditions. Following 3 
day serum restoration, the fraction of quiescent cells decreased dramatically from 77.6% to 
26.3% of the population in NC-treated cells. However, the decreased fraction of G0 cells was 
less in C4-2B cells treated with siUBE2C, from approximately 80% to 55% of the total 
population (Figure 3-30). Furthermore, the percentage of proliferative cells was lower in 
UBE2C-knockdown cells compared with NC-treated cells following release from quiescence. 
Taken together, these data suggest that knockdown UBE2C is capable of impeding cell cycle 
re-entry by quiescent PCa cells. 
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Figure 3-30. The effect of siUBE2C on the distribution of cell cycles in C4-2B cells during cell 
cycle re-entry. 
SWD7: C4-2B cells were synchronised to G0 by serum deprivation in T25 flasks for 7 days. 
C4-2B cells were then transfected with NC, C1 or C3 at the time when the cells were 
induced to cell cycle re-entry. SRD1–3, cell cycle re-entry was rendered by restoration of 
serum to serum-deprived cells for up to 7 days. A. Representative immunoblotting image in 
C4-2B cells. B. Histogram representing densitometric analysis are mean±SD (n=3).  *, P< 
0.05 vs. NC at each time point. The effect of siUBE2C on the proportion of cells in G0 
phase during cell cycle re-entry was determined by using HP double staining. The cell cycle 
distribution was analysed using the same gating. C. Representative flow image in C4-2B 
cells. D. Histogram illustrates the cell cycle distribution during cell cycle re-entry. * 
p<0.05 vs. NC at each time point. 
 
3.4. Discussion 
In normal circumstances, most cells are arrested at a quiescent state (Hartwell et al., 1974; 
Kriegenburg et al., 2008). The transition from quiescence to proliferation is an important self-
repair mechanism utilised to replace cell loss (Cooper, 2003; Pardee, 1974). However, 
disruption of the regulation of the cell cycle is a recurrent theme in carcinogenesis (Kastan 
and Bartek, 2004). The objective of this study was to determine the effect of UBE2C on cell 
cycle control in PCa cells. The choice of three cell lines – PC-3, LNCaP and C4-2B – was 
based on the fact that PCa is either HSPC or CRPC. LNCaP (AR positive) is a cell model of 
HSPC; PC-3 (AR negative) is a model of CRPC cells, while C4-2B was chosen as it is an AR 
positive CRPC cell line (Chen et al., 2011; Thalmann et al., 2000; Wang et al., 2009). In this 
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study, we investigated the relationship of UBE2C in regulating the proportion of quiescent 
cancer cells using two genetic approaches, i.e., gene silencing with siRNA and 
overexpression with expression vectors. We also verified the HP double staining method to 
quantify the proportion of G0 cells in a population of PCa cells, as well as during transition 
from quiescence to proliferation. Our observations clearly demonstrated there is a correlation 
between UBE2C protein levels and cell cycle exit and re-entry. More importantly, our data 
indicated that UBE2C plays a causal role in cell cycle exit and re-entry. As UBE2C effect on 
cell cycle regulation is consistent overall in all three PCa cell lines, it is most likely that the 
UBE2C action is AR independent. 
3.4.1. Expression level of UBE2C in cancerous and non-
cancerous prostate cell lines 
UBE2C mRNA and protein have been shown to be overexpressed in PCa (Tzelepi et al., 
2012; Wang et al., 2009). In this study, we determined the expression of UBE2C in five 
prostate cell lines. We found that the expression of UBE2C is high in all three cancerous PCa 
cell lines compared to the two non-cancerous prostate cell lines (Figure 3-1). Our findings 
suggest that the cell lines used in our study are consistent with the reported role of UBE2C in 
promoting tumour grade and progression (Chen et al., 2010; Cunha et al., 2010; Loussouarn 
et al., 2009). 
3.4.2. Expression of UBE2C correlated with cellular 
proliferation  
In PCa cells, overexpression of UBE2C increases, whereas silencing of UBE2C decreases, 
cell proliferation and invasiveness (Wang et al., 2011). Our observation of cell proliferation 
124 | P a g e  
Chanlu (Amber) Xie   17382058   Chapter 3 
assays showed a similar pattern. That is, a positive correlation between UBE2C levels and 
cell proliferation in PCa cells. Silencing of UBE2C decreased cell proliferation, whereas 
overexpression of UBE2C increased, when measured by DNA content (Figure 3-3 & Figure 
3-16). 
3.4.3. Validation of HP double staining 
UBE2C is a mitotic cyclin-specific E2 ubiquitin-conjugating enzyme; we speculated that, the 
cell cycle might be distorted and might arrest in G2/M phase after UBE2C is 
downregulated(Reddy et al., 2007). The knockdown of UBE2C by siRNA increases cells in 
G2/M phase in PC-3 cells and C4-2B cells but not in LNCaP cells (Chen et al., 2011; Walker 
et al., 2008; Wang et al., 2011; Wang et al., 2009). However, in this study, the fraction of 
cells in G0/G1 phase remained unchanged or decreased following UBE2C knockdown in PCa 
cell lines (Table 3-1). Our immunostaining of Ki-67 protein in PC-3 cells showed a decrease 
in positivity, suggested the proportion of quiescent cells could be increased (Figure 3-6). The 
conventional method of DNA content analysis was unable to distinguish G0 from G1, as both 
G1 and G0 cells are diploid (2N). However, ribosomes were degraded in quiescent G0 cells. 
Shapiro (1981) first proposed a method to differentiate staining of cellular RNA and DNA by 
HP double staining (Shapiro, 1981). Hoechst 33258 is an exclusive DNA dye while Pyronin 
Y reacts with both DNA and RNA. However, in the presence of Hoechst 33258, the staining 
of Pyronin Y for DNA content is blocked, and Pyronin Y stains RNA only (Zbigniew 
Darzynkiewicz et al., 2004). Hence, the G0 cells could be distinguished as diploid and as 
having low RNA content by using multi-parameter flow cytometry based on simultaneously 
labelling the cell nuclear DNA and RNA.  
In this study, flow cytometric analysis with HP double staining was validated by using 
synchronised PCa cells. The experimental model of quiescent PCa cells was induced by 3 
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days contact inhibition or 7 days serum withdrawal. Flow analysis of cells with HP double 
staining showed a time-dependent increase in the proportion of quiescent cells during 
synchronisation (Figure 3-7–Figure 3-9). The HP double staining was further validated by co- 
staining with p-Rb (Ser807/811). Cells with 2N DNA and low RNA content were low in Rb at 
p-Ser807/811 (Figure 3-10 & Figure 3-11), which is hypo-phosphorylated in quiescent cells 
(Serrano et al., 1993; Sherr and Roberts, 1995). Hence, flow cytometric analysis with HP 
double staining was an effective method to identify quiescence in PCa cells. 
3.4.4. UBE2C expression is associated with the proportion of 
quiescent prostate cancer cells 
The HP double staining method was subsequently applied to determine if manipulating 
UBE2C changes the proportion of cells in G0 phase. PCa cell lines were transfected with 
UBE2C siRNA or UBE2C expression plasmid. Depletion of UBE2C led to accumulation of 
quiescent cells (Figure 3-12–Figure 3-14), while overexpression of UBE2C decreased the 
proportion of quiescent PCa cells (Figure 3-17-Figure 3-19). 
In our studies, the UBE2C protein levels were depleted prior to the change occurring in 
accumulation of G0 cells in each cell line (Table 3-2). The UBE2C was knocked down 24 h 
after induction of siUBE2C in PC-3 and C4-2B cells, whereas the accumulation of quiescent 
cells became significant at 48 h. Similarly, the significant increase of G0 cells in LNCaP cells 
occurred 24 h after successful UBE2C depletion. These observations suggest a causal role of 
UBE2C in cellular quiescence. 
To assess whether or not this observation was associated with UBE2C catalytic activity, PCa 
cells were transfected with UBE2C or UBE2C-DN plasmid to render gene overexpression. 
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Overexpressed UBE2C in PCa cells decreased the proportion of cells in G0 phase, whereas no 
change was observed in UBE2C-DN induced cells (Figure 3-17-Figure 3-19).  
UBE2C-DN is created by changing the catalytic Cysteine to Serine, which blocks UBE2C-
mediated protein ubiquitination and destruction (Townsley et al., 1997). Our result suggests 
that the catalytic Cys114 of UBE2C could be important for UBE2C-mediated cell cycle 
progression. It is worth noting that, although transfecting UBE2C-DN has no impact in G0 
cells, it increased the proportion of cells in G2/M phase in LNCaP cells. Similar results have 
also been reported by Townsley (1997). More recent studies suggest the mitosis arrest caused 
by induction of UBE2C-DN is due to its capacity to compete with endogenous UBE2C to 
bind to its E3 ligands, thus inhibiting degradation of mitotic cyclins and subsequently mitotic 
arrest (Bose et al., 2012; Townsley et al., 1997).  
3.4.5. Cellular mechanism of UBE2C regulating cell cycle exit 
and re-entry 
To further evaluate the relationship of UBE2C with cell cycle exit and re-entry, we utilised 
contact inhibition in PC-3 or serum withdrawal in LNCaP and C4-2B cells to induce 
experimental quiescence, as previously published in our laboratory (Yao et al., 2015). The 
quiescent state of PCa cells were confirmed by flow cytometric analysis with HP double 
staining (Figure 3-7–Figure 3-9). Cell cycle re-entry was rendered by replating the quiescent 
cells at low density, or by restoration of serum to serum-deprived cells (Figure 3-24–Figure 
3-26). The protein level of UBE2C protein was decreased during cell cycle exit and increased 
upon cell cycle re-entry in PCa cells (Table 3-3 & Table 3-4). In line with this observation, 
UBE2C levels have been shown to be cell cycle-regulated (Okamoto et al., 2003).  
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We then determined the effect of UBE2C expression in regulating cell cycle re-entry in 
quiescent PCa cells by two independent genetic approaches. Firstly, PCa cells were 
transfected with UBE2C overexpression vector, and then induced to quiescence by contact 
inhibition or serum withdrawal. Synchronisation of PCa cells was slowed down by 
overexpression of UBE2C compared with control cells, whereas no impact was found in 
UBE2C-DN expressed cells (Figure 3-21–Figure 3-23). These results suggest overexpression 
of UBE2C delayed cell cycle exit. It was noted that the C4-2B cells transfected with empty 
vector had a higher proportion of cells at G0 phase compared with the non-transfected cells 
following synchronisation at G0. In PC-3 cells, a decrease in the proportion of cells at G0 
phase was noted following synchronisation in the empty vector transfected cells in 
comparison to the non-transfected cells. This phenomenon reminds us the importance to use 
empty vector-transfected cells as contrl, but not non-transfected cells. Moreover, this 
discrepancy should not affect the validity of the results, as the comparison in the study is 
always between wildtype-UBE2C and empty vector/DN-transfected cells. 
In addition, PCa cells were induced to quiescence, and cells were treated with siUBE2C 
during cell cycle re-entry by replating the quiescent cells at low density or by restoring serum 
to serum-deprived cells. The proportion of G0 cells was higher in PCa cells with UBE2C-
knockdown compared with control cells (Figure 3-28-Figure 3-30). Therefore, loss of 
UBE2C delayed cell cycle re-entry by quiescent PCa cells. These observations further 
support the regulatory role of UBE2C in the transition of quiescent cells to proliferative cells.  
In summary, we have established three novel observations:  
i. UBE2C protein levels were decreased during cell cycle exit and increased upon cell 
cycle re-entry in three PCa cell lines.  
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ii. Depletion of UBE2C led to accumulation of quiescent cells, while overexpression of 
UBE2C decreased quiescent cells in PCa cell lines.  
iii. Overexpression of UBE2C impeded cell cycle exit and its knockdown delayed cell 
cycle re-entry by quiescent PCa cells.  
Further studies are needed to investigate the mechanism underlying UBE2C action on cell 
cycle exit and re-entry.
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4.1. Introduction 
Ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and ubiquitin 
ligases (E3) are three enzymes required for UPS to work in concert to facilitate ubiquitination 
of target protein substrates (Rape, 2010). UBE2C is an E2 enzyme, which is an exclusive 
partner of APC/C. By orchestrating the sequential degradation of a large number of cell cycle 
regulators, UBE2C together with APC/C is essential for cell cycle control (Song and Rape, 
2011). The human APC/C has more than 55 reported target proteins. Of these, 37 are 
involved in cell cycle S and M phases (e.g., cyclin A/B, p21 and securin), 11 are cell-cycle 
related in general (e.g., E2-C, E2F1, JNK and SKP2), and two are APC/C co-activators 
(CDC20 and CDH1) (Meyer and Rape, 2011).  
Unlike the ample information gathered regarding the E3 APC/C, the E2s participating in the 
cell cycle have not been fully understood. UBE2C regulates the mitotic SAC by targeting 
securin for degradation, which in turn activates separase to degrade cohesin rings, leading to 
separation of sister chromatids and anaphase onset (Hao et al., 2012; Reddy et al., 2007; 
Williamson et al., 2011). Overexpression of UBE2C leads to uncontrolled APC/C activity 
and genomic instability, including chromosome mis-segregation, chromosomal lagging 
during mitosis and aneuploidy (Hao et al., 2012). UBE2C also participates in the destruction 
of mitotic cyclins, including cyclin B. Degradation of cyclin B inactivates CDK1, which 
leads to unphosphorylation and activation of CDH1. APC/CCDH1 and low activity of CDK1 
are prerequisite steps for mitotic exit and G1 and S progression (Aristarkhov et al., 1996; 
Arvand et al., 1998; Rape and Kirschner, 2004; Rape et al., 2006). Accumulation of UBE2C 
stimulates cell proliferation, whereas silencing of UBE2C decreases cell proliferation (Chen 
et al., 2011; Wang et al., 2009). Expression of UBE2C-DN arrests cells in mitosis (Townsley 
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et al., 1997). Knockdown of PC-3 cells delays cell cycle progression from G2/M to G1 phase, 
highlighting the role of UBE2C in regulating mitotic exit (Chen et al., 2011).  
Observations outlined in Chapter 3 indicated that UBE2C is a vital cell cycle regulation 
factor involved in regulating the proportion of quiescent over proliferative PCa cells and 
transition to proliferating state by quiescent cancer cells. A key question is how UBE2C 
influences cell quiescence in PCa cells. Understanding how UBE2C regulates the transition 
of quiescent cells to proliferating cells is limited. To address this question, we examined a 
range of cell cycle regulators that had previously been associated with cell quiescence: G0-
regulatory proteins, including p27 and its regulators, c-MYC and FBXW7. Moreover, the 
mechanism of how UBE2C influences these proteins was investigated. 
4.2. Materials and Methods 
4.2.1. Prostate cancer cell lines 
The PCa cell lines LNCaP, PC-3 and C4-2B cells were cultured as described in Chapter 
2.1.1.  
4.2.2. Transfection of prostate cancer cells with siRNA 
Prostate cancer cells were transfected with 20 nM NC, C1 or C3. The cells were incubated for 
the indicated time and the media was replenished. The cells were left to propagate for the 
time indicated. Thereafter, cells were harvested for SYBR Green assay, immunoblotting, RT-
PCR or flow cytometry analysis. 
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4.2.3. Transfection of prostate cancer cells with plasmid  
For overexpression, PCa cells were gown in T75 flasks until semi-confluent, then trypsinised 
and transfected with plasmid according to Chapter 2.2.2.   
4.2.4. Immunoblotting 
The cells were treated in 6-well plates and cell lysates prepared with a lysis buffer. 
Immunoblotting was performed as described in Chapter 2.5. The primary antibodies used are 
listed in Table 2-4. 
4.2.5. RT-PCR 
RT-PCR was performed as described in Chapter 2.7. All the primer sequences used for RT-
PCR in this study are listed in Chapter 2.7.3. 
4.2.6. Statistical analysis  
The statistical software NCSS version 12.0 was used for statistical analysis as described in 
Chapter 2.8  
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4.3. Results 
4.3.1. Knockdown of UBE2C increased p27 protein 
expression in prostate cancer cells 
The G0-maintenance protein p27 is a CDK/cyclin inhibitor, which is found in quiescent cells 
and its elevated level is required for blocking cell cycle re-entry and the maintenance of 
quiescent state (Chu et al., 2007; Rivard et al., 1996). To verify whether the mode of UBE2C 
involves the G0-maintenance protein p27, we determined the effect of siUBE2C on p27 
protein levels in three PCa cell lines (PC-3, LNCaP and C4-2B cells; Figure 4-1). In PC-3 
cells, the protein level of p27 was clearly increased by knockdown UBE2C at 24 h after 
exposure to siUBE2C. Accumulation of p27 protein was also observed in LNCaP and C4-2B 
cells 48 h post-transfection of siUBE2Cs.  
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Figure 4-1. Effect of siUBE2C on p27 protein levels in PC-3, LNCaP and C4-2B cells by immunoblotting. 
A. PC-3, B. LNCaP and C. C4-2B cells were transfected with 20 nM NC, C1 or C3. The cell culture medium was replenished 24 h following 
transfection. The cells were harvested 24, 48 and 72 h following transfection. Cell lysate protein (50 µg/lane) was analysed by 
immunoblotting. GAPDH and α-TUBULIN: loading control. Left. Representative immunoblotting image in PCa cells. Right. Histogram 
representing densitometric analysis are mean±SD (n=3).  *, P< 0.05 vs. NC at each time point.  
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4.3.2. Knockdown of UBE2C by siRNA decreased p27 
negative regulators in prostate cancer cells 
To further elucidate the mechanistic basis and action of UBE2C on G0-maintenance protein 
p27, immunoblot analysis was conducted to examine the expression of p27 regulators (SKP2, 
PIRH2 and CRM1). SKP2 and PIRH2 are components of E3 ligases responsible for p27 
proteolysis by proteasome, while CRM1 is a carrier protein for p27 nuclear export. These 
three proteins can influence p27 protein levels via regulation of p27 protein stability and 
subcellular localisation. 
4.3.2.1. Knockdown of UBE2C decreased SKP2 and PIRH2 in PC-3 
cells 
To investigate whether p27 protein regulators were affected by UBE2C in PC-3 cells, 
immunoblotting analysis of CRM1, SKP2 and PIRH2 was performed. While CRM1 levels 
were not largely affected by siUBE2C, a reduction of UBE2C protein levels and coincident 
reduction of SKP2 and PIRH 2 and accumulation of p27 were observed 24 h post-transfection 
(Figure 4-2).  
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Figure 4-2. Effect of siUBE2C on p27 protein levels in PC-3 cells by immunoblotting.  
PC-3 cells were transfected with 20 nM NC, C1 or C3. The cell culture medium was 
replenished 24 h following transfection. The cells were harvested 24, 48 and 72 h following 
transfection. Cell lysate protein (50 µg/lane) was analysed by immunoblotting. α-
TUBULIN: loading control. A. Representative immunoblotting image in PC-3 cells. B. 
Histogram representing densitometric analysis are mean±SD (n=3).  *, P< 0.05 vs. NC at 
each time point.  
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4.3.2.2. Downregulation of UBE2C led to a reduction of SKP2 and 
PIRH2 followed by a decrease in c-MYC levels in PC-3 cells 
Since the key cell cycle regulators were all changed 24 h post-transfection, we then 
determined the effect of siRNA in a shorter time course to determine the sequence of the 
change in these key proteins. PC-3 cells were treated with siUBE2Cs or NC for 4, 8, 12, 16, 
20 and 24 h. The UBE2C level was verified by immunoblotting at indicated times with or 
without siUBE2C treatment. siUBE2C treatment for 8 h was sufficient for UBE2C 
knockdown (Figure 4-3). The protein levels of PIRH2 and SKP2 were reduced by UBE2C 
knockdown at 16 h post-transfection. The increase of G0-maintenance protein p27 was 
observed 8 h after the reduction of SKP2 and PIRH2 occurred (Figure 4-3). The change of 
SKP2 and PIRH2 were 8 h ahead of the increased p27 protein, suggesting regulation of 
UBE2C on p27 is through downregulating SKP2- and PIRH2-mediated p27 degradation. 
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Figure 4-3. Effect of siUBE2C on p27 protein levels in PC-3 cells by immunoblotting with short time points.  
PC-3 cells were transfected with 20 nM NC, C1 or C3. The cells were harvested every 4 h following transfection till 24 h. Cell lysate protein 
(50 µg/lane) was analysed by immunoblotting. α-TUBULIN: loading control. Left. Representative immunoblotting image in PC-3 cells. 
Right. Histogram representing densitometric analysis are mean±SD (n=3).  *, P< 0.05 vs. NC at each time point.
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4.3.2.3. Knockdown of UBE2C decreased SKP2 and PIRH2 in LNCaP 
cells 
To extend the observation to another cell line, the protein level of p27 regulators was also 
examined in LNCaP cells. A reduction of UBE2C protein levels and concordant reduction of 
SKP2 and PIRH 2 and accumulation of p27 were observed over 3 days following siUBE2C 
treatment (Figure 4-4). We found that the transfection of siUBE2C in LNCaP was effective 
48 h post-transfection (Figure 3-5); whereas the reduction of SKP2 and PIRH2 occurred 48–
72 h following transfection of siUBE2C. However, the protein level of CRM1 remained 
unchanged after UBE2C knockdown in LNCaP cells. 
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Figure 4-4. Effect of siUBE2C on p27 protein levels in LNCaP cells by immunoblotting. 
LNCaP cells were transfected with 20 nM NC, C1 or C3. The cell culture medium was 
replenished 24 h following transfection. The cells were harvested 24, 48 and 72 h following 
transfection. Cell lysate protein (50 µg/lane) was analysed by immunoblotting. α-
TUBULIN: loading control. A. Representative immunoblotting image in LNCaP cells. B. 
Histogram representing densitometric analysis are mean± SD (n=3).  *, P< 0.05 vs. NC at 
each time point.  
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4.3.2.4. Knockdown of UBE2C decreased SKP2 and PIRH2 in C4-2B 
cells 
To further determine the effect of UBE2C on the expression of p27 and its regulators, we 
evaluated CRM1, SKP2 and PIRH2 using immunoblotting in another PCa cell line. C4-2B 
cells were exposed to siUBE2Cs for up to 72 h (Figure 4-5). Both sets of siUBE2Cs were 
effective in repressing the expression of UBE2C, showing an accumulation of p27 and a 
decrease of PIRH2 and SKP2 protein levels within the first 24 h after exposure to siUBE2C. 
However, there was no impact on protein level of CRM1 after transfection over a period of 
72 h in comparison to control (Figure 4-5).  
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Figure 4-5. Effect of siUBE2C on p27 protein levels in C4-2B cells by immunoblotting. 
C4-2B cells were transfected with 20 nM NC, C1 or C3. The cell culture medium was 
replenished 24 h following transfection. The cells were harvested 24, 48 and 72 h following 
transfection. Cell lysate protein (50 µg/lane) was analysed by immunoblotting. GAPDH: 
loading control. A. Representative immunoblotting image in C4-2B cells. B. Histogram 
representing densitometric analysis are mean±SD (n=3).  *, P< 0.05 vs. NC at each time 
point.  
 
Overall, it is interesting to note that the change in SKP2 and PIRH2 occurred prior to the 
change in p27 in PCa cells. Comparing with the timeframe of protein scheduled to change 
could provide evidence to prove that the effect of UBE2C on p27 is possibly due to the 
decrease of its E3 ligase-mediated degradation. 
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4.3.2.5. Downregulation of UBE2C led to an accumulation of FBWX7 
and a decrease in c-MYC levels in prostate cancer cells 
c-MYC is a positive regulator of UBE2C (Zhao et al., 2012) and a transcriptional repressor of 
p27. FBXW7 plays a key role in c-MYC protein degradation (Amati, 2004; Farrell and Sears, 
2014). The effect of siUBE2C on c-MYC and FBXW7 protein levels was tested in PC-3, 
LNCaP and C4-2B cells. Silencing of UBE2C reduced c-MYC levels, suggesting a possible 
positive feedback loop between UBE2C and c-MYC (Figure 4-6). We then determined 
FBXW7 protein levels after 3 days of siUBE2C treatment. In all three PCa cells, suppression 
of UBE2C led to an elevated protein level of FBXW7 (Figure 4-6). Overall, these 
experiments show that the repression of UBE2C led to a downregulation of c-MYC and an 
upregulation of FBXW7.  
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Figure 4-6. Effect of siUBE2C on c-MYC and FBXW7 protein levels in prostate cancer cell lines. 
A. PC-3, B. LNCaP and C. C4-2B cells were transfected with 20 nM NC, C1 or C3. The cell culture medium was replenished 24 h following 
transfection. The cells were harvested 24, 48 and 72 h following transfection. Cell lysate protein (50 µg/lane) was analysed by 
immunoblotting. α-TUBULIN: loading control. Left. Representative immunoblotting image in PCa cells. Right. Histogram representing 
densitometric analysis are mean± SD (n=3).  *, P< 0.05 vs. NC at each time point.
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4.3.2.6. Downregulation of UBE2C led to an accumulation of FBWX7 
followed by a decrease in c-MYC levels in PC-3 cells 
Since the protein level of UBE2C was knocked down by siUBE2C 8 h post-transfection, the 
sequence of the change in UBE2C, c-MYC and FBXW7 was determined. PC-3 cells were 
treated with siUBE2Cs or NC for 4, 8, 12, 16 and 20 h. The UBE2C level was verified by 
immunoblotting at indicated times with or without siUBE2C treatment. The increase of 
FBXW7 protein level occurred 16 h followed by UBE2C knockdown, and prior to the 
decrease of c-MYC protein levels in PC-3 cells (Figure 4-6 & Figure 4-7). Comparing with 
the timeframe of protein scheduled to change could provide some evidence to prove that the 
effect of UBE2C on c-MYC is possibly due to the increase of its E3 ligase-mediated 
degradation. 
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Figure 4-7. Effect of siUBE2C on c-MYC protein levels and its regulator FBXW7 in PC-3 cells 
by immunoblotting with short time points.  
PC-3 cells were transfected with 20 nM NC, C1 or C3. The cells were harvested every 4 h 
following transfection till 20 h. Cell lysate protein (50 µg/lane) was analysed by 
immunoblotting. α-TUBULIN: loading control. The results are representative of three 
experiments. A. Representative immunoblotting image in PC-3 cells. B. Histogram 
representing densitometric analysis are mean±SD (n=3).  *, P< 0.05 vs. NC at each time 
point. 
 
4.3.2.7. Knockdown of UBE2C had no effect on mRNA of p27 and  
c-MYC in PC-3 cells 
The accumulation of p27 following siUBE2C could be a result of a decrease in p27 
proteasomal degradation, as supported by the reduction of SKP2 and PIRH2, or an increase in 
p27 gene transcription. Similarly, the siUBE2C-induced reduction of c-MYC could be a 
result of an increase in c-MYC proteasomal degradation, as suggested by the elevation of 
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FBXW7, or a decrease in c-MYC gene transcription. Hence, mRNA levels of UBE2C, 
p27and c-MYC after 24 h siUBE2C treatment were determined by RT-PCR. The mRNA 
level of UBE2C was significantly reduced (p<0.05), while there was no change in p27 or c-
MYC mRNA levels (Figure 4-8). 
 
Figure 4-8. Effect of siUBE2C on p27 and c-MYC mRNA levels in PC-3 cells by RT-PCR. 
PC-3 cells were transfected with 20 nM NC or UBE2C siRNA. The cells were harvested 24 
h following transfection. Samples was analysed by RT-PCR. HK, housekeeping protein 
TBP was used as loading control. The results are representative of three experiments. * 
p<0.05 vs. NC.  
 
Although there was some difference between the cell lines in their response to siUBE2C, the 
increase in p27 and decrease in c-MYC protein level in LNCaP and C4-2B cells needed 
longer time than for PC-3 cells (Table 4-1). The effect of UBE2C on p27 was likely via the 
regulation of the SKP2 and PIRH2-mediated post-translational degradation. This is because 
the knockdown of UBE2C reduced SKP2 and PIRH2 levels, which occurred prior to the 
change of p27 protein, whereas the mRNA level of p27 remained unchanged. Also, the 
reduction of c-MYC was mostly likely through FBXW7 mediated post-translational 
destruction, because the siUBE2C led to increase of FBXW7 followed by a decrease in c-
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MYC protein level, while no change was found in c-MYC mRNA level. Although SKP2 can 
also contribute to c-MYC protein degradation, that was unlikely to have happened, because 
SKP2 levels were decreased after UBE2C knockdown. 
Table 4-1. The summary of the timeframe required for siUBE2C to affect the levels of key 
proteins in LNCaP, PC-3 and C4-2B cells compared to NC.  
 
*G0 increase refers to the proportion of cells at G0 phase that were significantly increased at 
the indicated time. 
 
4.4. Discussion 
In our experiment, the expression of UBE2C in PCa played a vital role in cell cycle 
regulation, involved in regulating the transition between quiescent and proliferative cells. The 
objective of this study was to identify the underlying mechanism of UBE2C in regulation of 
cell quiescence. We first defined a role of UBE2C on p27 and its regulators, including SKP2 
and PIRH2. In addition, we showed the level of c-MYC also decreased, whereas FBXW7, 
which targets c-MYC for proteolysis, was increased by siUBE2C.  
4.4.1. UBE2C influenced cell quiescence via mechanisms 
involving p27 
In our study, we screened several key cell cycle regulators for their ability to regulate cell 
quiescence, including G0-maintained protein p27. p27, a tumour suppressor, overexpression 
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of p27 is sufficient to arrest cells in quiescent state (Chu et al., 2008). Downregulation of 
UBE2C expression by siUBE2C increased p27 protein level. Knockdown of UBE2C 
decreased the protein levels of SKP2 and PIRH2, which are components of E3 ligases 
responsible for p27 proteolysis. However, depleting UBE2C did not result in changed p27 
mRNA levels. Therefore, the effect of UBE2C on p27 was likely via regulation of the SKP2- 
and PIRH2-mediated post-translational degradation.  
Further investigation on the sequential change of UBE2C, p27 and its regulators, confirmed 
that the change in levels of p27 occurred after SKP2 and PIRH2 were reduced (Table 4-1). 
Although there was some difference between the cell lines in their response to siUBE2C – the 
increase in p27 and decrease in c-MYC protein level in LNCaP and C4-2B cells took longer 
than that required in PC-3 cells – the accumulation of quiescent PCa cells occurred after the 
accumulation of p27 in all three PCa cell lines. Collectively, under siRNA treatment of 
UBE2C, at least in part, p27 functioned as a G0-maintenance protein to retain cells in a 
quiescent state. The control mechanism of UBE2C was likely via SKP2 and PIRH2, rather 
than a more direct relationship with p27. 
In addition, it is generally believed that the degradation of p27 requires its cytoplasmic 
relocalisation (Rodier et al., 2001). Low cytoplasmic levels of p27 are associated with cancer 
aggressiveness and poor clinical prognosis (Chu et al., 2008). CRM1, a p27 nuclear exporter, 
remained unchanged by siUBE2C. Therefore, downregulation of UBE2C had no impact in 
CRM1-mediated p27 cytoplasm translocation, suggesting the mechanism behind UBE2C in 
regulating cell cycle is irrelevant to the regulation of p27 subcellular location. 
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4.4.2. UBE2C influenced cell quiescence via mechanisms 
involving c-MYC 
In addition, c-MYC is a cellular proto-oncogene. The expression of c-MYC is low in 
quiescent cells and increase upon cell cycle re-entry (Kelly et al., 1983). Amplification of c-
MYC is found in nearly half of all human solid tumours (Beroukhim et al., 2010), including 
thirty percent of PCa (Bretones et al., 2015). Suppression of UBE2C decreased c-MYC 
protein levels together with an increase of FBXW7 level. FBXW7 is one of the few proteins 
targeting c-MYC for degradation and inhibiting c-MYC transcriptional activity (Amati, 2004; 
Farrell and Sears, 2014). Although SKP2 is another component of E3 ligases responsible for 
c-MYC proteolysis, SKP2 is decreased in UBE2C knockdown cells and is therefore unlikely 
to be involved in c-MYC degradation. Additionally, UBE2C knockdown led to a decrease in 
c-MYC protein level, while no impact was found in c-MYC mRNA level. Thus, our results 
indicated that the reduction of UBE2C mediated c-MYC was more likely post-translational 
and FBXW7-dependent. Our observation suggested that knockdown of UBE2C increased 
FBXW7 level, resulting in the sequential degradation of c-MYC protein levels and 
subsequent G0 accumulation (Table 4-1). Therefore, the effect of UBE2C on the proportion 
of quiescent cancer cells was via a pathway involving c-MYC. 
In addition, early studies showed the regulation of c-MYC on `cell quiescence, at least in part 
through its ability to directly repress p27 gene transcription (Bretones et al., 2015; 
Chandramohan et al., 2008). However, the change in c-MYC and p27 occurred at a similar 
time, so it is unlikely the increase of p27 was due to the decrease of c-MYC. Further study is 
required to determine whether c-MYC plays a role in regulating p27 in PCa cells with 
UBE2C knockdown. 
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It is unclear whether the regulation of E3 ligases by UBE2C, including SKP2, PIRH2 and 
FBXW7, is direct or indirect. Further study is needed to determine the mechanism of how 
UBE2C controls p27 and c-MYC through its post-translational regulation. There are three 
possible steps of overexpression of UBE2C in regulating cell proliferation: (1) increase the 
pool of active APC/C; (2) inactivate the mitotic checkpoint; and (3) enhance cell cycle 
progression from G2/M to G1 phase (Chen et al., 2011; Reddy et al., 2007; Wang et al., 2011; 
Wang et al., 2009). However, the current understanding of the catalytic role of UBE2C in 
UPS is unable to explain our observations of p27 protein levels. SKP2 is one of 55 targets of 
APC/C; we speculated that knockdown of UBE2C would increase APC/C target proteins, and 
thus decrease p27. Unexpectedly, downregulation of UBE2C decreased SKP2 protein levels. 
Although c-MYC is also reported to induce the expression of SKP2 (Bretones et al., 2011; 
Keller et al., 2007; O'Hagan et al., 2000); a decrease in c-MYC by UBE2C can explain the 
decrease in SKP2. However, the SKP2 protein level was decreased before the decrease of c-
MYC. Also, we found no change in SKP2 mRNA following UBE2C siRNA treatment (data 
not shown). Hence, c-MYC is unlikely to be the cause of the reduction of SKP2 protein level. 
Further study is required to identify the role of UBE2C in SKP2 regulation. 
In summary, we have established two novel observations:  
i. UBE2C can downregulate p27 expression, possibly through augmenting SKP2 and 
PIRH 2 expression. 
ii.  UBE2C can upregulate c-MYC, possibly through reducing FBXW7 expression.  
The possible pathway of UBE2C in regulating cell quiescence is proposed in Figure 4-9. 
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Figure 4-9. The proposed mechanism of UBE2C in regulating cell quiescence. 
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5. Concordance Between 
UBE2C Expression Levels 
and Progression of Prostate 
Cancer 
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5.1. Introduction  
Worldwide, one patient dies from PCa every 4 minutes (Assinder et al., 2015). This 
significant mortality is a result of limited treatment options available (Assinder et al., 2015). 
Active surveillance is a viable management option for men with low-grade, clinically 
localised PCa. However, approximately 30–40% of men on active surveillance will progress 
to high-grade disease over 5 years, which mandates surgery or radiation (Singh et al., 2010). 
At the advanced stage, when metastases occur, PCa is treated with ADT but development of 
CRPC becomes inevitable in a majority of cases when ADT fails. Patients with CRPC have 
an average survival time of 16–18 months after recurrence (Liu et al., 2015). Recently 
treatment of PCa entered the era of personalised therapy. Treatment on a personal basis now 
involves a simultaneous case-specific analysis of clinical and pathological characteristics and 
distinguishes at diagnosis men who have a potentially lethal, indolent course of disease. 
Analysis of a patient’s genetic and tumour biomarker profiles enables selection of suitable 
individualised treatment for PCa. Therefore, there is an acute need to discover predictive 
prognostic biomarkers.  
The UBE2C gene has been associated with malignant transformation and aggressiveness of 
many solid tumours. UBE2C mRNA is barely detectable in the majority of normal tissues 
(Okamoto et al., 2003). In contrast, UBE2C mRNA and/or protein is expressed at high levels 
in leukaemia, lymphoma and melanoma, and various cancers – thyroid, oesophageal, breast, 
ovarian, lung, gastric, colon, bladder and uterine (Okamoto et al., 2003; Vasiljevic et al., 
2013; Wagner et al., 2004; Xie et al., 2014). An association between the levels of UBE2C 
protein and tumour grade/poor prognosis is reported in cancers of the adrenal gland, breast, 
colon, liver, lung and ovary (Okamoto et al., 2003; van Ree et al., 2010; Zhao et al., 2012). 
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In PCa, UBE2C level is undetectable in normal prostate tissue (Okamoto et al., 2003), low in 
HSPC and high in CRPC (Tzelepi et al., 2012; Wang et al., 2009).  
To date, only one report exits with regard to the protein level of UBE2C in PCa progression, 
describing evidence for an overexpression of UBE2C in CRPC (n=230) compared to HSPC 
(n=98) and BPH (n=44) (Wang et al., 2009). Although this previous study was based on large 
numbers of patients with PCa, the association between UBE2C expression and clinical 
prognosis of PCa patients has not been fully defined. Hence, in this chapter, we aimed to 
determine whether UBE2C expression was associated with PCa stage and grade. The 
expression of UBE2C in PCa and non-cancerous prostate tissues was detected by 
immunohistochemical analysis. The association between UBE2C expression and 
clinicopathological characteristics of PCa patients was also evaluated in public gene 
expression datasets to test the hypothesis that UBE2C is a potential prognostic biomarker and 
therapeutic target for PCa.  
5.2. Materials and Methods 
5.2.1. Human tissue preparation 
The collection of patient specimens for the analysis in this study was approved under the 
Central Sydney Area Health Service (X04-318) and Western Area Health Service Ethics 
Committee [HREC2000/9/4.18 (1089)]. Human tissue samples were prepared as described in 
Chapter 2.6.2. 
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5.2.2. Immunohistochemistry  
Expression of UBE2C in the human PCa sample was determined by immunohistochemical 
staining. The staining was performed as described in Chapter 2.6.3. The staining intensity 
was graded by a pathologist.  
5.2.3. Gene expression analysis of human prostate cancer 
dataset 
The mRNA correlation analysis on UBE2C was performed across ONCOMINE datasets 
corresponding to metastatic PCa. All data were log-transformed provided by ONCOMINE. 
Pairwise signature comparisons were performed using a student t-test or one-way ANOVA. 
p<0.01 was considered significant. The description of datasets is summarised in Table 5-1. 
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Table 5-1. Summary of prostate datasets downloaded from ONCOMINE. 
Dataset BPH Primary Metastasis Total (n) p value Year Source Platform 
Arredouani 8 13 - 21 8.20E-03 2009 Clin Cancer Res Human Gene U133 Plus 2.0 array 
Chandran - 10 21 31 p<0.0001 2007 BMC CodeLink UniSet Human 20K I Bioarray 
Grasso 28 59 34 122 p<0.0001 2012 Nature Agilent Human Genome 44K 
laTulippe - 23 9 32 p<0.0001 2002 Cancer Res Human Genome U95A-Av2 Array 
Lapointe 41 62 9 112 p<0.0001 2004 Proc Natl Acad Sci USA not defined 
Luo 9 16 - 25 3.00E-04 2001 Cancer Res not defined 
Magee 4 8 3 15 1.10E-03 2001 Cancer Res Human GeneFL Array 
Taylor 29 131 19 179 p<0.0001 2010 Cancer cell RefSeq Genes 
Varambally 5 7 6 18 p<0.0001 2005 Cancer cell Human Gene U133 Plus 2.0 array 
Yu 23 64 24 111 p<0.0001 2004 J Clin Oncol  Human Genome U95A-Av2 Array 
  Grade 2 Grade 3 Grade 4 
   
    
Bittner 23 32 3 58 1.00E-04 2005 not published Human Gene U133 Plus 2.0 array 
Gleason Grade 6 3+4 4+4 8 9 10 
   
    
Setlur 110 98 55 41 54 5 363 p<0.0001 2008 J Natl Cancer Inst Illumina DASL Transcriptionally 
Informative Gene Panel 
p value indicates statistical significance vs. BPH in Arredouani, Grasso, Taylor, Varambally, Magee, Lapointe, Luo and Yu dataset. 
p value indicates statistical significance vs. primary PCa in Chandran and LaTulippe dataset. 
p value indicates statistical significance vs. Grade 2 in Bittner dataset. 
p value indicates statistical significance vs. Gleason grade 6 in Setlur dataset. 
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5.2.4. Statistical analysis  
The statistical software NCSS version 12.0 was used for statistical analysis as described in 
Chapter 2.8. ONCOMINE analysis used the student t-test or one-way ANOVA in GraphPad 
Prism v.6. Data are expressed as mean±SD. 
5.3. Results 
5.3.1. Protein level of UBE2C in human prostate cancer 
tissue 
5.3.1.1. Expression of UBE2C was higher in prostate cancer tissues 
compared with unpaired BPH  
To determine the expression of UBE2C in human prostate tissue, immunohistochemistry 
staining against UBE2C was performed. Negative UBE2C staining was observed in 95% of 
unpaired BPH samples (n=36; Figure 5-1A, left). Weak staining of UBE2C was exhibited in 
2 out of 36 (5.5%) BPH patients. In contrast, positive staining of UBE2C protein was found 
in 52 of 70 (74.3%) PCa cases treated with radical prostatectomy and transurethral resection 
of prostate specimens (Figure 5-1A right). Analysis of the UBE2C positivity of cells with low 
or high intensity staining between BPH and cancer specimens was significantly different 
(p=0.001; Figure 5-1B). The staining was localised in both nucleus and cytoplasmic staining 
(Figure 5-1A). 
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Figure 5-1. Expression of UBE2C in prostate tissues by immunohistochemical staining of 
UBE2C.  
UBE2C was immunostained in human prostate tissue containing unpaired BPH (n=36) and 
PCa (n=70). A. Representative tissue stained with antibody against UBE2C (magnification 
X200). BPH tissue (Left) and PCa tissue (Right). B. p=0.001 between unpaired BPH and 
cancer by unpaired t-test. IHC staining for UBE2C in tissues was scored by pathologist: 0, 
negative; 1, weak staining; 2, intermediate; and 3, strong.  
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5.3.1.1 Expression of UBE2C was higher in prostate cancer compared 
with adjacent non-malignant tissue  
To further verify the expression of UBE2C in human prostate tissue, we compared the 
immunostaining of UBE2C in PCa areas with adjacent non-malignant tissue (n=17). The 
staining of UBE2C was significantly higher in PCa tissue compared with non-malignant 
prostate epithelia by immunohistochemical analysis (p<0.01; Figure 5-2A). In 13 out of 17 
(76.5%) paired samples, there was a clear increase in UBE2C staining in the PCa disease 
status (p=0.001; Figure 5-2B). The remaining 4 pair samples were negative for UBE2C 
staining in both non-malignant prostate and PCa tissues.  
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Figure 5-2. Expression of UBE2C in paired non-malignant and malignant prostate tissues by 
immunohistochemical staining of UBE2C. 
UBE2C was immunostained in tissues containing adjacent BPH and PCa tissue (n=17).  
A. Representative tissue stained with anti-UBE2C antibody (magnification X100). B. 
p=0.001 between paired BPH and PCa by paired t-test. IHC staining for UBE2C was scored 
by pathologist: 0, negative; 1, weak staining; 2, intermediate; and 3, strong. 
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5.3.1.2 Expression of UBE2C was higher  in castration-resistant 
prostate cancer (CRPC) compared with patient-matched 
hormone sensitive prostate cancer (HSPC)  
To further investigate whether development of hormone refractory PCa is associated with 
changes in UBE2C, we compared the immunostaining of UBE2C in HSPC obtained by 
transurethral resection of prostate (n=8; Figure 5-3A, left) with the same patient samples once 
the patient had reached castration-resistant status and required a repeat transurethral resection 
of the prostate (Figure 5-3A, right). The protein levels of UBE2C were found to increase in 
CRPC tissue compared with that in HSPC tissue in six out of eight (75.0%) paired samples  
(p =0.003; Figure 5-3B). While the other two sets were stained with UBE2C with 
intermediate intensity in both HSPC and CRPC tissues, the staining intensity did not change 
appreciably with disease progression.  
Collectively, high-grade PCa showed intense, uniform staining for UBE2C that was 
significantly different from that in adjacent BPH or HSPC, both of which showed only focal 
or weak UBE2C staining. Further, UBE2C was associated with high-grade histological 
tumours in individual cases. 
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Figure 5-3. Expression of UBE2C in paired HSPC and CRPC tissues by immunohistochemical 
staining.  
UBE2C was immunostained in TMA containing paired hormone sensitive (HSPC) and 
castration resistant PCa (CRPC; n=8). A. Representative tissue stained with antibody 
against UBE2C (magnification X200). HSPC tissue (Left) and CRPC tissue (Right).  
B. p=0.003 between paired HSPC and CRPC by paired t-test. The IHC staining for UBE2C 
in tissues was scored by pathologist: 0, negative; 1, weak staining; 2, intermediate; and 3, 
strong. 
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5.3.2 mRNA of UBE2C in human prostate cancer tissues 
UBE2C was found to be aberrantly overexpressed in CRPC when compared to HSPC, 
offering a rationale to investigate UBE2CmRNA in primary, advanced by tumour grade, and 
metastatic PCa. Twelve datasets was downloaded from the ONCOMINE database 
(www.oncomine.org), which is a web-based database of a curated collection of cancer 
microarrays. The studies used Affymetrix, the spotted cDNA or oligonucleotide microarray 
platforms for gene expression analysis (Table 5-1), except the Lapointe and Luo prostate 
datasets, for which the microarray platforms were not specified in ONCOMINE. 
 
5.3.2.1 Overexpression of UBE2C in prostate cancer tissues 
To determine whether PCa is associated with UBE2C expression, UBE2C mRNA expression 
was examined in the Arredouani and Luo prostate datasets. Arredouani (n=21) and Luo 
(n=25) prostate datasets contain microarray results of BPH and primary PCa samples. 
Examining the mRNA level of UBE2C in the two independent datasets revealed a positive 
correlation of PCa and UBE2C expression (p<0.01; Figure 5-4A&B).  
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Figure 5-4. UBE2C mRNA level in BPH and prostate cancer tissues. 
The UBE2C mRNA levels in BPH and primary cancer tissue are plotted in A. Arredouani 
dataset (n=21) and B. Luo dataset (n=25). Data are mean±SD. * p<0.01 compared to BPH 
by unpaired t-test. 
 
5.3.2.2 Overexpression of UBE2C in high grade prostate cancer tissues 
To determine whether UBE2C expression is associated with tumour grade, the UBE2C 
mRNA expression was examined in the Bittner prostate dataset. The expression of UBE2C 
showed a significant correlation with increased tumour grade (Figure 5-5A). In addition, PCa 
patients were sorted by Gleason grade in the Setlur prostate dataset. There were significant 
differences in expression of UBE2C in tumours with Gleason grades of 8/9 (n=95) versus 
Gleason grades of 6 (n=110; p<0.01; Figure 5-5B). Nevertheless, there was no statistical 
difference in UBE2C expression between tumours with Gleason 7 (n=153) and Gleason 6 
(n=110).  
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Figure 5-5. Association of UBE2C mRNA level and tumour grade in prostate cancer tissues. 
A. UBE2C expression in tissues with different Gleason scores (n=58) * p<0.01 compared to 
Grade 2 by unpaired t-test, # p<0.01 compared to Grade 3 PCa by unpaired t-test.  
B. UBE2C expression in tissues with different Gleason score (n=363). Data are mean±SD.  
* p<0.01 compared to Gleason Grade 6 by unpaired t-test. 
 
5.3.2.3 High expression of UBE2C in metastatic prostate cancer tissues 
To compare the microarray signature of PCa with or without metastasis studies, eight datasets 
were analysed (Figure 5-6). The mRNA level of UBE2C was investigated in six prostate 
datasets (Grasso, Lapointe, Magee, Taylor, Varambally and Yu), containing BPH, primary 
and metastatic PCa samples. In six independent prostate datasets, enriched UBE2C 
expression was found in metastatic PCa versus primary PCa and BPH samples (p<0.01; 
Figure 5-6A–F). Additionally, in the Chandran and LaTulippe datasets, there was a 
significant increase in UBE2C expression in the presence of PCa metastatic samples 
compared to primary PCa (p<0.01; Figure 5-6G–H). Furthermore, analysis of the Taylor 
prostate dataset also revealed significant increases in UBE2C expression in primary PCa 
compared with BPH (p<0.01; Figure 5-6B).  
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Taken together, enhanced UBE2C expression was positively correlated to tumour stage and 
grade, suggesting UBE2C is a prognostic biomarker as well as a potential therapeutic target 
in PCa. 
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Figure 5-6. Association of UBE2C mRNA level and pathological features in prostate cancer 
tissues. 
A–F. UBE2C relative expression in BPH, primary and metastasised PCa samples in  
A, Grasso dataset (n=122); B, Taylor dataset (n=179); C, Varambally dataset (n=18);  
D, Magee dataset (n=15); E, Lapointe dataset (n=112); and F, Yu dataset (n=111). UBE2C 
mRNA expression in primary and metastasised PCa tissues in G, Chandran dataset (n=31) 
and H, La Tulippe dataset (n=32). Data are mean±SD. * p<0.01 compared to BPH by 
unpaired t-test, # p<0.01 compared to primary PCa by unpaired t-test. 
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5.4 Discussion 
UBE2C is highly expressed in PCa (Tzelepi et al., 2012; Wang et al., 2009), whereas it is 
undetectable in normal prostate tissue (Okamoto et al., 2003). UBE2C has been associated 
with malignant progression and aggressive invasion of tumours, and is predictive of poor 
survival and a high risk of relapse in wide range of solid tumours (Ma et al., 2016; Xie et al., 
2014). Since UBE2C is a prominent proto-oncogene, which is causally involved in tumour 
development, the association of UBE2C to PCa progression has attracted attention (van Ree 
et al., 2010). The objective of this study was to determine whether UBE2C expression is a 
potential prognostic biomarker and therapeutic target for PCa. The expression of UBE2C in 
PCa and non-cancerous prostate tissues was detected by immunohistochemical analysis. The 
paired HSPC and CRPC samples from the same patients were also included to verify the 
correlation of UBE2C expression to disease progression, so that individual variation could be 
avoided. We also used a public gene expression dataset to determine the association between 
UBE2C mRNA expression and clinicopathological characteristics. 
5.4.1 UBE2C protein level in human prostate cancer tissue 
The present study evaluated the expression levels of UBE2C in 70 human PCa tissues and 36 
non-cancerous prostate tissue specimens. We have shown that UBE2C is present in PCa 
tissue, but absent in the majority (95%) of non-cancerous prostate tissues. The expression 
levels of UBE2C in PCa tissues were significantly higher compared to BPH by 
immunohistochemistry analysis. In 17 patient-matched pairs, 76% of patients with PCa 
showed higher UBE2C staining compared to their corresponding matched BPH. This result 
was consistent with previous data published by Okamoto et al. (2003). 
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Furthermore, the immunohistochemical analysis of paired specimens indicated that UBE2C 
protein expression was increased in CRPC compared with HSPC, suggesting the relation of 
UBE2C with disease progression (p<0.01; Figure 5-3). Although this study was small in 
numbers, the expression of UBE2C was determined in PCa tissue before disease progressed, 
and the tissues from the same men were examined when they reached castration resistant 
status; thus, each man acted as his own control.  
Our results were consistent with previous studies, which have revealed the association of 
UBE2Cwith the malignant transformation and tumour progression of PCa tissues (LaTulippe 
et al., 2002). UBE2C gene expression has also been reported to increase with advancing 
pathological stages in nasopharyngeal carcinoma, thyroid cancer, esophageal squamous cell 
carcinoma,  colorectal cancer and glioma (Ma et al., 2016; Wang et al., 2009; Xie et al., 
2014). Additionally, an overexpression of UBE2C stimulated cell proliferation and invasion 
in PCa cells (Shuliang et al., 2013; Wang et al., 2009). Collectively, the 
immunohistochemical analysis shows that UBE2C may be vital in the aggressive progression 
of PCa. 
5.4.2 UBE2C mRNA level in human prostate cancer tissue 
The association between UBE2C expression and the clinical prognosis of PCa patients has 
not been fully assessed. ONCOMINE datasets on PCa have shown an upregulation of UBE2C 
gene expression. We incorporated the expression of UBE2C for primary-localised, 
metastasised and advanced tumour grade PCa. A higher UBE2C expression was associated 
with a significantly increased tumour stage and tumour grade. There is limited prior work 
examining UBE2C gene expression compared with both disease stage and grade. Setlur et al. 
(2008) and his colleagues yielded a list of about 100 pathways that were significantly 
dysregulated by comparing the program of gene expression in a model of the progression of 
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HSPC to CRPC. The ubiquitin proteasome pathway is one of the few identified pathways that 
are dysregulated during PCa aggressive invasion. By comparing the program of gene 
expression of UBE2C in a model of the progression of HSPC to CRPC and protein 
expression from actual CRPC cases, we found that the expression of UBE2C – an E2 enzyme 
in the ubiquitin proteasome pathway – was involved in PCa disease progression. This is 
consistent with Penney (2011), who found expression of UBE2C predicted tumour grade in 
PCa by measuring the mRNA expression in the Swedish Watchful Waiting cohort (n=358) 
and Physician’s Health Study (n=109). The UBE2C mRNA signature to PCa Gleason grade 
was comparing in individuals with tumours of Gleason scores ≤6 to those ≥ 8, and Gleason of 
7 was applied to differentiate lethal cases (Penney et al., 2011). More recently, similar results 
were reported in Kuner’s group which found maternal embryonic Leucine zipper kinase 
(MELK) – which was highly associated with UBE2C expression – also correlated with PCa 
tumour grade (Gleason grade ≥4+3 vs. ≤3+4) (Kuner et al., 2013). These clinical findings 
were replicated in vitro, with overexpression of UBE2C found to increase PCa cell 
proliferation and invasion by MTT assay, colony formation and matrigel invasive assay 
(Shuliang et al., 2013).  
In summary, it has been suggested that UBE2C represents a promising cancer biomarker. 
Therefore, UBE2C overexpression may be used as a predictor of poor prognosis in patients 
with PCa. We hope our finding will facilitate further research, ultimately leading to the 
improved understanding of cancer and the development of novel diagnostic and therapeutic 
strategies. 
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6.1 Discussion 
UBE2C is an E2 enzyme that facilitates UPS-mediated precise destruction of key cell cycle 
regulators during cell division (Rape, 2010; Reddy et al., 2007). Aberrantly expressed 
UBE2C has been reported in a variety of cancers including PCa (Hao et al., 2012; Xie et al., 
2014). Earlier studies showed that accumulation of UBE2C stimulates cell proliferation, 
whereas silencing UBE2C decreases cell proliferation in PCa cells (Chen et al., 2011; Wang 
et al., 2011; Wang et al., 2009). However, the effect of UBE2C on cell quiescence has not 
been examined.  
In this PhD project, I found that UBE2C may play a causal role in cell cycle exit and re-entry 
in PCa cell lines. Inhibition of UBE2C by genetic silencing led to accumulation of quiescent 
cells, while increase in UBE2C expression by expression vector decreased the proportion of 
quiescent PCa cells. Overexpression of UBE2C impeded cell cycle exit to G0, and 
knockdown of UBE2C delayed cell cycle re-entry by quiescent PCa cells. Therefore, UBE2C 
may regulate the proportion of cells at quiescence through two possible cellular mechanisms: 
UBE2C inhibits cell exit to G0 and promotes cell re-entry by quiescent cells.  
The molecular mechanism of UBE2C action on the regulation of cell quiescence is likely via 
G0 regulatory proteins including p27 and c-MYC. The RT-PCR results suggested the 
regulation of UBE2C on p27 and c-MYC expression was post-translational, as no significant 
change in mRNA levels of p27 and c-MYC was detected. The immunoblotting results also 
suggested that UBE2C may have played a regulatory role in E3 ligases responsible for p27 
(i.e., SKP2 and PIRH2) and c-MYC (i.e., FBXW7) degradation. The effect of UBE2C on p27 
did not involve p27 nuclear exporter CRM1, because silencing of UBE2C had no impact on 
the protein level of CRM1.  
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6.1.1 UBE2C expression influenced the proportion of 
quiescent prostate cancer cells 
In this project, the association of UBE2C and cell quiescence was verified by carefully 
designed experiments. Important considerations for these experimental designs included the 
choice of cell lines, methods to induce quiescence and to quantify the fraction of G0 cells, and 
the genetic approach to intervene UBE2C expression.  
First, three PCa cell lines with moderate UBE2C expression were chosen in this experiment. 
LNCaP (AR positive) was a cell model of HSPC; PC-3 (AR negative) was a model of CRPC 
cells, while C4-2B was chosen as it is an AR positive CRPC cell line (Chen et al., 2011; 
Thalmann et al., 2000; Wang et al., 2009). AR has been found to play a crucial role in the 
development of CRPC, at least in part, through a mechanism of enhanced expression of 
UBE2C (Kato et al., 2015; Wang et al., 2009). Although our study did not examine the effect 
of manipulating androgen or AR on UBE2C expression, the UBE2C action on quiescence 
was similar in all three cell lines in the presence or absence of AR. Hence, it suggested that 
the regulation of cell cycle exit and re-entry by UBE2C may be AR-independent.  
Second, experimental quiescence was induced by two complementary methods. Instead of 
using drugs to synchronise cells, serum removal and contact inhibition are believed to induce 
relatively less  perturbations to the cells (Schorl and Sedivy, 2007). Our synchronising 
condition, which induced the maximum percentage of cells in G0/G1 phase, caused minimal 
impact to cell viability in PCa cell lines. Culture for 7 days of serum-deprived LNCaP cells or 
3 days of contact inhibited PC-3 cells can enrich G0/G1 cells by 80–90%, as shown by our 
group recently (Yao et al., 2015). It is worth noting that by including both serum-deprived 
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LNCaP cells and contact inhibited PC-3 cells, any bias due to choice of synchronisation 
method can be avoided.  
Third, to investigate the effect of UBE2C on cell quiescence, we established a method to 
directly quantify G0 cells. PI staining is a useful technique that allows analysis of DNA 
content and cell cycle distribution. However, as noted previously, it is impossible to 
distinguish G0 from G1, as both G1 and G0 cells are diploid. Based on the fact quiescent cells 
degrade their polyribosomes leading to low RNA content (Darzynkiewicz et al., 1975), the 
G0 cell distribution can be determined by simultaneously labelling DNA and RNA with HP 
double staining and then analysing by two-parameter flow cytometry (Shapiro, 1981). Indeed, 
contact inhibition and serum starvation enriched the G0 phase cells in this study by 
approximately 70–90%, determined by HP double staining. This double staining method was 
further validated by co-staining with p-Rb (Ser807/811), because quiescent cells should be 
hypophosphorylated (Serrano et al., 1993; Sherr and Roberts, 1995). The cells with low RNA 
content were also found to be low in Rb at p-Ser807/811. Hence, flow cytometric analysis with 
HP double staining was an effective method to identify quiescence in PCa cells. 
Finally, to ensure the most accurate assessment of the true experimental outcome, two genetic 
approaches were employed for this study. Depletion of UBE2C was achieved by using two 
siRNAs targeting different sequences for specific knockdown of UBE2C. There was no 
significantly different outcome between the two siUBE2Cs. In addition, overexpression of 
UBE2C was induced by expression vector, and a UBE2C-DN control. Overexpressed 
UBE2C in PCa cells decreased the proportion of cells in G0 phase, compared with no change 
observed in UBE2C-DN-induced cells. Collectively, there was no pharmacological inhibitor 
of UBE2C present. Using two genetic approaches provided strong and clear evidence to 
support a relation between UBE2C protein levels and cell cycle exit and re-entry. 
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6.1.2 UBE2C regulated the proportion of quiescent prostate 
cancer cells probably via p27 
High levels of p27 have been found in quiescent cells and maintain cells in a quiescent state 
(Arvand et al., 1998; Chu et al., 2007). Downregulation of p27 is observed when cells are 
recruited to the cell cycle (Carrano et al., 1999; Fukuda et al., 1997; Hattori et al., 2007; 
Sgambato et al., 2000). Moreover, p27 is a tumour suppressor. Overexpression of p27 alone 
is sufficient to arrest cells in the quiescent state and low levels of p27 are associated with 
poor clinical prognosis (Chu et al., 2008; Deng et al., 2009; Sgambato et al., 2000; Yao et al., 
2015). The post-translational regulation of p27 is mediated by several key regulators 
including SKP2, PIRH2 and CRM1. This study showed knockdown of UBE2C lead to a 
decrease in protein levels of SKP2 and PIRH2. Importantly, the decrease in these protein 
levels occurred before the increase in p27 protein levels. Together with no change of p27 
mRNA levels, we propose that UBE2C controlled the turnover of p27 through SKP2 and 
PIRH2. Notably, high levels of SKP2 and PIRH2 have been found to link with low levels of 
p27 and poor prognosis in several malignancies (Carrano et al., 1999; Huang et al., 2011; 
Shimada et al., 2009; Wu et al., 2013; Yao et al., 2015).  
6.1.3 UBE2C regulated the proportion of quiescent prostate 
cancer cells probably via c-MYC 
c-MYC is another important regulator of G0 cells that was implicated as one of the first 
identified oncogenes (Wasylishen and Penn, 2010). Amplification of c-MYC has been 
reported to accelerate the G1–S transition, immortalise cells, promote cell proliferation and 
lead to genomic instability (Luoto et al., 2010; Wasylishen and Penn, 2010; Yin et al., 1999). 
Excess expression of c-MYC is found in nearly half of human solid tumours (Beroukhim et 
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al., 2010), including thirty percent of PCa (Bretones et al., 2015). FBXW7 is one of the few 
proteins that targets c-MYC for degradation and inhibits c-MYC transcriptional activity 
(Amati, 2004; Farrell and Sears, 2014). Previously, our lab found that silencing FBXW7 by 
siRNA led to an accumulation of c-MYC in LNCaP and PC-3 cells (paper in press). 
In this study, siUBE2C led to a decrease in c-MYC protein level, while no impact was found 
on c-MYC mRNA level. Additionally, silencing of UBE2C increased FBXW7 levels, prior to 
the decrease of c-MYC. Thus, our results indicate that the reduction of UBE2C mediated a 
change in c-MYC, which was most likely post-translational and FBXW7-dependent. SKP2 is 
another component of E3 ligases responsible for c-MYC proteolysis, as SKP2 is decreased in 
UBE2C knockdown cells, and is therefore unlikely to be involved in c-MYC degradation 
(Bretones et al., 2011). Therefore, the effect of UBE2C on the proportion of quiescent cancer 
cells was possibly via c-MYC and FBXW7. 
6.1.4 Concordance between UBE2C expression and prostate 
cancer progression 
Previous studies have shown an aberrant overexpression of UBE2C mRNA and protein in 
PCa tissue (Hao et al., 2012; LaTulippe et al., 2002; Stanbrough et al., 2006; Wang et al., 
2009). However, we have shown for the first time change in UBE2C protein levels in paired 
specimens of HSPC and CRPC from same patient. Although there were only eight patients in 
this study (as it is very rare to be able to collect TURP specimens twice from same patient), 
the increase in UBE2C levels in CRPC compared with HSPC were significant (p=0.003). 
Together with confirmation by immunostaining of our collected human PCa tissue specimens 
(n=70), and analysis of UBE2C mRNA levels across 12 prostate datasets using ONCOMINE, 
it was clear that UBE2C mRNA and protein were highly expressed in an advanced 
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metastasised form of PCa compared with organ-confined primary PCa or BPH. Hence, 
developing new treatment strategies by targeting UBE2C may be warranted. 
6.2 Future Directions 
UBE2C is an E2 enzyme, which is an exclusive partner of APC/C. Silencing UBE2C may 
reduce the destruction of APC/C target proteins and therefore APC/C target proteins are 
expected to increase as a result of knockdown of UBE2C. However, SKP2, one of 55 targets 
of APC/C, was significantly decreased when UBE2C was downregulated in this study. This 
unexpected observation suggested that the action of UBE2C on cell quiescence can be 
APC/C independent (Chen et al., 2011; Reddy et al., 2007; Wang et al., 2011; Wang et al., 
2009). Although c-MYC was also reported to induce the expression of the SKP2 gene 
(Bretones et al., 2011; Keller et al., 2007; O'Hagan et al., 2000), the SKP2 protein level is 
decreased before the decrease of c-MYC. Also, we found no change in SKP2 mRNA 
following UBE2C siRNA treatment (data not shown). Hence, c-MYC was unlikely to be the 
cause of the reduction of SKP2 protein levels. Further study is therefore required to identify 
the role of UBE2C in SKP2 regulation. 
Interestingly, there was a clear difference between wild type and UBE2C-DN in regulating 
the proportion of quiescent PCa cells. Forced expression of UBE2C in PCa cells decreased 
the proportion of cells in G0 phase, whereas no change was observed in UBE2C-DN-induced 
cells, suggesting the catalytic Cys114 of UBE2C could be important for UBE2C-mediated cell 
cycle progression. It is worth noting that, although transfection of UBE2C-DN had no impact 
on G0 cells, it increased the proportion of cells in G2/M phase in LNCaP cells. Similar results 
have also been reported by Townsley (1997). Other recent studies suggested the mitosis arrest 
caused by induction of UBE2C–DN was due to its capacity to compete with endogenous 
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UBE2C to bind to its E3 ligands, thus inhibiting the degradation of mitotic cyclins and 
causing subsequent mitotic arrest (Bose et al., 2012; Townsley et al., 1997). Further study is 
needed to verify the underlining mechanism of how the UBE2C catalytic site is involved in 
regulating the proportion of quiescent cells. This could be achieved by overexpressing 
UBE2C and UBE2C-DN and pulling down the physical partner by immunoprecipitation of 
UBE2C. Mass spectrometry could then be used to identify the possible difference in partner 
proteins of UBE2C and UBE2C-DN.   
6.3 Conclusion 
This project has revealed that UBE2C plays a previously unrecognised role in regulating the 
proportion of quiescent PCa cells and their transition to a proliferating state. Our findings 
suggest:  
i. UBE2C impedes cell cycle exit and promotes cell cycle re-entry. 
ii. UBE2C can upregulate SKP2 and PIRH2, which possibly promote p27 turnover. 
iii. UBE2C can inhibit FBXW7 expression, which may prevent c-MYC from degrading. 
iv. UBE2C mRNA and/or protein levels are aberrantly increased in the advanced form of 
prostate cancers, and the increased expression of UBE2C is associated with PCa 
progression.  
To induce PCa cells arrested at quiescence is an interesting and important strategy and may 
lead to prevention of PCa progression and recurrence. UBE2C can be one of the therapeutic 
targets to achieve exactly that.
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